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Preface
Reported Tuberculosis in the United States, 
2009 presents summary data for tuberculosis 
(TB) cases verified and counted in 2009.  Re-
ports of verified cases of tuberculosis (RVCT) 
are submitted to the Division of Tuberculo-
sis Elimination (DTBE), Centers for Disease 
Control and Prevention (CDC) by 60 reporting 
areas (the 50 states, the District of Columbia, 
New York City, Puerto Rico, and seven other 
jurisdictions in the Pacific and Caribbean). First 
released in 1993, the RVCT was expanded in 
2009 to collect additional information for each 
reported TB case in order to better monitor 
trends in TB and TB control.  
Reported Tuberculosis in the United States, 
2009 is similar to previous publications (see 
page xi, #19) and contains an Executive Com-
mentary, Technical Notes, and six major sec-
tions. The Executive Commentary includes 
highlights of the 2009 data, and Technical 
Notes provides information about how the data 
were collected and reported; these sections are 
included to help the reader interpret the data. 
Morbidity Trend Tables, United States, pres-
ents trends in the overall TB case counts and 
case rates by selected demographic and clinical 
characteristics. Morbidity Tables, United States, 
2009, presents overall case counts and case 
rates for the United States by selected demo-
graphic characteristics. Morbidity Tables, Re-
porting Areas, United States, 2009, presents TB 
case counts and case rates by state and other ju-
risdictions with tables of selected demographic 
and clinical characteristics.  Morbidity Tables, 
Reporting Areas, United States, 2009 and 2007, 
presents the most recent year for which data are 
available on selected variables, such as comple-
tion of therapy, by reporting area. Morbidity 
Tables, Cities and Metropolitan Statistical 
Areas, 2009, provides TB case counts and case 
rates by metropolitan statistical areas (MSAs: 
see Technical Notes, page 9, for further de-
tails) with tables of selected demographic and 
clinical characteristics. Surveillance Slide Set, 
2009, presents figures from the annual surveil-
lance slide set, which emphasize key recent trends 
in TB epidemiology in the United States. The 
slides with accompanying text can also be viewed 
and downloaded from the DTBE website, which is 
accessible via the Internet at http://www.cdc.gov/
tb/.
The current Tuberculosis Case Definition for 
Public Health Surveillance and Recommendations 
for Reporting and Counting Tuberculosis Cases 
are provided in Appendices A and B, respectively 
(page 121).  
National Surveillance for Severe Adverse 
Events Associated with Treatment for Latent 
Tuberculosis Infection - Reporting Information
This information is included to alert our public 
health partners of the importance of reporting se-
vere adverse events (i.e., hospitalization or death) 
associated with treatment for latent TB infection 
(LTBI). Data on severe adverse events (SAEs) 
among persons receiving treatment for LTBI are 
needed to assist in the prevention of SAEs and to 
serve as a basis for periodic evaluation of guide-
lines for treatment of LTBI. 
 In April 2000, after the publication of updated 
Guidelines for Targeted Tuberculin Testing and 
Treatment of Latent Tuberculosis Infection1, 
DTBE began receiving reports of SAEs related 
to the use of a 2-month course of rifampin and 
pyrazinamide (RZ) for treatment of LTBI.  In re-
sponse, DTBE requested and received reports and 
conducted on-site investigations of liver injury 
in persons on treatment for LTBI, and treatment 
guidelines were revised accordingly.2, 3 In January 
2004, DTBE implemented the National Surveil-
lance System for Severe Adverse Events Asso-
ciated with Treatment for LTBI to quantify the 
frequency of SAEs and to characterize the clinical 
features of affected patients. A summary report 
from this surveillance system has recently been 
published.4 
xLocal medical providers should report pos-
sible LTBI-treatment associated SAEs to their 
respective local/state health departments. State 
health departments should report SAEs that oc-
curred after January 1, 2004, to DTBE 
(e-mail: LTBIdrugevents@cdc.gov).
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AL http://www.adph.org/tb/
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MN http://www.health.state.mn.us/divs/idepc/diseases/tb/stats.html
MO http://www.dhss.mo.gov/Tuberculosis/Data.html
MT http://www.dphhs.mt.gov/PHSD/epidemiology/commun-disease-epi-tuberculosis.shtml
MS http://www.msdh.state.ms.us/msdhsite/_static/14,0,125.html 
ND http://www.ndhealth.gov/disease/tb/
NC http://www.epi.state.nc.us/epi/tb
NE http://www.dhhs.ne.gov/cod/Tuberculosis/tbindex.htm
NH http://www.dhhs.state.nh.us/DHHS/CDCS/tbinfo.htm
NJ http://www.state.nj.us/health/cd/tbhome.htm
NM http://nmhealth.org/ERD/HealthData/tb_data.shtml
NYC http://www.nyc.gov/html/doh/html/tb/tb-reports.shtml
NV http://www.health.nv.gov/CD_HIV_TBProgram.htm
NY http://www.nyhealth.gov/statistics/diseases/communicable/tuberculosis/
OH http://www.odh.ohio.gov/healthstats/disease/tb/tb1.aspx
OK http://www.ok.gov/health/Disease,_Prevention,_Preparedness/Acute_Disease_Service/Disease_Information/ 
 Tuberculosis.html
OR http://oregon.gov/DHS/ph/tb/
PA http://www.health.state.pa.us/PHP/TB/tb.htm
RI http://www.health.ri.gov/disease/communicable/tb/index.php
PR http://www.salud.gov.pr/Programas/ProgramaTuberculosis/ Pages/DatosEstadisticosTuberculosis.aspx 
SC http://www.scdhec.net/health/disease/tb/index.htm
SD http://doh.sd.gov/tb
TN http://health.state.tn.us/CEDS/TB/index.htm 
TX http://www.dshs.state.tx.us/idcu/disease/tb/statistics/
UT http://www.health.utah.gov/cdc/tb_home.htm
VA http://www.vdh.virginia.gov/epidemiology/DiseasePrevention/Programs/Tuberculosis/Epidemiology/
VT http://healthvermont.gov/prevent/tb/Tuberculosis.aspx
WA http://www.doh.wa.gov/cfh/tb
WI http://www.dhs.wisconsin.gov/tb/
WV http://www.wvtb.org
WY http://www.health.wyo.gov/PHSD/tb
*As	reported	to	CDC	by	U.S.	reporting	area	TB	programs	as	of	July	2010.	Includes	responses	from	the	reporting	areas	of	New	York	City	
(NYC)	and	Puerto	Rico	(PR).
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3Executive Commentary
Highlights of 2009 Report
Since 1953, in cooperation with state and local health departments, the Centers for Disease Control and 
Prevention (CDC), Division of Tuberculosis Elimination (DTBE) has collected information on each 
newly reported case of tuberculosis (TB) disease in the United States.  Currently, each individual TB case 
report (Report of Verified Case of Tuberculosis or RVCT) is submitted electronically. The following are 
the highlights of the 2009 report:
1. Updated case counts for each year from 1993 through 2008.
2. Case counts:  11,545 TB cases were reported to CDC from the 50 states and the District of Columbia 
(DC) for 2009, representing a 10.5% decrease from 2008 (Table 1).
• Thirteen states reported increased case counts from 2008 (Table 28).
• California, Texas, New York, and Florida accounted for 50% of the national case total (Table 28). 
• For the sixth consecutive year, Hispanics (29%) exceeded all other racial or ethnic groups with 
the largest percentage of total cases (Table 2).
• For the first time, Asians (28%) surpassed non-Hispanic blacks or African-Americans1 (25%) as 
the second largest racial or ethnic group.
• Blacks or African-Americans born in the United States represented 42% of TB cases in U.S.-born 
persons and accounted for approximately 17% of the national case total (Tables 17, 18).
• Asians born outside the United States represented 44% of TB cases in foreign-born persons and 
accounted for approximately 26% of the national case total (Tables 17, 18).
3. Case rates:  In 2009, the TB case rate declined from 4.2 to 3.8 per 100,000 persons, representing a 
11.3% decrease from 2008. 
• Eleven states and DC reported rates above the national average (Table 20).
• Thirty-four states met the definition for low incidence, or ≤3.5 cases per 100,000 population, an 
increase of four states from 2008 (Table 20).
• The TB case rate was 1.7 per 100,000 for U.S.-born persons and 18.7 for foreign-born persons 
(Table 5). 
• Asians continued to have the highest case rate (23.3 per 100,000 persons) among all racial or 
ethnic groups (Table 2).
4. Burden among the foreign-born:  In 2009, as in 2008, the percentage of cases occurring in foreign-
born persons was 59% of the national case total.
• Foreign-born Hispanics and Asians together represented 80% of TB cases in foreign-born per-
sons, and accounted for 48% of the national case total (Tables 17, 18).
• In 30 states, ≥ 50% of TB cases occurred among foreign-born persons (Table 23).
• In 14 states, ≥70% of TB cases occurred among foreign-born persons (Table 23).
• The top five countries of origin of foreign-born persons with TB were Mexico, Philippines, Viet-
nam, India and China (Table 6).
5. Drug resistance:  1.2% of reported cases, compared to 1.0% in 2008, had primary multidrug resis-
tance, which is defined as no previous history of TB disease and resistance to at least isoniazid and 
rifampin (Table 10).
1Hispanic and non-Hispanic are ethnicities. All races are non-Hispanic. The category “non-Hispanic blacks or 
African-Americans” includes U.S. - born and foreign-born persons unless otherwise specified.   
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In 2009, the number of TB cases reported (11,545) 
and case rate (3.8 cases per 100,000) both de-
creased; this represented declines of 10.5% and 
11.3%, respectively, compared to 2008.  Since the 
1992 TB resurgence peak in the United States, the 
number of TB cases reported annually has de-
creased by approximately 57% (Table 1).
The proportion of total cases occurring in foreign-
born persons has increased every year from 1993 
- 2008.  In 2009, 59% of TB cases occurred in 
foreign-born persons, unchanged from 2008. For-
eign-born persons have accounted for the majority 
of TB cases in the United States every year since 
2001.  Moreover, the case rate among foreign-born 
persons in 2009 was approximately 11 times higher 
than among U.S.-born persons (Table 5).
Tuberculosis deaths decreased by 14.0%, from 
644 deaths in 2006 to 554 deaths in 2007, the most 
recent year for which data are available (Table 1).
Age
Since 1993, TB case rates have declined annually 
for all age groups.  TB case rates vary by well-
known factors such as age, race and ethnicity, and 
country of origin.  In 2009, TB case rates declined 
for all age groups.  The highest burden of disease 
continues to be among older adults.  In 2009, 
adults aged 65 years and older had a case rate of 
5.8 cases per 100,000, while children aged <14 
years had the lowest rate at 1.0 case per 100,000 
(Table 4).    
Race and Ethnicity
In 2003, the race and ethnicity category, “non-
Hispanic, Asian or Pacific Islander,” was split 
into “non-Hispanic Asian” and “non-Hispanic 
Native Hawaiian or Other Pacific Islander.”  In 
2009, Asians had the highest TB case rate at 23.3 
cases per 100,000, which was a slight decrease 
from 25.4 in 2008.  In 2009, Native Hawaiians 
or Other Pacific Islanders had the second-highest 
TB case rate at 16.7 cases per 100,000, which is a 
slight increase compared to 15.5 cases per 100,000 
reported in 2008.  Due to low case numbers among 
Native Hawaiians or Other Pacific Islanders, case 
rates fluctuate and must be interpreted with caution 
(Table 2).
Since 1993, TB case rates have declined between 
64% and 75% in the following racial and ethnic 
groups:  among Hispanic or Latinos from 19.9 to 
7.0 cases per 100,000; among non-Hispanic blacks 
or African-Americans from 28.5 to 7.6 cases per 
100,000; and among non-Hispanic whites from 3.6 
to .9 cases per 100,000.  In 2009, the TB case rate 
for Asians was approximately three times higher 
than that for Hispanics or blacks or African-Ameri-
cans (Table 2).
Origin of Birth
Since 1993, the TB case rate among U.S.-born 
persons has declined annually.  In 2009, the TB 
case rate for U.S.-born persons was 1.7 cases per 
100,000 representing a 77% decrease from 7.4 cas-
es per 100,000 in 1993. The TB case rate among 
foreign-born persons also declined during the same 
interval, but less substantially.  In 2009, the TB 
case rate among foreign-born persons was 18.7 
cases per 100,000 representing a 45% decrease 
from 34.0 cases per 100,000 in 1993 (Table 5). 
The proportion of TB cases among persons born in 
the United States also has declined annually since 
1993.  In 2009, 40% of TB cases were among U.S-
born persons compared to 69% in 1993 (Table 5).  
In 30 states, ≥50% of TB cases occurred among 
foreign-born persons.  In 14 states (California, 
Colorado, Connecticut, Maryland, Minnesota, Ne-
braska, New Hampshire, New Jersey, New York, 
North Dakota, Rhode Island, Utah, Vermont, and 
Washington), ≥70% of TB cases occurred among 
foreign-born persons (Table 23).
Country of Origin and World Region
From 2005 through 2009, the top five countries 
of origin of foreign-born persons with TB were 
Mexico, Philippines, Vietnam, India, and China 
(Table 6).  The distribution of TB cases by world 
region of origin reflects immigration patterns 
among persons settling in the United States.2   Of 
the 6,854 TB cases reported among foreign-born 
persons in 2009, 40% occurred among persons 
born in the Americas region, and 30% occurred 
among persons born in the Western Pacific region 
2 World Health Organization (WHO).  Global Tu-
berculosis Control 2009:  Epidemiology, Strategy, 
Financing.  Geneva, Switzerland:  World Health 
Organization, 2009 (WHO/HTM/TB/2009.411)
5(Table 19).  From 1993 to 2009, the proportion of 
cases increased among persons born in the East-
ern Mediterranean region (3% in 1993 to 4.6% in 
2009), the Southeast Asia region (6% in 1993 to 
13% in 2009), and the African region (2% in 1993 
and 8% in 2009) (Table 19).
Multidrug-Resistant Tuberculosis
From 1993, when the RVCT was expanded to 
include drug-susceptibility results, the propor-
tion of patients with primary multidrug-resistant 
TB (MDR TB), which is defined as no previous 
history of TB disease and resistance to at least 
isoniazid and rifampin, decreased from 2.5% to 
1.0% by 1998. However, there was an increase in 
the number of MDR TB cases from 89 in 2008, 
(1.0% percent of the total number of reported TB 
cases), to 94 in 2009(1.2% of the total number of 
reported TB cases). Since 1998, the percentage of 
U.S.-born patients with MDR TB has remained ≤ 
0.7%.  However, of the total number of reported 
primary MDR TB cases, the proportion occurring 
in foreign-born persons increased from 25.3% (103 
of 407) in 1993 to 88% (83 of 94) in 2009 (Table 
10).
Extensively Drug-Resistant Tuberculosis
CDC has included an updated case count of ex-
tensively drug-resistant TB (XDR TB) cases from 
1993 to 2009 in the slide set that accompanies this 
report.  XDR TB is defined as resistance to isoni-
azid and rifampin plus resistance to any fluoroqui-
nolone and at least one of three injectable second-
line anti-TB drugs (i.e., amikacin, kanamycin, 
or capreomycin)3,4.  No cases of XDR TB were 
reported during 2009, compared to four cases in 
2008.
Tuberculosis Therapy
The proportion of TB patients prescribed an initial 
treatment regimen of three or more anti-TB drugs 
increased from 72% in 1993 to 87% in 2009.  The 
3 Centers for Disease Control and Prevention (CDC).  
Notice to readers:  revised definition of XDR-TB.  
MMWR 2006; 55:1176 
4 WHO.  Extensively drug-resistant tuberculosis 
(XDR-TB):  recommendations for prevention and 
control.  Weekly Epidemiological Record 2006; 81:  
430–432 
proportion of patients who completed therapy 
within 1 year increased from 64% in 1993 to 
84% in 2007 (the latest year for which complete 
outcome data are available).  The proportion of 
persons receiving directly observed therapy at 
least for a portion of the treatment duration also 
increased from 36% in 1993 to 89% in 2007, the 
latest year for which complete outcome data are 
available (Table 12).
Summary 
Case count and case rate declines in 2009 were 
considerably steeper than in recent years.  During 
2000 - 2008, the TB rate decreased an average of 
3.8% annually5, compared to a decrease of 11.3% 
in 2009.  Through epidemiologic assessments 
and confirmation with reporting area, surveil-
lance artifact has been excluded as a cause of the 
decline. Although 2009 TB case reports and annual 
TB rate reached all-time lows in the United States, 
disproportionately high rates of TB persist among 
foreign-born persons and racial/ethnic minorities, 
particularly among U.S.-born blacks.  To achieve 
TB elimination, intensified efforts are needed to 
address the persistent disparities that exist between 
U.S.-born and foreign-born persons, and between 
whites and minorities in the United States.
To address the high TB case rates among foreign-
born persons, CDC is collaborating with other 
national and international public health organi-
zations to 1) improve overseas screening of im-
migrants and refugees by systematically moni-
toring and evaluating the screening process; 2) 
strengthen the current notification system that 
alerts local health departments about the arrival of 
immigrants or refugees who have suspected TB 
to enhance the evaluation and treatment of such 
persons; 3) improve coordination of TB control 
activities between the United States and Mexico 
to ensure completion of treatment among TB 
patients who cross the border; 4) test recent arriv-
als from high-incidence countries for latent TB 
infection and monitor treatment completion; and 
5) survey foreign-born TB patients in the United 
States to determine opportunities for improving 
prevention and control interventions.  In addition, 
5 CDC. Decrease in reported tuberculosis cases -- 
United States, 2009. MMWR 2010;59:289-94. 
6CDC continues to strengthen collaborations with 
international partners, including the World Health 
Organization’s Stop TB Partnership, to improve 
TB control in high-incidence countries.
Accelerating progress in national TB elimination 
activities will require broader prevention efforts 
among high-risk population groups such as black 
or African-American and Asian communities, 
persons who are incarcerated, persons with excess 
alcohol and drug use, persons with human im-
munodeficiency virus infection, persons who are 
homeless, and persons living in poverty with lim-
ited access to medical care and stable housing.  
In addition, low-incidence areas in the United 
States require continued support to maintain the 
capacity and expertise needed to respond to future 
TB cases6 especially in light of changing immigra-
tion patterns.  CDC has updated the comprehensive 
national action plan to reflect the alignment of 
CDC priorities with the 2000 Institute of Medicine 
report on TB and to ensure that priority prevention 
activities are undertaken with optimal collaboration 
and coordination among national and international 
public health partners7,8.  
6 CDC.  Progressing toward tuberculosis elimination 
in low-incidence areas of the United States:  Recom-
mendations of the Advisory Council for the Elimina-
tion of Tuberculosis.  MMWR 2002; 51 (No. RR-5): 
1–20 
7 Institute of Medicine.  Ending Neglect:  The Elimi-
nation of Tuberculosis in the United States.  Washing-
ton, DC:  National Academy Press, 2000. 
8 CDC.  CDC’s Response to Ending Neglect:  The 
Elimination of Tuberculosis from the United States.  
Atlanta, GA:  U.S. Department of Health and Human 
Services, CDC, 2000. 
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Technical Notes
National Surveillance for Tuberculosis
Reporting areas (i.e., the 50 states, the District of 
Columbia, New York City, Puerto Rico, and other 
U.S. jurisdictions in the Pacific and Caribbean1) report 
tuberculosis (TB) cases to CDC using a standard case 
report form, Report of Verified Case of Tuberculosis 
(RVCT), through 2009. TB cases are verified accord-
ing to the Tuberculosis Case Definition for Public 
Health Surveillance in Appendix A. TB cases are 
reported and counted according to the Recommenda-
tions for Reporting and Counting Tuberculosis Cases 
in Appendix B.  
TB Case Definition
In 2009 the case definition was modified. TB cases 
are verified according to the following specified labo-
ratory and clinical criteria:
Laboratory criteria for diagnosis
A case may be verified by the laboratory case defini-
tion with at least one of the following criteria: 1.) 
isolation of M. tuberculosis complex from a clinical 
specimen, OR 2.) demonstration of M. tuberculosis 
complex from a clinical specimen by nucleic acid 
amplification test (NAAT), OR 3.) demonstration of 
acid-fast bacilli (AFB) in a clinical specimen when 
a culture has not been or cannot be obtained or is 
falsely negative or contaminated.
Clinical case criteria
 A case may be verified by the clinical case defini-
tion in the presence of ALL of the following clini-
cal criteria: 1.) a positive tuberculin skin test (TST) 
result or positive interferon gamma release assay 
(IGRA) for M. tuberculosis, AND 2.) other signs and 
symptoms compatible with TB  (e.g., abnormal chest 
radiograph, abnormal chest computerized tomography 
scan or other chest imaging study, or clinical evidence 
of current disease, AND 3.) treatment with two or 
more anti-TB drugs, AND 4.) a completed diagnostic 
evaluation.  
Provider Diagnosis
 Provider diagnosis is not a component of the case 
definition for TB as described in Appendix A. How-
ever, when cases of TB are diagnosed but do not 
meet either the clinical or laboratory case definition, 
reporting areas have the option of verifying TB cases 
based on provider diagnosis as described in Ap-
pendix B. Through 2008, the RVCT did not collect 
information on results from IGRA.  If an IGRA was 
performed in lieu of the TST, then the RVCT would 
have indicated that the TST was not performed. Thus, 
culture- and smear-negative cases without a TST that 
are diagnosed by a positive IGRA result prior to 2008 
were considered to have been confirmed by provider 
diagnosis.  However, starting in 2009, positive results 
for an IGRA are included as part of the clinical case 
definition for TB confirmation. Anergic patients with 
a clinical presentation consistent with TB but with-
out laboratory evidence of M. tuberculosis complex 
would also be an example of provider diagnosis and 
one which has not changed over time.
TB Case Verification Criteria Calculation
The software for TB surveillance developed by CDC 
includes a calculated variable for TB case verifica-
tion called “Vercrit” which was modified in 2009.  
The new variables: Nucleic Acid Amplification Test 
Result, Interferon Gamma Release Assay (IGRA) 
for Mycobacterium tuberculosis at Diagnosis and 
Initial Chest CT Scan or Other Chest Imaging 
Study were added in the Vercrit calculation.
“Vercrit” is calculated by using the following criteria 
in hierarchical order:
Positive culture1. 
Positive nucleic acid amplification test2. 
Positive acid-fast bacilli test3. 
Clinical case confirmation4. 
Provider diagnosis5. 
Changes in Reporting and Counting TB Cases
In 2009, the Recommendations for Reporting and 
Counting Tuberculosis Cases in Appendix B were 
modified. TB cases that are verified but not countable 
for morbidity statistics can now be reported to CDC 
as a measure of programmatic and case management 
burden. However, data on noncountable TB cases are 
incomplete and not included in this report. 
The recommendations for counting TB cases among 
immigrants, refugees and foreign visitors were 
revised based on the recommendations in the 2007 
Technical Instructions for Tuberculosis Screening 
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and Treatment for Panel Physicians.2 Regardless of 
Class B or citizenship status, immigrants and refu-
gees examined after arriving in the United States and 
diagnosed with clinically active TB requiring anti-TB 
medications should be reported and counted by the 
locality of their current residence at the time of diag-
nosis. Foreign visitors diagnosed with TB, receiving 
anti-TB therapy, and planning to remain in the United 
States for 90 days or more should be reported and 
counted by the locality of current residence.
New and Expanded RVCT Variables
Data on demographic, clinical, laboratory, initial 
treatment, and treatment outcomes are collected 
through the RVCT’s three data collection reports:
Report of Verified Case of Tuberculosis: for 1. 
all patients with a verified case of TB.
Initial Drug Susceptibility Report (Follow-2. 
Up Report 1): for all patients who had a 
culture that was positive for M. tuberculosis 
complex. 
Case Completion Report (Follow-Up Report 3. 
2): for all patients who were alive when TB 
was diagnosed. 
In 2009, the RVCT was modified and expanded to 
include 11 additional variables. Modifications to the 
RVCT accommodate the changing epidemiology of 
TB in terms of risk factors, new drug treatments, and 
enhanced laboratory capacity for diagnostic tests.  
These new variables will be made available in a 
future Annual Report.
The instructions for completing the RVCT forms 
and the definitions for all data items are available 
at: CDC. Report of Verified Case of Tuberculosis 
(RVCT) Instruction Manual.  Atlanta, GA: U.S. De-
partment of Health and Human Services, CDC, June 
2009. 
Tabulation and Presentation of TB Data  
This report presents summary data for TB cases 
reported to CDC in 2009. TB cases are tabulated 
by year in which the reporting area verified that the 
patient had TB and included the patient in its official 
annual TB case count. Since 2004, the published 
report has reflected updated information on the 
numbers of cases of confirmed TB for each year from 
1993 onward. Totals for the United States include 
2CDC. Immigration Requirements: Technical Instructions for Tuberculosis Screening and Treatment, 2007.  Atlanta: CDC, Division of 
Global Migration and Quarantine, revised September 2007; http://www.cdc.gov/ncidod/dq/pdf/ti_tb_8_9_2007.pdf.  
data from the 50 states, the District of Columbia, and 
New York City.  
Trend data are presented in Tables 1 through 14. Age 
group tabulations are based on the patient’s age in 
the month and year the patient was reported to the 
health department as a suspected TB case.  State or 
metropolitan area data tabulations are based on the 
patient’s residence at diagnosis of TB.
Rates
Rates are expressed as the number of cases reported 
each calendar year per 100,000 population. Popula-
tion denominators used in calculating TB rates were 
based on official census and midyear (July 1) post-
censal estimates from the U.S. Census Bureau.  In 
Tables 1 and 20, the U.S. total populations for 2000 - 
2009 were obtained from the Annual Estimates of the 
Population for the United States and the individual 
States, and for Puerto Rico (July 1, 2000 – July 1, 
2009). In 2003, two modifications were made to the 
RVCT form: 1.) entries for multiple race (two or 
more races reported for a person) were allowed, and 
2.) the previous category of “Asian/Pacific Islander” 
was divided into “Asian” and “Native Hawaiian or 
Other Pacific Islander.” To calculate rates in Tables 2 
and 3, denominators for 2000 - 2009 were obtained 
from the Annual Estimates of the Population by Sex, 
Race, and Hispanic or Latino Origin for the United 
States: April 1, 2000, - July 1, 2009. 
To calculate rates for Table 4, denominators were 
obtained from the Annual Estimates of the Popula-
tion by Sex and Five-Year Age Groups for the United 
States: April 1, 2000, to July 1, 2009.  Denominators 
for computing 2009 rates in Table 16 were obtained 
from U.S. Census Bureau Monthly Postcensal Resi-
dent Population, by single year of age, sex, race, and 
Hispanic origin: July 1, 2009. In 2004, the method 
for calculating the annual percentage change in the 
TB case rate was modified. Unrounded figures are 
applied to calculate the percentage change in the case 
rate.
In Table 5, the populations for U.S.-born and foreign-
born persons for 1993 and 1994 were obtained from 
Quarterly Estimates of the United States Foreign-
born and Native Resident Populations: April 1, 1990, 
- July 1, 1999.  Denominators for computing the 
1995–2009 rates were based on extrapolations from 
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the U.S. Census Current Population Survey (March 
Supplement). 
Mortality Data
Official TB mortality statistics for the United States 
are compiled by the National Center for Health 
Statistics (NCHS), CDC. The annual mortality rate 
is calculated as the number of deaths due to TB in 
that year, divided by the estimated population for the 
year, multiplied by 100,000 (Table 1). The number of 
deaths for 2007 (preliminary) was obtained from the 
National Center for Health Statistics, National Vital 
Statistics Report, Vol. 56, No. 16, June 11, 2009. The 
numbers of deaths for years subsequent to 2007 were 
not available at the time of this publication.
Completion of Tuberculosis Therapy
Tables 12, 41, 43, and 44 present rates of completion 
of TB therapy (COT).  Data collected by RVCT Fol-
low Up Report-2 on date and reason therapy stopped 
(e.g., patient completed therapy) were used to calcu-
late rates of COT.  Cases were stratified by the indi-
cated length of therapy, based on American Thoracic 
Society/CDC/Infectious Diseases Society of America 
treatment guidelines3 in effect during the period cov-
ered, and the patient’s initial drug susceptibility test 
results, age, and site of disease.  The adequacy of the 
treatment regimen (e.g., the sufficiency of the dura-
tion of therapy, the appropriateness of the prescribed 
TB drugs) was not evaluated in this analysis. Ac-
quired drug resistance from an inadequate duration of 
therapy was also not considered in this analysis.
In Table 41, the first column shows the total num-
ber of cases reported during 2007.  The remaining 
columns are grouped under three headings: therapy 
of 1 year or less indicated therapy, greater than 1 year 
indicated, and overall. Patients eligible to complete 
therapy within one year had to have been alive at di-
agnosis, and initiated therapy with at least one drug. 
Eligible patients did not have rifampin resistance, did 
not die during therapy, and did not have meningeal 
TB, regardless of age.  In addition, TB cases under 
the age of 15 were not eligible to complete therapy 
within one year if they had disseminated disease (dis-
seminated disease is defined as miliary tuberculosis 
and/or a positive tuberculosis blood culture). Patients 
with culture-negative disease, those with an unknown 
culture status, and those with culture-positive disease 
but unknown initial drug-susceptibility test results 
were included under the category of 1 year or less of 
therapy indicated.    
In Table 41, each group under an indicated length of 
therapy has an initial column showing the number 
of cases in persons who were alive at diagnosis and 
prescribed an initial regimen of one or more drugs, 
and who did not die during therapy. This number was 
used as the denominator in COT rate calculations.
COT rates, shown as percentages, were only calcu-
lated for areas reporting reason therapy stopped for 
at least 90% of cases shown in the overall column. 
For the group with an indicated length of therapy of 
1 year or less, rates are shown for both COT in 1 year 
or less (COT <1 year) and for COT, regardless of 
duration (i.e., duration of therapy <1 year, >1 year, or 
unknown).  For COT <1 year, the numerator included 
only those patients completing therapy in <366 days 
(based on the dates therapy started and stopped).  
Patients with missing dates were classified as “treat-
ment not completed” for this calculation.
Rates of COT, regardless of duration, were calculated 
by dividing the number of patients reported as having 
completed therapy by the number of total eligible pa-
tients.  Patients with an outcome other than complet-
ed therapy (i.e., moved, lost, refused treatment, and 
other) were classified as “treatment not completed.”  
Patients with an unknown outcome were also classi-
fied as “treatment not completed.”  For the remaining 
two groups of indicated therapy length (greater than 
1 year and overall), only rates of COT, regardless of 
duration, are presented.  Table 12 provides rates for 
COT <1 year and for COT, regardless of duration, 
only for the group with an indicated therapy of 1 year 
or less.  Table 43 presents rates of COT by ethnic-
ity and non-Hispanic race and by state for those in 
whom therapy less than 1 year was indicated.
Because streptomycin is no longer being used as part 
of the standard treatment for TB disease, streptomy-
cin has been removed from the calculated variable 
for initial drug regimen. Consequently, in this report, 
the isoniazid, rifampin, pyrazinamide (IRZ), etham-
butol, streptomycin (E/S) column was removed  from 
Tables 12 and 35.
3CDC.  Treatment of Tuberculosis, American Thoracic Society, CDC, and the Infectious Diseases Society of America.  MMWR 
2003;52(No.RR-11):1-77.  
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Site of TB Disease
Miliary disease is classified as both an extrapulmo-
nary and a pulmonary form of TB (Tables 8, 9, 26, 
27, and 47).  In publications prior to 1997, miliary 
disease was classified as extrapulmonary TB unless 
pulmonary disease was reported as the major site 
of TB disease.  In 2009, miliary disease could not 
be classified as a site of TB disease because it is a 
clinical or radiologic finding and should be recorded 
under Initial Chest Radiograph, Initial Chest CT 
Scan or Other Chest Imaging Study.
Reporting of HIV Status 
Table 37 shows information on HIV status for 
persons with TB aged 25–44 years, the age group in 
which 71% of AIDS cases occur (CDC. HIV/AIDS 
Surveillance Report 2007; 15).  The information on 
HIV status for TB cases reported in 2009 is incom-
plete.  Reasons for incomplete reporting of HIV test 
results to the national TB surveillance system include 
concerns about confidentiality, which may limit the 
exchange of data between TB and HIV/AIDS pro-
grams; laws and regulations in certain states and local 
jurisdictions that have been interpreted as prohibiting 
the HIV/AIDS program from sharing the HIV status 
of TB patients with the TB program, or from report-
ing patients with TB and AIDS to the TB program; 
and reluctance by health care providers to report HIV 
test results to the TB surveillance program staff.  In 
addition, health care providers may not offer HIV 
counseling, testing, and referral to some TB patients 
because of a lack of resources or of appropriately 
trained staff, or due to the perception that selected 
patients (e.g., foreign-born persons) are not at risk for 
HIV infection.
Data on the HIV-infection status of reported TB cases 
should be interpreted with caution.  These data are 
not representative of all TB patients with HIV infec-
tion.  HIV testing is performed after a patient re-
ceives counseling and gives informed consent.  Since 
testing is voluntary, some TB patients may decline 
HIV testing.  TB patients who are tested anonymous-
ly may choose not to share the results of HIV testing 
with their health care provider.  TB patients managed 
in the private sector may receive confidential HIV 
testing, but results may not be reported to the TB 
program in the health department.  In addition, many 
factors may influence HIV testing of TB patients, 
including the extent to which testing is targeted 
or routinely offered to specific groups (e.g., 25- to 
44-year-old males, injecting drug users, homeless 
persons), and the availability of and access to HIV 
testing services.  These data may overrepresent or 
underrepresent the proportion of TB patients known 
to be HIV infected in a reporting area.
 
Primary Occupation for the Past Year
Table 38, except for ten states, now reflects the new 
2009 RVCT variable, Primary Occupation Within 
the Past Year, which replaces the Occupation 
Within Past 24 months of TB diagnosis in previous 
reports. “Multiple Occupation” was removed and the 
“Retired” and “Not Seeking Employment” categories 
were added.
Metropolitan Statistical Areas
Tables 46 through 50 present data by metropolitan 
statistical areas (MSAs) with an estimated 2008 
population of 500,000 or more.  MSAs are defined by 
the federal Office of Management and Budget, and 
the definitions effective as of November 2008 were 
used for this publication (http://www.whitehouse.
gov/sites/default/files/omb/bulletins/fy2009/09-01.
pdf).  On June 6, 2003, the OMB announced new 
MSA definitions based on Census 2000 data and the 
information has been updated annually. Some MSA’s 
added or dropped counties and some MSA’s merged. 
The MSA definitions apply to all areas except the 
six New England states; for these states, the New 
England County Metropolitan Areas (NECMAs) are 
used.  MSAs are named for a central city in the MSA 
or NECMA, may include several cities and coun-
ties, and may cross state boundaries.  For example, 
the TB cases and case rates presented for the District 
of Columbia in Table 20 include only persons resid-
ing within the geographic boundaries of the District.  
However, the TB cases and case rates for the Wash-
ington, D.C., MSA (Table 46) include persons resid-
ing within the several counties in the metropolitan 
area, including counties in Maryland, Virginia, and 
West Virginia.   
A city/MSA with incomplete or unavailable data was 
not included in the tables and some cities or MSA’s 
total numbers may be underreported due to missing 
information.
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Morbidity Trend Tables
United States
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15
1953 84,304 52.6 -- -- 19,707 12.4 -- --
1954 79,775 48.9 -5.4 -7.0 16,527 10.2 -16.1 -17.7
1955 77,368 46.6 -3.0 -4.7 15,016 9.1 -9.1 -10.8
1956 69,895 41.4 -9.7 -11.1 14,137 8.4 -5.9 -7.7
1957 67,149 39.0 -3.9 -5.8 13,390 7.8 -5.3 -7.1
1958 63,534 36.3 -5.4 -6.9 12,417 7.1 -7.3 -9.0
1959 57,535 32.4 -9.4 -10.7 11,474 6.5 -7.6 -8.5
1960 55,494 30.7 -3.5 -5.2 10,866 6.0 -5.3 -7.7
1961 53,726 29.2 -3.2 -4.9 9,938 5.4 -8.5 -10.0
1962 53,315 28.6 -0.8 -2.1 9,506 5.1 -4.3 -5.6
1963 54,042 28.6 1.4 0.0 9,311 4.9 -2.1 -3.9
1964 50,874 26.5 -5.9 -7.3 8,303 4.3 -10.8 -12.2
1965 49,016 25.2 -3.7 -4.9 7,934 4.1 -4.4 -4.7
1966 47,767 24.3 -2.5 -3.6 7,625 3.9 -3.9 -4.9
1967 45,647 23.0 -4.4 -5.3 6,901 3.5 -9.5 -10.3
1968 42,623 21.2 -6.6 -7.8 6,292 3.1 -8.8 -11.4
1969 39,120 19.3 -8.2 -9.0 5,567 2.8 -11.5 -9.7
1970 37,137 18.1 -5.1 -6.2 5,217 2.6 -6.3 -7.1
1971 35,217 17.0 -5.2 -6.1 4,501 2.2 -13.7 -15.4
1972 32,882 15.7 -6.6 -7.6 4,376 2.1 -2.8 -4.5
1973 30,998 14.6 -5.7 -7.0 3,875 1.8 -11.4 -14.5
1974 30,122 14.1 -2.8 -3.4 3,513 1.7 -9.3 -5.6
1975 33,989 15.7 -- -- 3,333 1.6 -5.1 -5.9
1976 32,105 14.7 -5.5 -6.4 3,130 1.5 -6.1 -6.3
1977 30,145 13.7 -6.1 -6.8 2,968 1.4 -5.2 -6.7
1978 28,521 12.8 -5.4 -6.6 2,914 1.3 -1.8 -7.1
19792 27,669 12.3 -3.0 -3.9 2,007 0.9 -31.1 -30.8
1980 27,749 12.2 0.3 -0.7 1,978 0.9 -1.4 0.0
1981 27,373 11.9 -1.4 -2.3 1,937 0.8 -2.1 -11.1
1982 25,520 11.0 -6.8 -7.7 1,807 0.8 -6.7 0.0
1983 23,846 10.2 -6.6 -7.4 1,779 0.8 -1.5 0.0
1984 22,255 9.4 -6.7 -7.5 1,729 0.7 -2.8 -12.5
1985 22,201 9.3 -0.2 -1.1 1,752 0.7 1.3 0.0
1986 22,768 9.5 2.6 1.6 1,782 0.7 1.7 0.0
1987 22,517 9.3 -1.1 -2.0 1,755 0.7 -1.5 0.0
1988 22,436 9.2 -0.4 -1.3 1,921 0.8 9.5 14.3
1989 23,495 9.5 4.7 3.7 1,970 0.8 2.6 0.0
1990 25,701 10.3 9.4 8.2 1,810 0.7 -8.1 -12.5
1991 26,283 10.4 2.3 0.9 1,713 0.7 -5.4 0.0
1992 26,673 10.4 1.5 0.1 1,705 0.7 -0.5 0.0
1993 25,107 9.7 -5.9 -7.1 1,631 0.6 -4.3 -14.3
1994 24,205 9.2 -3.6 -4.8 1,478 0.6 -9.4 0.0
1995 22,728 8.5 -6.1 -7.2 1,336 0.5 -9.6 -16.7
1996 21,210 7.9 -6.7 -7.8 1,202 0.5 -10.0 0.0
1997 19,751 7.2 -6.9 -8.0 1,166 0.4 -3.0 -20.0
1998 18,287 6.6 -7.4 -8.5 1,112 0.4 -4.6 0.0
1999 17,501 6.3 -4.3 -5.4 930 0.3 -16.4 -25.0
2000 16,309 5.8 -6.8 -7.8 776 0.3 -16.6 0.0
2001 15,945 5.6 -2.2 -3.2 764 0.3 -1.6 0.0
2002 15,056 5.2 -5.6 -6.5 784 0.3 2.6 0.0
2003 14,836 5.1 -1.5 -2.3 711 0.2 -10.2 -33.3
2004 14,499 4.9 -2.3 -3.2 662 0.2 -6.9 0.0
2005 14,064 4.8 -3.0 -3.9 648 0.2 -2.1 0.0
2006 13,734 4.6 -2.3 -3.3 644 0.2 -0.6 0.0
2007 13,280 4.4 -3.3 -4.3 554 0.2 -14.0 0.0
2008 12906 4.2 -2.8 -3.7 … … … …
2009 11545 3.8 -10.5 -11.3 … … … …
Table 1. Tuberculosis Cases, Case Rates per 100,000 Population, Deaths, and Death Rates 
per 100,000 Population, and Percent Change:  United States, 1953–2009
Tuberculosis Cases Tuberculosis Deaths
Percent ChangePercent Change
Number Rate Number RateNumber Number1Rate Rate1Year
1 Official tuberculosis mortality statistics were compiled by the National Center for Health Statistics, CDC, National Vital Statistics 
Reports. TB mortality statistics were unavailable at time of publication for years after 2007.
2 The large decrease in death rate in 1979 occurred because late effects of tuberculosis (e.g., bronchiectasis or fibrosis) and pleurisy 
with effusion (without mention of cause) are no longer included in tuberculosis deaths.
Percent change in tuberculosis death rates is calculated with rounded figures. See Technical Notes (page 9). 
Note: 1993 to 2009 tuberculosis case counts and rates updated as of July 1, 2010, using Bridged-Race 1990–1999 Intercensal 
Population Estimates for 1990–1999 (ftp://ftp.cdc.gov/pub/health_statistics/nchs/datasets/nvss/bridgepop/documentationbridge-
dintercena1.doc) (accessed August 30, 2010) and Annual Estimates of the Population for the United States and States, and for 
Puerto Rico (July 1, 2000– July 1, 2009)  (www.census.gov/popest/states/tables/NST-EST2009-01.xls) (accessed August 30, 2010).  
Percentage change results reported to one decimal. Ellipses indicate data not available. Case data after 1974 are not comparable to 
prior years due to changes in the surveillance case definition that became effective in 1975.  See Surveillance Slides #2 and #3.
16
19
93
25
10
7
51
40
(2
0.
0)
19
.9
…
…
…
27
2
(1
.0
)
14
.0
…
…
…
34
54
(1
4.
0)
41
.2
89
48
(3
6.
0)
28
.5
…
…
…
69
03
(2
7.
0)
3.
6
39
0
(2
.0
)
19
94
24
20
5
50
17
(2
1.
0)
18
.6
…
…
…
32
7
(1
.0
)
16
.4
…
…
…
36
33
(1
5.
0)
41
.4
83
83
(3
5.
0)
26
.2
…
…
…
65
73
(2
7.
0)
3.
4
27
2
(1
.0
)
19
95
22
72
8
48
34
(2
1.
0)
17
.2
…
…
…
32
0
(1
.0
)
15
.7
…
…
…
38
32
(1
7.
0)
41
.7
75
54
(3
3.
0)
23
.2
…
…
…
59
71
(2
6.
0)
3.
1
21
7
(1
.0
)
19
96
21
21
0
44
92
(2
1.
0)
15
.2
…
…
…
28
7
(1
.0
)
13
.7
…
…
…
36
62
(1
7.
0)
38
.1
70
97
(3
3.
0)
21
.5
…
…
…
54
87
(2
6.
0)
2.
8
18
5
(1
.0
)
19
97
19
75
1
42
18
(2
1.
0)
13
.7
…
…
…
26
4
(1
.0
)
12
.3
…
…
…
36
83
(1
9.
0)
36
.6
66
04
(3
3.
0)
19
.7
…
…
…
48
24
(2
4.
0)
2.
5
15
8
(1
.0
)
19
98
18
28
7
40
90
(2
2.
0)
12
.6
…
…
…
25
4
(1
.0
)
11
.5
…
…
…
35
16
(1
9.
0)
33
.5
58
23
(3
2.
0)
17
.0
…
…
…
44
75
(2
4.
0)
2.
3
12
9
(1
.0
)
19
99
17
50
1
38
64
(2
2.
0)
11
.4
…
…
…
24
2
(1
.0
)
10
.7
…
…
…
35
19
(2
0.
0)
32
.1
55
50
(3
2.
0)
16
.0
…
…
…
42
28
(2
4.
0)
2.
1
98
(1
.0
)
20
00
16
30
9
38
03
(2
3.
0)
10
.7
…
…
…
23
2
(1
.0
)
11
.0
…
…
…
33
92
(2
1.
0)
31
.3
51
49
(3
2.
0)
15
.0
…
…
…
36
38
(2
2.
0)
1.
9
95
(1
.0
)
20
01
15
94
5
40
09
(2
5.
0)
10
.8
…
…
…
22
6
(1
.0
)
10
.6
…
…
…
34
99
(2
2.
0)
31
.2
47
82
(3
0.
0)
13
.7
…
…
…
33
46
(2
1.
0)
1.
7
83
(1
.0
)
20
02
15
05
6
39
74
(2
6.
0)
10
.3
…
…
…
18
5
(1
.0
)
8.
6
…
…
…
33
23
(2
2.
0)
28
.6
44
67
(3
0.
0)
12
.7
…
…
…
30
42
(2
0.
0)
1.
5
65
(0
.0
)
20
03
14
83
6
41
05
(2
8.
0)
10
.3
37
(0
.0
)
1.
0
17
9
(1
.0
)
8.
2
34
60
(2
3.
0)
29
.9
…
…
…
41
60
(2
8.
0)
11
.7
64
(0
.0
)
16
.2
27
92
(1
9.
0)
1.
4
39
(0
.0
)
20
04
14
49
9
41
81
(2
9.
0)
10
.2
34
(0
.0
)
0.
9
15
7
(1
.0
)
7.
1
33
36
(2
3.
0)
28
.0
…
…
…
40
69
(2
8.
0)
11
.4
63
(0
.0
)
15
.6
26
31
(1
8.
0)
1.
3
28
(0
.0
)
20
05
14
06
4
40
42
(2
9.
0)
9.
5
45
(0
.0
)
1.
1
15
2
(1
.0
)
6.
8
32
04
(2
3.
0)
26
.1
…
…
…
39
57
(2
8.
0)
10
.9
54
(0
.0
)
13
.1
25
67
(1
8.
0)
1.
3
43
(0
.0
)
20
06
13
73
4
40
52
(3
0.
0)
9.
2
39
(0
.0
)
0.
9
16
3
(1
.0
)
7.
2
32
98
(2
4.
0)
26
.1
…
…
…
37
32
(2
7.
0)
10
.2
52
(0
.0
)
12
.3
23
86
(1
7.
0)
1.
2
12
(0
.0
)
20
07
13
28
0
38
74
(2
9.
0)
8.
5
24
(0
.0
)
0.
6
13
4
(1
.0
)
5.
8
34
42
(2
6.
0)
26
.5
…
…
…
34
74
(2
6.
0)
9.
4
95
(1
.0
)
22
.1
22
09
(1
7.
0)
1.
1
28
(0
.0
)
20
08
12
90
6
38
00
(2
9.
0)
8.
1
41
(0
.0
)
0.
9
13
7
(1
.0
)
5.
9
33
97
(2
6.
0)
25
.4
…
…
…
32
86
(2
5.
0)
8.
8
68
(1
.0
)
15
.5
21
47
(1
7.
0)
1.
1
30
(0
.0
)
20
09
11
54
5
33
80
(2
9.
0)
7.
0
39
(0
.0
)
0.
9
10
2
(1
.0
)
4.
3
31
92
(2
8.
0)
23
.3
…
…
…
28
68
(2
5.
0)
7.
6
75
(1
.0
)
16
.7
18
29
(1
6.
0)
0.
9
60
(1
.0
)
Ye
ar
 Ta
bl
e 
2.
  T
ub
er
cu
lo
si
s 
C
as
es
, P
er
ce
nt
ag
es
, a
nd
 C
as
e 
R
at
es
 p
er
 1
00
,0
00
 P
op
ul
at
io
n 
by
 H
is
pa
ni
c 
Et
hn
ic
ity
 a
nd
 n
on
-H
is
pa
ni
c 
R
ac
e:
 
U
ni
te
d 
St
at
es
, 1
99
3–
20
09
W
hi
te
1 P
er
so
ns
 o
f H
is
pa
ni
c 
or
 L
at
in
o 
et
hn
ic
ity
 m
ay
 b
e 
of
 a
ny
 ra
ce
 o
r m
ul
tip
le
 ra
ce
.
 2 In
di
ca
te
s 
tw
o 
or
 m
or
e 
ra
ce
s 
re
po
rte
d 
fo
r a
 p
er
so
n.
 C
at
eg
or
y 
fir
st
 re
po
rte
d 
in
 2
00
3.
 D
oe
s 
no
t i
nc
lu
de
 p
er
so
ns
 o
f H
is
pa
ni
c 
or
 L
at
in
o 
or
ig
in
.
 3 A
si
an
 ra
ce
 fi
rs
t r
ep
or
te
d 
in
 2
00
3.
 4 A
si
an
 o
r P
ac
ifi
c 
Is
la
nd
er
 ra
ce
 re
po
rte
d 
19
93
–2
00
2.
 5 N
at
iv
e 
H
aw
ai
ia
n 
or
 O
th
er
 P
ac
ifi
c 
Is
la
nd
er
 ra
ce
 fi
rs
t r
ep
or
te
d 
in
 2
00
3.
 
6 T
he
 h
ig
he
r c
ou
nt
 fo
r u
nk
no
w
n 
or
 m
is
si
ng
 ra
ce
 re
su
lts
 fo
r 1
99
3 
- 2
00
1 
re
fle
ct
 th
e 
im
pa
ct
 o
f t
he
 tr
an
si
tio
na
l p
er
io
d 
of
 in
co
rp
or
at
in
g 
ne
w
 ra
ce
 d
efi
ni
tio
ns
 fo
r A
si
an
, N
at
iv
e 
H
aw
ai
ia
n,
 a
nd
 M
ul
tip
le
 R
ac
e 
in
 2
00
3.
 N
ot
e:
   
P
re
vi
ou
sl
y 
pu
bl
is
he
d 
ra
te
s 
fo
r 1
99
3–
19
99
 h
av
e 
be
en
 u
pd
at
ed
 u
si
ng
 B
rid
ge
d-
R
ac
e 
19
90
–1
99
9 
In
te
rc
en
sa
l P
op
ul
at
io
n 
E
st
im
at
es
 fo
r 1
99
3–
19
99
  (
ht
tp
://
w
w
w
.c
dc
.g
ov
/n
ch
s/
nv
ss
/b
rid
ge
d_
ra
ce
.
ht
m
) (
ac
ce
ss
ed
 A
ug
us
t 3
0,
 2
01
0)
.  
D
en
om
in
at
or
s 
fo
r c
om
pu
tin
g 
20
00
–2
00
9 
ca
se
 ra
te
s 
w
er
e 
ob
ta
in
ed
 fr
om
 th
e 
A
nn
ua
l E
st
im
at
es
 o
f t
he
 P
op
ul
at
io
n 
by
 S
ex
, R
ac
e,
 a
nd
 H
is
pa
ni
c 
or
 L
at
in
o 
O
rig
in
 fo
r 
th
e 
U
ni
te
d 
S
ta
te
s:
 A
pr
il 
1,
 2
00
0,
 to
 J
ul
y 
1,
 2
00
9 
(h
ttp
://
w
w
w
.c
en
su
s.
go
v/
po
pe
st
/n
at
io
na
l/a
sr
h/
N
C
-E
S
T2
00
9/
N
C
-E
S
T2
00
9-
03
.x
ls
) (
ac
ce
ss
ed
 A
ug
us
t 2
6,
 2
01
0)
.  
C
as
e 
co
un
ts
 fo
r r
ac
e 
ca
te
go
rie
s 
(A
m
er
ic
an
 In
di
an
 o
r A
la
sk
a 
N
at
iv
e,
 A
si
an
, B
la
ck
 o
r A
fri
ca
n 
A
m
er
ic
an
, N
at
iv
e 
H
aw
ai
ia
n 
or
 O
th
er
 P
ac
ifi
c 
Is
la
nd
er
, a
nd
 W
hi
te
) d
o 
no
t i
nc
lu
de
 p
er
so
ns
 o
f H
is
pa
ni
c 
et
hn
ic
ity
 o
r m
ul
tip
le
 ra
ce
.
D
at
a 
fo
r a
ll 
ye
ar
s 
up
da
te
d 
th
ro
ug
h 
Ju
ly
 1
, 2
01
0.
E
lli
ps
es
 in
di
ca
te
 d
at
a 
no
t a
va
ila
bl
e.
 S
ee
 T
ec
hn
ic
al
 N
ot
es
 (p
ag
e 
9)
.
 S
ee
 S
ur
ve
ill
an
ce
 S
lid
e 
#8
.
Ze
ro
 %
 (0
) d
en
ot
es
 <
0.
5%
.
N
on
-H
is
pa
ni
c
R
at
e
U
nk
no
w
n 
or
 
M
is
si
ng
6
N
o.
(%
)
H
is
pa
ni
c 
or
 L
at
in
o1
M
ul
tip
le
 R
ac
e2
A
m
er
ic
an
 In
di
an
 o
r 
A
la
sk
a 
N
at
iv
e
A
si
an
3
A
si
an
 o
r P
ac
ifi
c 
Is
la
nd
er
4
B
la
ck
 o
r A
fri
ca
n 
A
m
er
ic
an
N
at
iv
e 
H
aw
ai
ia
n 
or
 O
th
er
 P
ac
ifi
c 
Is
la
nd
er
5
N
o.
N
o.
N
o.
N
o.
N
o.
N
o.
N
o.
N
o.
(%
)
(%
)
(%
)
(%
)
(%
)
(%
)
(%
)
R
at
e
R
at
e
R
at
e
R
at
e
R
at
e
R
at
e
R
at
e
To
ta
l
C
as
es
(%
)
17
19
93
25
10
7
…
…
…
27
6
(1
.0
)
12
.1
…
…
…
34
83
(1
4.
0)
39
.5
91
40
(3
6.
0)
28
.0
0
(0
.0
)
…
11
92
0
(4
7.
0)
5.
5
28
8
(1
.0
)
19
94
24
20
5
…
…
…
33
6
(1
.0
)
14
.2
…
…
…
36
52
(1
5.
0)
39
.7
86
21
(3
6.
0)
25
.9
0
(0
.0
)
…
11
34
7
(4
7.
0)
5.
2
24
9
(1
.0
)
19
95
22
72
8
…
…
…
32
8
(1
.0
)
13
.4
…
…
…
38
55
(1
7.
0)
40
.1
77
59
(3
4.
0)
22
.9
0
(0
.0
)
…
10
56
5
(4
6.
0)
4.
8
22
1
(1
.0
)
19
96
21
21
0
…
…
…
29
3
(1
.0
)
11
.6
…
…
…
36
85
(1
7.
0)
36
.8
72
91
(3
4.
0)
21
.2
0
(0
.0
)
…
97
58
(4
6.
0)
4.
4
18
3
(1
.0
)
19
97
19
75
1
…
…
…
27
7
(1
.0
)
10
.5
…
…
…
37
10
(1
9.
0)
35
.5
67
90
(3
4.
0)
19
.4
0
(0
.0
)
…
88
13
(4
5.
0)
3.
9
16
1
(1
.0
)
19
98
18
28
7
…
…
…
26
3
(1
.0
)
9.
6
…
…
…
35
43
(1
9.
0)
32
.5
59
62
(3
3.
0)
16
.7
0
(0
.0
)
…
83
81
(4
6.
0)
3.
7
13
8
(1
.0
)
19
99
17
50
1
…
…
…
25
3
(1
.0
)
8.
9
…
…
…
35
39
(2
0.
0)
31
.2
56
61
(3
2.
0)
15
.6
0
(0
.0
)
…
79
30
(4
5.
0)
3.
5
11
8
(1
.0
)
20
00
16
30
9
…
…
…
24
1
(1
.0
)
9.
0
…
…
…
34
17
(2
1.
0)
30
.6
52
70
(3
2.
0)
14
.7
0
(0
.0
)
…
72
84
(4
5.
0)
3.
2
97
(1
.0
)
20
01
15
94
5
…
…
…
23
6
(1
.0
)
8.
7
…
…
…
35
27
(2
2.
0)
30
.5
48
82
(3
1.
0)
13
.5
0
(0
.0
)
…
72
08
(4
5.
0)
3.
1
92
(1
.0
)
20
02
15
05
6
…
…
…
20
4
(1
.0
)
7.
4
…
…
…
33
39
(2
2.
0)
27
.9
45
52
(3
0.
0)
12
.4
0
(0
.0
)
…
68
95
(4
6.
0)
3.
0
66
(0
.0
)
20
03
14
83
6
49
(0
.0
)
1.
1
18
9
(1
.0
)
6.
7
35
07
(2
4.
0)
29
.6
…
…
…
42
49
(2
9.
0)
11
.5
66
(0
.0
)
13
.1
67
49
(4
5.
0)
2.
9
27
(0
.0
)
20
04
14
49
9
43
(0
.0
)
1.
0
16
5
(1
.0
)
5.
7
33
67
(2
3.
0)
27
.6
…
…
…
41
83
(2
9.
0)
11
.2
65
(0
.0
)
12
.6
66
46
(4
6.
0)
2.
8
30
(0
.0
)
20
05
14
06
4
52
(0
.0
)
1.
1
17
0
(1
.0
)
5.
8
32
49
(2
3.
0)
25
.8
…
…
…
40
74
(2
9.
0)
10
.8
56
(0
.0
)
10
.6
64
35
(4
6.
0)
2.
7
28
(0
.0
)
20
06
13
73
4
43
(0
.0
)
0.
9
19
3
(1
.0
)
6.
5
33
23
(2
4.
0)
25
.7
…
…
…
38
54
(2
8.
0)
10
.1
59
(0
.0
)
10
.9
62
38
(4
5.
0)
2.
6
24
(0
.0
)
20
07
13
28
0
29
(0
.0
)
0.
6
17
5
(1
.0
)
5.
8
34
54
(2
6.
0)
26
.0
…
…
…
36
16
(2
7.
0)
9.
3
98
(1
.0
)
17
.7
58
66
(4
4.
0)
2.
4
42
(0
.0
)
20
08
12
90
6
46
(0
.0
)
0.
9
16
5
(1
.0
)
5.
3
34
19
(2
6.
0)
25
.0
…
…
…
34
15
(2
6.
0)
8.
7
75
(1
.0
)
13
.3
57
40
(4
4.
0)
2.
4
46
(0
.0
)
20
09
11
54
5
45
(0
.0
)
0.
8
13
3
(1
.0
)
4.
2
32
19
(2
8.
0)
23
.0
…
…
…
29
41
(2
5.
0)
7.
4
78
(1
.0
)
13
.5
50
28
(4
4.
0)
2.
1
10
1
(1
.0
)
 1 In
di
ca
te
s 
tw
o 
or
 m
or
e 
ra
ce
s 
re
po
rte
d 
fo
r a
 p
er
so
n.
 C
at
eg
or
y 
fir
st
 re
po
rte
d 
in
 2
00
3.
 2 A
si
an
 ra
ce
 fi
rs
t r
ep
or
te
d 
in
 2
00
3.
 3 A
si
an
 o
r P
ac
ifi
c 
Is
la
nd
er
 ra
ce
 re
po
rte
d 
19
93
–2
00
2.
 4 N
at
iv
e 
H
aw
ai
ia
n 
or
 O
th
er
 P
ac
ifi
c 
Is
la
nd
er
 ra
ce
 fi
rs
t r
ep
or
te
d 
in
 2
00
3.
 
5 T
he
 h
ig
he
r c
ou
nt
 fo
r u
nk
no
w
n 
or
 m
is
si
ng
 ra
ce
 fo
r 2
00
2 
re
fle
ct
 th
e 
im
pa
ct
 o
f t
he
 tr
an
si
tio
na
l p
er
io
d 
of
 in
co
rp
or
at
in
g 
ne
w
 ra
ce
 d
efi
ni
tio
ns
 fo
r A
si
an
, N
at
iv
e 
H
aw
ai
ia
n,
 a
nd
 M
ul
tip
le
 R
ac
e 
in
 2
00
3.
 N
ot
e:
  P
re
vi
ou
sl
y 
pu
bl
is
he
d 
ra
te
s 
fo
r 1
99
3–
19
99
 h
av
e 
be
en
 u
pd
at
ed
 u
si
ng
 B
rid
ge
d-
R
ac
e 
19
90
–1
99
9 
In
te
rc
en
sa
l P
op
ul
at
io
n 
E
st
im
at
es
 fo
r 1
99
3–
19
99
  (
ht
tp
://
w
w
w
.c
dc
.g
ov
/n
ch
s/
nv
ss
/b
rid
ge
d_
ra
ce
.h
tm
) (
ac
ce
ss
ed
 A
ug
us
t 3
0,
 2
01
0)
.  
D
en
om
in
at
or
s 
fo
r c
om
pu
tin
g 
20
00
–2
00
9 
ca
se
 ra
te
s 
w
er
e 
ob
ta
in
ed
 fr
om
 th
e 
A
nn
ua
l E
st
im
at
es
 o
f t
he
 P
op
ul
at
io
n 
by
 S
ex
, R
ac
e,
 a
nd
 H
is
pa
ni
c 
or
 L
at
in
o 
O
rig
in
 fo
r t
he
 U
ni
te
d 
S
ta
te
s:
 A
pr
il 
1,
 2
00
0,
 to
 J
ul
y 
1,
 2
00
9 
(h
ttp
://
w
w
w
.c
en
su
s.
go
v/
po
pe
st
/n
at
io
na
l/a
sr
h/
N
C
-E
S
T2
00
9/
N
C
-E
S
T2
00
9-
03
.x
ls
) (
ac
ce
ss
ed
 A
ug
us
t 2
6,
 2
01
0)
.  
D
at
a 
fo
r a
ll 
ye
ar
s 
up
da
te
d 
th
ro
ug
h 
Ju
ly
 1
, 2
01
0.
E
lli
ps
es
 in
di
ca
te
 d
at
a 
no
t a
va
ila
bl
e.
 S
ee
 T
ec
hn
ic
al
 N
ot
es
 (p
ag
e 
9)
.
S
ee
 S
ur
ve
ill
an
ce
 S
lid
e 
#1
0.
Ze
ro
 %
 (0
) d
en
ot
es
 <
0.
5%
.
U
nk
no
w
n 
or
 
M
is
si
ng
5 (%
)
 Ta
bl
e 
3.
  T
ub
er
cu
lo
si
s 
C
as
es
, P
er
ce
nt
ag
es
, a
nd
 C
as
e 
R
at
es
 p
er
 1
00
,0
00
 P
op
ul
at
io
n 
by
 R
ac
e 
O
nl
y:
 U
ni
te
d 
St
at
es
, 1
99
3–
20
09
N
o.
To
ta
l 
C
as
es
M
ul
tip
le
 R
ac
e1
A
m
er
ic
an
 In
di
an
 o
r 
A
la
sk
a 
N
at
iv
e
A
si
an
2
A
si
an
 o
r
P
ac
ifi
c 
Is
la
nd
er
3
B
la
ck
 o
r 
A
fri
ca
n 
A
m
er
ic
an
N
at
iv
e 
H
aw
ai
ia
n 
or
 
O
th
er
 P
ac
ifi
c 
Is
la
nd
er
4
(%
)
R
at
e
N
o.
(%
)
R
at
e
N
o.
(%
)
R
at
e
N
o.
(%
)
R
at
e
R
at
e
N
o.
(%
)
N
o.
(%
)
R
at
e
W
hi
te
N
o.
(%
)
R
at
e
N
o.
Ye
ar
18
1993 25107 17422 (69) 7.4 7403 (29) 34.0 282 1
1994 24205 16171 (67) 6.8 7741 (32) 34.4 293 1
1995 22728 14647 (64) 6.1 7987 (35) 34.8 94 0
1996 21210 13316 (63) 5.6 7725 (36) 31.5 169 1
1997 19751 11879 (60) 4.9 7742 (39) 30.0 130 1
1998 18287 10632 (58) 4.4 7599 (42) 28.9 56 0
1999 17501 9806 (56) 4.0 7602 (43) 29.2 93 1
2000 16309 8648 (53) 3.5 7619 (47) 27.3 42 0
2001 15945 7870 (49) 3.2 8010 (50) 26.9 65 0
2002 15056 7281 (48) 2.9 7719 (51) 25.4 56 0
2003 14836 6863 (46) 2.7 7928 (53) 23.5 45 0
2004 14499 6631 (46) 2.6 7845 (54) 23.2 23 0
2005 14064 6308 (45) 2.5 7727 (55) 22.4 29 0
2006 13734 5885 (43) 2.3 7819 (57) 22.0 30 0
2007 13280 5491 (41) 2.1 7753 (58) 20.7 36 0
2008 12906 5286 (41) 2.0 7599 (59) 20.4 21 0
2009 11545 4571 (40) 1.7 6854 (59) 18.7 120 1
 Table 4.  Tuberculosis Cases, Percentages, and Case Rates per 100,000 Population by Age 
Group: United States, 1993–2009 
Year
Total
Cases
0–14 15–24 25–44 45–64 >65 Unk.1
No. No. No. No. No. No. (%)(%)(%)(%)(%)(%) Rate Rate Rate Rate Rate
1Includes unknown and missing.
Note:  Previously published rates for 1993–1999 have been updated using Bridged-Race 1990–1999 Intercensal Population Estimates for 
1993–1999  (http://www.cdc.gov/nchs/nvss/bridged_race.htm) (accessed August 30, 2010). Denominators for computing 2000–2008 case 
rates were obtained from the Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 2000, to 
July 1, 2009  (http://www.census.gov/popest/national/asrh/NC-EST2009-sa.html) (accessed August 26, 2010).
Data for all years updated through July 1, 2010.
See Technical Notes (page 9).
Zero % (0) denotes <0.5%.
See Surveillance Slides #5 and #6.
Table 5.  Tuberculosis Cases, Percentages, and Case Rates per 100,000 
Population by Origin of Birth: United States, 1993–2009
Year
Total
Cases
U.S.-born Persons Foreign-born Persons1 Unknown or Missing
No. (%)No. (%) RateNo. (%) Rate
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the 
Republic of the Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, 
the Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
Note:  Denominators for computing rates for years 1993–1994 were obtained from Quarterly Estimates of the 
United States Foreign-born and Native Resident Populations: April 1, 1990–July 1, 1999, located at http://www.cen-
sus.gov/population/estimates/nation/nativity/fbtab001.txt (accessed August 26, 2010). Denominators for computing 
the 1995–2009 rates are based on the U.S. Census Bureau, Current Population Survey (March Supplement).  Data 
for all years updated through July 1, 2010.
 See Technical Notes (page 9).
Zero % (0) denotes <0.5%.
See Surveillance Slides #11, #12, #15, and #16.
1993 25107 1661 (7.0) 2.9 1821 (7.0) 5.0 9590 (38.0) 11.5 6197 (25.0) 12.4 5821 (23.0) 17.7 17 (0.0)
1994 24205 1659 (7.0) 2.9 1832 (8.0) 5.0 9043 (37.0) 10.7 6125 (25.0) 11.9 5540 (23.0) 16.6 6 (0.0)
1995 22728 1536 (7.0) 2.6 1697 (7.0) 4.6 8201 (36.0) 9.7 5960 (26.0) 11.3 5329 (23.0) 15.8 5 (0.0)
1996 21210 1356 (6.0) 2.3 1637 (8.0) 4.4 7564 (36.0) 8.9 5572 (26.0) 10.2 5076 (24.0) 14.9 5 (0.0)
1997 19751 1251 (6.0) 2.1 1674 (8.0) 4.5 6884 (35.0) 8.0 5278 (27.0) 9.4 4663 (24.0) 13.6 1 (0.0)
1998 18287 1077 (6.0) 1.8 1543 (8.0) 4.1 6336 (35.0) 7.4 4953 (27.0) 8.5 4378 (24.0) 12.6 0 (0.0)
1999 17501 1038 (6.0) 1.7 1518 (9.0) 3.9 6063 (35.0) 7.1 4860 (28.0) 8.1 4020 (23.0) 11.6 2 (0.0)
2000 16309 965 (6.0) 1.6 1618 (10.0) 4.1 5576 (34.0) 6.6 4635 (28.0) 7.4 3515 (22.0) 10.0 0 (0.0)
2001 15945 929 (6.0) 1.5 1597 (10.0) 4.0 5610 (35.0) 6.6 4515 (28.0) 7.0 3293 (21.0) 9.3 1 (0.0)
2002 15056 944 (6.0) 1.6 1498 (10.0) 3.7 5288 (35.0) 6.3 4182 (28.0) 6.3 3143 (21.0) 8.8 1 (0.0)
2003 14836 911 (6.0) 1.5 1573 (11.0) 3.8 5074 (34.0) 6.1 4284 (29.0) 6.3 2994 (20.0) 8.3 0 (0.0)
2004 14499 953 (7.0) 1.6 1603 (11.0) 3.8 4939 (34.0) 5.9 4192 (29.0) 5.9 2811 (19.0) 7.8 1 (0.0)
2005 14064 855 (6.0) 1.4 1542 (11.0) 3.7 4737 (34.0) 5.7 4123 (29.0) 5.7 2807 (20.0) 7.6 0 (0.0)
2006 13734 803 (6.0) 1.3 1532 (11.0) 3.6 4692 (34.0) 5.6 4042 (29.0) 5.4 2664 (19.0) 7.2 1 (0.0)
2007 13280 774 (6.0) 1.3 1580 (12.0) 3.7 4317 (33.0) 5.2 4039 (30.0) 5.3 2570 (19.0) 6.8 0 (0.0)
2008 12906 783 (6.0) 1.3 1443 (11.0) 3.4 4239 (33.0) 5.1 3941 (31.0) 5.1 2500 (19.0) 6.4 0 (0.0)
2009 11545 646 (6.0) 1.0 1274 (11.0) 3.0 3893 (34.0) 4.7 3434 (30.0) 4.3 2292 (20.0) 5.8 6 (0.0)
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 Table 6. Tuberculosis Cases and Percentages Among Foreign-born Persons1 by 
the Top 30 Countries2 of Origin of Birth: United States, 2005–2009
Country of Origin
2009 2008 2007 2006 2005
Year
No. No. No. No. No.(%) (%) (%) (%) (%)
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the 
Republic of the Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the 
Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
2The top 30 countries were selected based on their ranked 5-year average number of TB cases.
3 Includes Not Specified for Country of Origin. 
Note: Zero (0) denotes <0.5%.
Data for all years updated through July 1, 2010.
Total Cases 6854 (100) 7599 (100) 7753 (100) 7819 (100) 7727 (100)
Mexico 1,598 (23) 1,762 (23) 1,851 (24) 1,933 (25) 1,961 (25)
Philippines 806 (12) 859 (11) 950 (12) 861 (11) 829 (11)
Vietnam 526 (8) 584 (8) 571 (7) 628 (8) 573 (7)
India 533 (8) 600 (8) 627 (8) 549 (7) 562 (7)
China 340 (5) 406 (5) 386 (5) 373 (5) 397 (5)
Guatemala 212 (3) 251 (3) 248 (3) 230 (3) 211 (3)
Haiti 195 (3) 238 (3) 175 (2) 210 (3) 241 (3)
Ethiopia 167 (2) 183 (2) 178 (2) 203 (3) 151 (2)
Honduras 146 (2) 193 (3) 181 (2) 164 (2) 165 (2)
Korea, Republic of 158 (2) 149 (2) 155 (2) 204 (3) 176 (2)
Somalia 113 (2) 151 (2) 177 (2) 196 (3) 148 (2)
El Salvador 118 (2) 147 (2) 158 (2) 144 (2) 143 (2)
Peru 94 (1) 144 (2) 139 (2) 160 (2) 154 (2)
Ecuador 99 (1) 114 (2) 116 (2) 117 (2) 156 (2)
Cambodia 98 (1) 77 (1) 95 (1) 99 (1) 106 (1)
Dominican Republic 65 (1) 86 (1) 89 (1) 111 (1) 76 (1)
Pakistan 82 (1) 87 (1) 79 (1) 79 (1) 78 (1)
Kenya 74 (1) 82 (1) 70 (1) 75 (1) 66 (1)
Lao, PDR 60 (1) 69 (1) 78 (1) 59 (1) 77 (1)
Burma 101 (1) 111 (1) 65 (1) 41 (1) 39 (1)
Thailand 54 (1) 62 (1) 47 (1) 55 (1) 71 (1)
Nepal 70 (1) 70 (1) 52 (1) 45 (1) 33 (0)
Bangladesh 44 (1) 55 (1) 56 (1) 41 (1) 34 (0)
Liberia 32 (0) 33 (0) 46 (1) 52 (1) 64 (1)
Columbia 39 (1) 43 (1) 56 (1) 45 (1) 37 (0)
Indonesia 34 (1) 30 (0) 52 (1) 44 (1) 57 (1)
Nigeria 47 (1) 50 (1) 43 (1) 39 (1) 37 (0)
Cuba 35 (1) 42 (1) 41 (1) 42 (1) 55 (1)
Russia 29 (0) 36 (0) 40 (1) 47 (1) 43 (1)
Taiwan 26 (0) 32 (0) 38 (0) 38 (0) 37 (0)
All Others 859 (13) 853 (11) 894 (11) 935 (12) 950 (12)
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 Table 9.  Pulmonary Tuberculosis Cases and Percentages by Sputum Smear and Sputum 
Culture Results: United States, 1993–2009
Year
Total 
Pulmonary 
Cases1
Sputum Smear Result Sputum Culture Result
Positive Negative
Not Done or 
Unknown Positive Negative
Not Done or  
Unknown
No. (%) No. (%) No. No. No. No.(%) (%) (%) (%)
 1Includes cases among persons with both pulmonary and extrapulmonary disease and cases of miliary TB.
Note:   See Technical Notes (page 9).
Data for all years updated through July 1, 2010.
	Table	8.		Tuberculosis	Cases	and	Percentages	by	Case	Verification	Criterion	and	Site	of	
Disease: United States, 1993–2009
Year
Total
Cases
Verification Criterion1 Site of Disease5
Positive
Culture
Positive
Smear
Clinical
Case Definition
Provider
Diagnosis Pulmonary3
Extra-
pulmonary4
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
1Based on the public health surveillance case definition for tuberculosis; see Appendix A (page 121).
2 Nucleic Acid Amplification test
3Includes cases among persons with both pulmonary and extrapulmonary disease and cases of miliary TB.
4Includes cases among persons with extrapulmonary TB disease only.
5Excludes missing and unknowns.
Note: See Technical Notes (page 9).
Data for all years updated through July 1, 2010.
1993 25107 20307 (81) ... ... 185 (1) 3092 (12) 1523 (6) 21158 (84) 3940 (16)
1994 24205 19506 (81) ... ... 189 (1) 2916 (12) 1594 (7) 20318 (84) 3885 (16)
1995 22728 18267 (80) ... ... 189 (1) 2748 (12) 1524 (7) 18888 (83) 3835 (17)
1996 21210 17154 (81) ... ... 131 (1) 2606 (12) 1319 (6) 17387 (82) 3814 (18)
1997 19751 15979 (81) ... ... 155 (1) 2411 (12) 1206 (6) 16239 (82) 3509 (18)
1998 18287 14790 (81) ... ... 155 (1) 2253 (12) 1089 (6) 14801 (81) 3484 (19)
1999 17501 13995 (80) ... ... 172 (1) 2103 (12) 1231 (7) 14067 (80) 3431 (20)
2000 16309 13013 (80) ... ... 148 (1) 1951 (12) 1197 (7) 13086 (80) 3211 (20)
2001 15945 12750 (80) ... ... 123 (1) 1886 (12) 1186 (7) 12724 (80) 3217 (20)
2002 15056 11975 (80) ... ... 104 (1) 1821 (12) 1156 (8) 11902 (79) 3148 (21)
2003 14836 11684 (79) ... ... 116 (1) 1783 (12) 1253 (8) 11806 (80) 3020 (20)
2004 14499 11326 (78) ... ... 80 (1) 1824 (13) 1269 (9) 11523 (79) 2972 (21)
2005 14064 10953 (78) ... ... 96 (1) 1794 (13) 1221 (9) 11124 (79) 2932 (21)
2006 13734 10747 (78) ... ... 95 (1) 1628 (12) 1264 (9) 10852 (79) 2869 (21)
2007 13280 10423 (78) ... ... 71 (1) 1469 (11) 1317 (10) 10548 (80) 2674 (20)
2008 12906 10036 (78) ... ... 67 (1) 1415 (11) 1388 (11) 10257 (80) 2629 (20)
2009 11545 8876 (77) 57 (0) 91 (1) 1630 (14) 891 (8) 9004 (79) 2383 (21)
; 
1993 21158 9429 (45) 7915 (37) 3814 (18) 14878 (70) 2814 (13) 3466 (16)
1994 20318 8964 (44) 7914 (39) 3440 (17) 14210 (70) 2807 (14) 3301 (16)
1995 18888 8093 (43) 7713 (41) 3082 (16) 13282 (70) 2626 (14) 2980 (16)
1996 17387 7454 (43) 7352 (42) 2581 (15) 12270 (71) 2559 (15) 2558 (15)
1997 16239 6935 (43) 6916 (43) 2388 (15) 11568 (71) 2259 (14) 2412 (15)
1998 14801 6624 (45) 6038 (41) 2139 (14) 10486 (71) 2138 (14) 2177 (15)
1999 14067 6275 (45) 5662 (40) 2130 (15) 9820 (70) 2097 (15) 2150 (15)
2000 13086 5884 (45) 5346 (41) 1856 (14) 9251 (71) 1948 (15) 1887 (14)
2001 12724 5651 (44) 5322 (42) 1751 (14) 8904 (70) 2010 (16) 1810 (14)
2002 11902 5440 (46) 4791 (40) 1671 (14) 8331 (70) 1839 (15) 1732 (15)
2003 11806 5371 (45) 4881 (41) 1554 (13) 8208 (70) 1981 (17) 1617 (14)
2004 11523 5288 (46) 4901 (43) 1334 (12) 8049 (70) 2064 (18) 1410 (12)
2005 11124 5136 (46) 4744 (43) 1244 (11) 7701 (69) 2088 (19) 1335 (12)
2006 10852 5140 (47) 4579 (42) 1133 (10) 7689 (71) 1961 (18) 1202 (11)
2007 10548 4881 (46) 4520 (43) 1147 (11) 7368 (70) 1977 (19) 1203 (11)
2008 10257 4769 (46) 4401 (43) 1087 (11) 7121 (69) 1989 (19) 1147 (11)
2009 9004 4014 (45) 3907 (43) 1083 (12) 6119 (68) 1641 (18) 1244 (14)
Positive
NAA2
No. (%)
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1993 1399 (8.4) 804 (6.8) 579 (12.4) 407 (2.5) 301 (2.6) 103 (2.2)
1994 1360 (8.3) 711 (6.5) 635 (12.0) 353 (2.2) 238 (2.2) 110 (2.1)
1995 1174 (7.3) 555 (5.4) 618 (11.0) 254 (1.6) 169 (1.6) 85 (1.5)
1996 1137 (7.4) 495 (5.2) 639 (11.3) 207 (1.3) 105 (1.1) 101 (1.8)
1997 1079 (7.5) 435 (5.0) 640 (11.2) 155 (1.1) 76 (0.9) 79 (1.4)
1998 1013 (7.5) 367 (4.8) 644 (11.3) 132 (1.0) 55 (0.7) 76 (1.3)
1999 899 (7.1) 283 (4.0) 614 (11.0) 127 (1.0) 39 (0.6) 88 (1.6)
2000 890 (7.5) 269 (4.4) 618 (10.9) 120 (1.0) 40 (0.7) 80 (1.4)
2001 802 (7.0) 243 (4.4) 558 (9.5) 115 (1.0) 34 (0.6) 81 (1.4)
2002 825 (7.7) 205 (4.1) 619 (10.9) 132 (1.2) 35 (0.7) 97 (1.7)
2003 822 (7.7) 215 (4.5) 604 (10.4) 94 (0.9) 24 (0.5) 70 (1.2)
2004 801 (7.6) 214 (4.6) 587 (10.2) 100 (1.0) 26 (0.6) 74 (1.3)
2005 763 (7.6) 188 (4.3) 569 (10.1) 97 (1.0) 20 (0.5) 76 (1.3)
2006 773 (7.8) 172 (4.2) 599 (10.4) 102 (1.0) 18 (0.4) 84 (1.5)
2007 720 (7.5) 166 (4.3) 553 (9.6) 104 (1.1) 19 (0.5) 85 (1.5)
2008 768 (8.3) 189 (5.2) 578 (10.3) 89 (1.0) 21 (0.6) 68 (1.2)
2009 691 (8.6) 182 (6.0) 502 (10.1) 94 (1.2) 10 (0.3) 83 (1.7)
1993 164 (16.6) 85 (12.7) 76 (25.0) 76 (7.7) 30 (4.5) 46 (15.3)
1994 176 (17.0) 81 (11.7) 94 (27.9) 74 (7.2) 35 (5.1) 38 (11.3)
1995 168 (17.5) 77 (13.0) 91 (25.1) 70 (7.3) 28 (4.7) 42 (11.6)
1996 142 (16.5) 67 (12.0) 74 (24.4) 43 (5.0) 20 (3.6) 22 (7.3)
1997 109 (14.7) 35 (7.7) 74 (25.9) 44 (5.9) 12 (2.6) 32 (11.2)
1998 98 (13.0) 38 (7.8) 60 (22.8) 23 (3.1) 6 (1.2) 17 (6.5)
1999 82 (12.3) 25 (6.5) 55 (19.4) 28 (4.2) 6 (1.6) 22 (7.8)
2000 84 (13.3) 22 (6.1) 62 (22.8) 26 (4.1) 2 (0.6) 24 (8.8)
2001 86 (13.7) 28 (8.6) 58 (19.3) 32 (5.1) 7 (2.2) 25 (8.3)
2002 80 (14.1) 23 (7.6) 57 (21.6) 26 (4.6) 3 (1.0) 23 (8.7)
2003 65 (12.5) 16 (6.4) 49 (18.1) 21 (4.0) 2 (0.8) 19 (7.0)
2004 64 (11.9) 15 (5.5) 49 (18.6) 27 (5.0) 4 (1.5) 23 (8.7)
2005 70 (13.8) 18 (7.5) 52 (19.3) 22 (4.3) 1 (0.4) 21 (7.8)
2006 67 (13.6) 9 (4.4) 57 (19.7) 20 (4.0) 1 (0.5) 19 (6.6)
2007 70 (14.2) 14 (6.9) 56 (19.5) 18 (3.7) 3 (1.5) 15 (5.2)
2008 56 (13.1) 13 (7.7) 43 (16.6) 18 (4.2) 3 (1.8) 15 (5.8)
2009 49 (15.2) 5 (4.5) 43 (20.5) 19 (5.9) 1 (0.9) 17 (8.1)
 Table 10. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug 
Resistance1 in Persons with No Previous History of TB, by Origin of Birth: United 
States, 1993–2009
1Resistance to at least isoniazid and rifampin. 
2Isolates may be resistant to other drugs.
3All cases were culture positive, and initial drug susceptibility testing done.
4Includes persons of unknown country of birth.
5Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the Marshall Islands, Midway Is-
land, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
6Includes Not Specified for Country of Origin.  
Note:  Data for all years updated through July 1, 2010.
Percentages are of total cases for given year with no previous history of TB, culture positive, and initial drug susceptibility testing done (total cases not shown). 
More than 95% of all persons in each group had drug-susceptibility test results reported for an initial isolate.
See Surveillance Slides #19 through #22.
Year
Resistance to Isoniazid2 Resistance to Isoniazid and Rifampin2
Total Cases3,4 Foreign-born5,6U.S.-born Total Cases3,4 U.S.-born Foreign-born5,6
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
1Resistance to at least isoniazid and rifampin
2Isolates may be resistant to other drugs.
3All cases were culture positive, and initial drug susceptibility testing done.
4Includes persons of unknown country of birth.
5Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the Marshall Islands, Midway Is-
land, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin Islands, and U.S. minor and outlying Pacific islands.
6 Includes Not Specified for Country of Origin.  
Note:  Data for all years updated through July 1, 2010.
Percentages are of total cases for given year with previous history of TB, culture positive, and initial drug susceptibility testing done (total cases not shown). More 
than 95% of all persons in each group had drug-susceptibility test results reported for an initial isolate.
Table 11. Tuberculosis Cases and Percentages, by Resistance to INH or Multidrug 
Resistance1 in Persons with Previous History of TB, by Origin of Birth: United 
States, 1993–2009
Year
Resistance to Isoniazid2 Resistance to Isoniazid and Rifampin2
Total Cases3,4 Foreign-born5,6U.S.-born Total Cases3,4 U.S.-born Foreign-born5,6
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
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1993 (12.9) (31.2) (40.3) (21.7) (14.4) (64.0) (87.4)
1994 (7.0) (23.3) (55.7) (28.1) (20.5) (69.0) (87.9)
1995 (5.2) (20.3) (62.7) (37.2) (21.5) (73.9) (89.6)
1996 (4.2) (17.5) (67.3) (42.5) (22.4) (76.4) (90.5)
1997 (3.2) (15.1) (71.9) (46.9) (23.8) (78.2) (91.3)
1998 (2.6) (12.9) (74.3) (47.6) (26.6) (80.6) (92.4)
1999 (2.2) (11.2) (76.9) (49.4) (27.6) (80.8) (92.3)
2000 (2.0) (10.4) (78.5) (52.5) (25.8) (81.6) (92.6)
2001 (1.7) (9.6) (79.8) (53.6) (27.5) (81.6) (92.6)
2002 (1.8) (8.9) (80.3) (55.4) (27.8) (82.1) (92.4)
2003 (1.4) (8.1) (81.3) (56.5) (28.4) (82.8) (92.7)
2004 (1.5) (6.4) (82.4) (58.9) (27.8) (83.6) (92.6)
2005 (1.3) (5.5) (83.7) (57.9) (29.6) (83.2) (92.5)
2006 (1.2) (4.8) (83.2) (57.5) (30.4) (83.9) (93.0)
2007 (1.1) (4.6) (83.5) (56.2) (33.0) (84.3) (93.2)
2008 (0.9) (3.6) (83.7) ... ... ... ...
2009 (1.0) (3.0) (84.0) ... ... ... ...
 Table 13.  Tuberculosis Cases and Percentages in Persons with HIV Test Results1 and with 
HIV Coinfection by Age Group: United States, 1993–2009
Year
25–44 Years Old All Ages
HIV Test
Results HIV Positive
HIV Test
Results HIV Positive
No. No. No. No.(%) (%) (%) (%)
1Includes persons with positive, negative, or indeterminate HIV test results and persons from California with co-diagnosis of TB and 
AIDS. In California, the number of patients testing negative, indeterminate, refusing testing, not offered testing, test performed but status 
unknown, unknown, or missing HIV data is not reported to CDC. California has not reported AIDS test results since 2004. Rhode Island 
did not report HIV test results for years 1993–1997. Vermont did not report HIV test results for years 1993 - 2009.
Note:  Data for all years updated through July 1, 2010.
See Surveillance Slides #24 and #25. 
 Table 12.  Percentages of Tuberculosis Cases by Initial Drug Regimen, Use of Directly  
Observed Therapy (DOT), and Completion of Therapy (COT): United States, 1993–2009
Year
Initial Drug Regimen1,2
Directly Observed Therapy3
Therapy <1 Year Indicated4
IRZ DOT Only
Both DOT and Self-
Administered COT <1 Year COTI R
 1Includes persons alive at diagnosis.
2I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol.  Excludes cases with no information on initial drug regimen; 1.11% received no 
initial drug therapy, 0.09% were started on one drug, and 10.76% had an initial multidrug regimen other than IR, IRZ, or IRZE.
3Includes persons alive at diagnosis with initial drug regimen of one or more drugs prescribed.
4Includes persons alive at diagnosis, with initial drug regimen of one or more drugs prescribed, who did not die during therapy.  Excludes 
persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or 
positive blood culture.  
Note: Data for all years updated through July 1, 2010.
See Technical Notes for description of COT calculation (page 9).
See Surveillance Slides #26 and #27.
IRZE
1993 4382 (46) 2790 (29) 7457 (30) 3682 (15)
1994 4442 (49) 2669 (30) 7887 (33) 3601 (15)
1995 4277 (52) 2172 (26) 8179 (36) 3038 (13)
1996 4366 (58) 1856 (25) 8832 (42) 2615 (12)
1997 4141 (60) 1471 (21) 8771 (44) 2091 (11)
1998 3863 (61) 1241 (20) 8292 (45) 1831 (10)
1999 3811 (63) 1175 (19) 8420 (48) 1726 (10)
2000 3525 (63) 955 (17) 8117 (50) 1464 (9)
2001 3576 (64) 911 (16) 8095 (51) 1408 (9)
2002 3512 (66) 845 (16) 8022 (53) 1390 (9)
2003 3424 (67) 807 (16) 8118 (55) 1320 (9)
2004 3442 (70) 683 (14) 8509 (59) 1195 (8)
2005 3275 (69) 611 (13) 8225 (58) 1042 (7)
2006 3278 (70) 557 (12) 8277 (60) 961 (7)
2007 3153 (73) 488 (11) 8317 (63) 881 (7)
2008 3088 (73) 415 (10) 8179 (63) 826 (6)
2009 2754 (71) 399 (10) 7051 (61) 706 (6)
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Table 14.  Tuberculosis Cases and Percentages by Reason Tuberculosis Therapy Stopped: 
United States, 1993–2007
Year
Total
Cases1 Completed Therapy Moved Lost Refused Died2 Unknown3
1Includes all cases in persons reported as alive at diagnosis and taking one or more TB drugs.
2Died = died of any cause (not only TB).
3Includes cases in persons reporting reason therapy stopped = Other, Missing, or Unknown. 
Note: Data for all years are updated through July 1, 2010.
Data complete through 2007 only.  See Technical Notes (page 9) for details.
No. (%) No. No. No. No. No.(%) (%) (%) (%) (%)No.
1993 23756 18048 (76.0) 1120 (4.7) 1088 (4.6) 223 (0.9) 3053 (12.9) 224 (0.9)
1994 23051 17763 (77.1) 1194 (5.2) 739 (3.2) 183 (0.8) 2743 (11.9) 429 (1.9)
1995 21712 17285 (79.6) 969 (4.5) 566 (2.6) 156 (0.7) 2391 (11.0) 345 (1.6)
1996 20297 16510 (81.3) 783 (3.9) 520 (2.6) 156 (0.8) 1992 (9.8) 336 (1.7)
1997 18930 15654 (82.7) 667 (3.5) 435 (2.3) 119 (0.6) 1755 (9.3) 300 (1.6)
1998 17585 14763 (84.0) 534 (3.0) 400 (2.3) 104 (0.6) 1578 (9.0) 206 (1.2)
1999 16863 14221 (84.3) 456 (2.7) 356 (2.1) 104 (0.6) 1436 (8.5) 290 (1.7)
2000 15786 13402 (84.9) 408 (2.6) 392 (2.5) 112 (0.7) 1294 (8.2) 178 (1.1)
2001 15409 13203 (85.7) 377 (2.4) 364 (2.4) 98 (0.6) 1116 (7.2) 251 (1.6)
2002 14560 12440 (85.4) 335 (2.3) 365 (2.5) 86 (0.6) 1072 (7.4) 262 (1.8)
2003 14381 12396 (86.2) 311 (2.2) 361 (2.5) 84 (0.6) 993 (6.9) 236 (1.6)
2004 14080 12117 (86.1) 337 (2.4) 359 (2.5) 82 (0.6) 975 (6.9) 210 (1.5)
2005 13677 11725 (85.7) 323 (2.4) 337 (2.5) 90 (0.7) 984 (7.2) 218 (1.6)
2006 13320 11504 (86.4) 311 (2.3) 350 (2.6) 78 (0.6) 937 (7.0) 140 (1.1)
2007 12888 11239 (87.2) 284 (2.2) 309 (2.4) 72 (0.6) 813 (6.3) 171 (1.3)
25
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Table 15.  Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race, Sex, and Age 
Group: United States, 2009
1Persons of Hispanic or Latino ethnicity may be of any race or multiple race.             
2Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does 
not include persons of Hispanic ethnicity.
See Technical Notes (page 9).                 
See Surveillance Slide #10.
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >65
Not 
Stated
Total Cases 11,545 401 245 1,274 3,893 3,434 2,292 6
Male 6,990 214 126 713 2,247 2,278 1,409 3
Female 4,544 187 119 559 1,641 1,153 882 3
Unknown 11 0 0 2 5 3 1 0
Hispanic or Latino1 3,380 208 100 517 1,346 754 451 4
Male 2,132 116 45 316 878 500 275 2
Female 1,246 92 55 200 467 254 176 2
Unknown 2 0 0 1 1 0 0 0
Non-Hispanic
American Indian or Alaska Native 102 2 2 6 25 39 28 0
Male 60 2 1 5 15 21 16 0
Female 41 0 1 1 9 18 12 0
Unknown 1 0 0 0 1 0 0 0
Asian 3,192 61 47 340 1,096 888 760 0
Male 1,739 28 28 177 519 522 465 0
Female 1,451 33 19 163 575 366 295 0
Unknown 2 0 0 0 2 0 0 0
Black or African American 2,868 86 72 294 977 1,044 393 2
Male 1,752 44 38 156 566 707 240 1
Female 1,114 42 34 138 410 336 153 1
Unknown 2 0 0 0 1 1 0 0
Native Hawaiian or Other Pacific Islander 75 8 7 10 22 20 8 0
Male 41 6 5 5 12 9 4 0
Female 34 2 2 5 10 11 4 0
Unknown 0 0 0 0 0 0 0 0
White 1,829 31 16 94 396 661 631 0
Male 1,213 16 8 48 242 502 397 0
Female 612 15 8 45 154 157 233 0
Unknown 4 0 0 1 0 2 1 0
Multiple Race2 39 5 0 8 9 11 6 0
Male 18 2 0 3 5 6 2 0
Female 21 3 0 5 4 5 4 0
Unknown 0 0 0 0 0 0 0 0
Unknown 60 0 1 5 22 17 15 0
Male 35 0 1 3 10 11 10 0
Female 25 0 0 2 12 6 5 0
Unknown 0 0 0 0 0 0 0 0
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Table 16.  Tuberculosis Case Rates per 100,000 Population by Hispanic Ethnicity and Non-
Hispanic Race, Sex, and Age Group: United States, 2009
1Persons of Hispanic or Latino origin may be of any race or multiple race.             
2Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Denominators for computing case rates were obtained from the U.S. Census Bureau Monthly Postcensal Resident Population, by 
single year of age, sex, race, and Hispanic origin: July 1, 2009 (http://www.census.gov/popest/national/asrh/files/NC-EST2009-ALLDATA-
R-File16.csv) (Accessed August 26, 2010).
Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other Pacific 
Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does not 
include persons of Hispanic ethnicity.
See Technical Notes (page 9).                 
See Surveillance Slide #7.                 
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45 –64 >65
Total Rate 3.8 1.9 0.6 3.0 4.7 4.3 5.8
Male 4.6 2.0 0.6 3.2 5.3 5.9 8.4
Female 2.9 1.8 0.6 2.7 4.0 2.8 3.9
Hispanic or Latino1 7.0 3.8 1.1 6.5 8.8 9.2 16.3
Male 8.5 4.1 1.0 7.6 10.6 12.2 23.2
Female 5.3 3.4 1.3 5.3 6.7 6.3 11.2
Non-Hispanic
American Indian or Alaska Native 4.3 1.0 0.6 1.5 3.8 7.0 14.0
Male 5.2 2.0 0.6 2.4 4.6 7.9 18.1
Female 3.4 0.0 0.6 0.5 2.8 6.2 10.8
Asian 23.3 6.4 2.7 19.8 23.6 26.9 57.3
Male 26.3 5.7 3.2 20.2 23.0 33.8 81.4
Female 20.5 7.0 2.2 19.4 24.0 20.8 39.1
Black or African American 7.6 3.0 1.3 4.6 9.1 11.9 11.9
Male 9.8 3.0 1.3 4.8 11.0 17.8 18.9
Female 5.7 2.9 1.2 4.4 7.4 7.1 7.6
Native Hawaiian or Other Pacific Islander 16.7 21.6 10.4 14.0 15.6 20.4 23.8
Male 18.2 31.5 14.5 13.7 16.8 18.5 26.1
Female 15.2 11.1 6.1 14.2 14.4 22.3 21.9
White 0.9 0.3 0.1 0.4 0.8 1.1 2.0
Male 1.2 0.3 0.1 0.4 0.9 1.8 2.9
Female 0.6 0.3 0.1 0.4 0.6 0.5 1.3
Multiple Race2 0.9 0.7 0.0 1.0 0.9 1.7 2.4
Male 0.8 0.6 0.0 0.7 1.0 1.9 1.9
Female 0.9 0.9 0.0 1.2 0.8 1.4 2.8
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Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >65
Not 
Stated
Table 17.  Tuberculosis Cases in U.S.-born Persons by Hispanic Ethnicity and Non-Hispanic 
Race, Sex, and Age Group: United States, 2009
1Persons of Hispanic or Latino origin may be of any race or multiple race.             
2Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does 
not include persons of Hispanic ethnicity.
See Technical Notes (page 9).
See Surveillance Slide #13.
Total Cases 4,571 350 154 385 1,047 1,637 997 1
Male 2,900 183 72 207 635 1,172 631 0
Female 1,667 167 82 178 411 463 365 1
Unknown 4 0 0 0 1 2 1 0
Hispanic or Latino1 846 201 75 139 178 150 102 1
Male 476 109 31 69 109 95 63 0
Female 370 92 44 70 69 55 39 1
Unknown 0 0 0 0 0 0 0 0
American Indian or Alaska Native 97 2 2 5 23 38 27 0
Male 57 2 1 5 14 20 15 0
Female 39 0 1 0 8 18 12 0
Unknown 1 0 0 0 1 0 0 0
Asian 151 39 16 34 33 10 19 0
Male 77 15 10 17 18 6 11 0
Female 74 24 6 17 15 4 8 0
Unknown 0 0 0 0 0 0 0 0
Black or African American 1,925 68 42 137 521 836 321 0
Male 1,240 35 20 81 312 591 201 0
Female 685 33 22 56 209 245 120 0
Unknown 0 0 0 0 0 0 0 0
Native Hawaiian or Pacific Islander 67 8 7 10 20 16 6 0
Male 37 6 5 5 10 8 3 0
Female 30 2 2 5 10 8 3 0
Unknown 0 0 0 0 0 0 0 0
White 1,454 27 12 56 265 576 518 0
Male 996 14 5 28 169 444 336 0
Female 455 13 7 28 96 130 181 0
Unknown 3 0 0 0 0 2 1 0
Multiple Race2 19 5 0 3 4 6 1 0
Male 8 2 0 1 2 3 0 0
Female 11 3 0 2 2 3 1 0
Unknown 0 0 0 0 0 0 0 0
Unknown 12 0 0 1 3 5 3 0
Male 9 0 0 1 1 5 2 0
Female 3 0 0 0 2 0 1 0
Unknown 0 0 0 0 0 0 0 0
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Table 18.  Tuberculosis Cases in Foreign-born Persons1 by Hispanic Ethnicity and Non-
Hispanic Race, Sex, and Age Group: United States, 2009
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.                 
2Persons of Hispanic or Latino ethnicity may be of any race or multiple race.            
3Indicates two or more races reported for a person. Category first reported in 2003.        
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple race does 
not include persons of Hispanic ethnicity.
See Technical Notes (page 9). 
See Surveillance Slide #13.
Age Group
Race/Ethnicity and Sex All Ages Under 5 5–14 15–24 25–44 45–64 >65
Not 
Stated
Total Cases 6,854 51 91 878 2,810 1,749 1,270 5
Male 4,019 31 54 499 1,591 1,080 761 3
Female 2,829 20 37 377 1,215 669 509 2
Unknown 6 0 0 2 4 0 0 0
Hispanic or Latino2 2,498 7 25 372 1,155 594 342 3
Male 1,634 7 14 244 759 399 209 2
Female 862 0 11 127 395 195 133 1
Unknown 2 0 0 1 1 0 0 0
American Indian or Alaska Native 5 0 0 1 2 1 1 0
Male 3 0 0 0 1 1 1 0
Female 2 0 0 1 1 0 0 0
Unknown 0 0 0 0 0 0 0 0
Asian 3,006 22 31 304 1,047 866 736 0
Male 1,646 13 18 159 495 511 450 0
Female 1,358 9 13 145 550 355 286 0
Unknown 2 0 0 0 2 0 0 0
Black or African American 913 18 30 156 452 188 67 2
Male 493 9 18 74 251 104 36 1
Female 419 9 12 82 200 84 31 1
Unknown 1 0 0 0 1 0 0 0
Native Hawaiian or Pacific Islander 8 0 0 0 2 4 2 0
Male 4 0 0 0 2 1 1 0
Female 4 0 0 0 0 3 1 0
Unknown 0 0 0 0 0 0 0 0
White 363 4 4 36 130 82 107 0
Male 207 2 3 18 72 56 56 0
Female 155 2 1 17 58 26 51 0
Unknown 1 0 0 1 0 0 0 0
Multiple Race3 20 0 0 5 5 5 5 0
Male 10 0 0 2 3 3 2 0
Female 10 0 0 3 2 2 3 0
Unknown 0 0 0 0 0 0 0 0
Unknown 41 0 1 4 17 9 10 0
Male 22 0 1 2 8 5 6 0
Female 19 0 0 2 9 4 4 0
Unknown 0 0 0 0 0 0 0 0
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Eastern Mediterranean Region
Total Cases = 315
Algeria 1 Ethiopia 168 Niger 2
Angola 1 Gabon 2 Nigeria 47
Benin 0 Gambia 6 Rwanda 3
Botswana 2 Ghana 15 Sao Tome and Principe 0
Burkina Faso 1 Guinea 16 Senegal 14
Burundi 3 Guinea-Bissau 1 Seychelles 0
Cameroon 26 Kenya 74 Sierra Leone 16
Cape Verde 3 Lesotho 0 South Africa 12
Central African Republic 2 Liberia 32 Swaziland 0
Chad 1 Madagascar 1 Tanzania, UR 16
Comoros 2 Malawi 1 Togo 3
Congo, Republic of 14 Mali 6 Uganda 8
Côte d’Ivoire 9 Mauritania 1 Zambia 8
DR Congo 1 Mauritius 0 Zimbabwe 7
Equatorial Guinea 0 Mozambique 7   
Eritrea 18 Namibia 1
Anguilla 0 Cuba 35 Panama 7
Antigua and Barbuda 1 Dominica 1 Paraguay 0
Argentina 7 Dominican Republic 65 Peru 94
Bahamas 2 Ecuador 99 Puerto Rico 58
Barbados 0 El Salvador 118 St. Kitts and Nevis 0
Belize 5 Grenada 1 St. Lucia 0
Bermuda 0 Guatemala 213 St. Vincent & Grenadines 0
Bolivia 18 Guyana 20 Suriname 0
Brazil 23 Haiti 197 Trinidad and Tobago 10
British Virgin Islands 1 Honduras 147 Turks and Caicos Islands 1
Canada 7 Jamaica 16 Uruguay 1
Cayman Islands 1 Mexico U.S. Virgin Islands 1
Chile 2 Montserrat 2 United States of America 4451
Colombia 39 Netherland Antilles 0 Venezuela 10
Costa Rica 6 Nicaragua 24   
 
Afghanistan 20 Lebanon 3 Sudan 22
Bahrain 0 Libyan Arab Jamahiriya 1 Syrian Arab Republic 2
Djibouti 1 Morocco 12 Tunisia 1
Egypt 7 Oman 1 United Arab Emirates 2
Iran, Islamic Republic of 14 Pakistan 82 West Bank and Gaza 0
Iraq 15 Qatar 1 Yemen 10
Jordan 2 Saudi Arabia 3
Kuwait 2 Somalia 114
Table 19. Tuberculosis Cases by Country of Origin1: United States, 2009
African Region
Total Cases = 551 
Americas Region
Total Cases = 7,283
33
Albania 6  Germany 10 Norway 1
Andorra 0 Greece 7  Poland 22
Armenia 5 Hungary 3 Portugal 10
Austria 2 Iceland 0 Romania 18
Azerbaijan 2 Ireland 6 Russian Federation 29
Belarus 2 Israel 0 San Marino 0
Belgium 0 Italy 7 Serbia 2
Bosnia and Herzegovina 26 Kazakhstan 1 Slovakia 0
Bulgaria 2 Kyrgyzstan 1 Slovenia 0
Croatia 1 Latvia 0 Spain 1
Cyprus 0 Lithuania 3 Sweden 0
Czech Republic 1 Luxembourg 0 Switzerland 1
Czechoslovakia* 0 Macedonia, TFYR 1 Tajikistan 1
Denmark 1 Malta 0 Turkey 4
Estonia 1 Moldova, Republic of 7 Turkmenistan 2
Finland 0 Monaco 0 Ukraine 21
France 4 Montenegro 1 United Kingdom 3
Georgia 2 Netherlands 3 Uzbekistan 3
Yugoslavia 6
Bangladesh 45 Korea, DPR 9 Sri Lanka 8
Bhutan 33 Maldives 0 Thailand 54
India Myanmar 101 Timor-Leste 0
Indonesia 35 Nepal 71
American Samoa 3 Korea, Rep. 158 Philippines 806
Australia 1 Lao, PDR 60 Samoa 1
Brunei Darussalam 1 Malaysia 10 Singapore 1
Cambodia 98 Marshall Islands, Republic of 22 Solomon Islands 1
China Micronesia, Federated States of 20 Tokelau 0
China, Hong Kong SAR 21 Mongolia 12 Tonga 2
China, Macao SAR 1 Nauru 0 Tuvalu 0
Cook Islands 1 New Caledonia 0 Vanuatu 1
Fiji 5 New Zealand 0 Vietnam 527
French Polynesia 0 Niue 0 Wallis and Futuna 2
Guam 1 N. Mariana Islands, Commonwealth of 0
Japan 14 Palau, Republic of 1
Kiribati 0 Papua New Guinea 0
1Country as reported by patient.
2Includes country codes currently reported via the National Tuberculosis Surveillance System that are not represented by WHO member 
states.
Note:  Regional composition of countries based on WHO Report Global Tuberculosis Control 2009, Epidemiology, Strategy, Financing, 
World Health Organization  (WHO/HTM/TB/2009.411) (http://www.who.int/tb/publications/global_report/en/).
Table 19.  (Cont’d) Tuberculosis Cases by Country of Origin1: United States, 2009
European Region
Total Cases = 229
Other2
Total Cases = 46
Unknown
Total Cases = 120
Southeast Asia Region
Total Cases = 891
Western	Pacific	Region
Total Cases = 2,110
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Morbidity Tables
Reporting Areas, 2009
36
37
United States 11,545 12,906 3.8 4.2 -- -- 307,006,550
Alabama 168 176 3.6 3.8 16 17 4,708,708
Alaska 37 50 5.3 7.3 4 3 698,473
Arizona 232 227 3.5 3.5 17 21 6,595,778
Arkansas 82 85 2.8 3 22 26 2,889,450
California 2,470 2,699 6.7 7.4 2 2 36,961,664
Colorado 85 103 1.7 2.1 36 31 5,024,748
Connecticut 95 98 2.7 2.8 24 27 3,518,288
Delaware 19 23 2.1 2.6 31 29 885,122
District of Columbia1 41 54 6.8 9.2 -- -- 586,409
Florida 821 957 4.4 5.2 7 6 18,537,969
Georgia 415 478 4.2 4.9 9 8 9,829,211
Hawaii 117 124 9 9.6 1 1 1,295,178
Idaho 18 11 1.2 0.7 44 48 1,545,801
Illinois 418 466 3.2 3.6 19 19 12,910,409
Indiana 119 118 1.9 1.8 33 38 6,423,113
Iowa 42 49 1.4 1.6 39 40 3,007,856
Kansas 64 57 2.3 2 29 32 2,818,747
Kentucky 77 101 1.8 2.4 34 30 4,314,113
Louisiana 194 227 4.3 5.1 8 7 4,492,076
Maine 9 9 0.7 0.7 49 49 1,318,301
Maryland 218 278 3.8 4.9 13 9 5,699,478
Massachusetts 243 261 3.7 4 14 14 6,593,587
Michigan 144 189 1.4 1.9 38 35 9,969,727
Minnesota 161 211 3.1 4 21 13 5,266,214
Mississippi 122 117 4.1 4 10 15 2,951,996
Missouri 80 107 1.3 1.8 40 39 5,987,580
Montana 8 9 0.8 0.9 47 47 974,989
Nebraska 32 33 1.8 1.9 35 36 1,796,619
Nevada 106 102 4 3.9 11 16 2,643,085
New Hampshire 16 19 1.2 1.4 42 42 1,324,575
New Jersey 405 421 4.7 4.9 6 10 8,707,739
New Mexico 48 60 2.4 3 26 25 2,009,671
New York 1,006 1,197 5.1 6.1 5 5 19,541,453
North Carolina 251 335 2.7 3.6 25 20 9,380,884
North Dakota 5 3 0.8 0.5 48 50 646,844
Ohio 180 213 1.6 1.8 37 37 11,542,645
Oklahoma 102 100 2.8 2.7 23 28 3,687,050
Oregon 89 75 2.3 2 27 34 3,825,657
Pennsylvania 236 387 1.9 3.1 32 24 12,604,767
Rhode Island 24 36 2.3 3.4 28 23 1,053,209
South Carolina 164 188 3.6 4.2 15 12 4,561,242
South Dakota 18 16 2.2 2 30 33 812,383
Tennessee 202 282 3.2 4.5 20 11 6,296,254
Texas 1,501 1,501 6.1 6.2 3 4 24,782,302
Utah 37 27 1.3 1 41 44 2,784,572
Vermont 7 6 1.1 1 45 45 621,760
Virginia 273 292 3.5 3.7 18 18 7,882,590
Washington 256 228 3.8 3.5 12 22 6,664,195
West Virginia 19 28 1 1.5 46 41 1,819,777
Wisconsin 67 68 1.2 1.2 43 43 5,654,774
Wyoming 2 5 0.4 0.9 50 46 544,270
American Samoa1,2 4 3 6.1 4.6 -- -- 65,628
Fed. States of Micronesia1,2 143 182 133.1 169 -- -- 107,434
Guam1,2 102 90 57.2 51.1 -- -- 178,430
Marshall Islands1,2 140 125 217 197.9 -- -- 64,522
N. Mariana Islands1,2 32 34 62.2 61.5 -- -- 51,484
Puerto Rico1,2 63 95 1.6 2.4 -- -- 3,967,288
Republic of Palau1,2 18 17 86.6 82.1 -- -- 20,796
U.S. Virgin Islands1,2 ... 4 ... 3.6 -- -- 109,809
Table 20. Tuberculosis Cases and Case Rates per 100,000 Population: 
Reporting Areas, 2009 and 2008
1Not ranked with the states. See Table 28 for District of Columbia ranking among states.
2Not included in U.S. totals. 
Note: Denominators for computing 2008 and 2009 rates for states, the District of Columbia, and Puerto Rico were obtained from An-
nual Estimates of the Population for the United States and States, and for Puerto Rico: April 1, 2000–July 1, 2009 (NST-EST2009-01) 
(accessed August 30, 2010)  (http://www.census.gov/popest/states/tables/NST-EST2009-01.xls); for all other areas, from IDB Summary 
Demographic Data (http://www.census.gov/ipc/www/idb/summaries.html).
Ellipses indicate data not available.
See Technical Notes (page 9).
See Surveillance Slide #4.
Reporting Area
Cases Case Rates Rank According to Rate
Population Estimates
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1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
Note: See Surveillance Slide #14.
Table 23. Tuberculosis Cases and Percentages, U.S.-born and Foreign-born Persons: 
States, 2009
States
Total
Cases No. No. No.(%) (%) (%)
U.S.-born Persons Foreign-born Persons1 Unknown Origin
United States 11,545 4,571 (39.6) 6,854 (59.4) 120 (1.0)
Alabama 168 126 (75.0) 42 (25.0) 0 (0.0)
Alaska 37 28 (75.7) 9 (24.3) 0 (0.0)
Arizona 232 78 (33.6) 154 (66.4) 0 (0.0)
Arkansas 82 67 (81.7) 15 (18.3) 0 (0.0)
California 2,470 588 (23.8) 1,860 (75.3) 22 (0.9)
Colorado 85 25 (29.4) 60 (70.6) 0 (0.0)
Connecticut 95 23 (24.2) 72 (75.8) 0 (0.0)
Delaware 19 7 (36.8) 12 (63.2) 0 (0.0)
District of Columbia 41 21 (51.2) 20 (48.8) 0 (0.0)
Florida 821 424 (51.6) 392 (47.7) 5 (0.6)
Georgia 415 238 (57.3) 176 (42.4) 1 (0.2)
Hawaii 117 35 (29.9) 81 (69.2) 1 (0.9)
Idaho 18 13 (72.2) 5 (27.8) 0 (0.0)
Illinois 418 157 (37.6) 261 (62.4) 0 (0.0)
Indiana 119 64 (53.8) 55 (46.2) 0 (0.0)
Iowa 42 13 (31.0) 29 (69.0) 0 (0.0)
Kansas 64 24 (37.5) 40 (62.5) 0 (0.0)
Kentucky 77 50 (64.9) 27 (35.1) 0 (0.0)
Louisiana 194 164 (84.5) 30 (15.5) 0 (0.0)
Maine 9 5 (55.6) 4 (44.4) 0 (0.0)
Maryland 218 53 (24.3) 165 (75.7) 0 (0.0)
Massachusetts 243 57 (23.5) 102 (42.0) 84 (34.6)
Michigan 144 73 (50.7) 71 (49.3) 0 (0.0)
Minnesota 161 32 (19.9) 129 (80.1) 0 (0.0)
Mississippi 122 112 (91.8) 10 (8.2) 0 (0.0)
Missouri 80 34 (42.5) 46 (57.5) 0 (0.0)
Montana 8 3 (37.5) 5 (62.5) 0 (0.0)
Nebraska 32 4 (12.5) 28 (87.5) 0 (0.0)
Nevada 106 35 (33.0) 71 (67.0) 0 (0.0)
New Hampshire 16 2 (12.5) 14 (87.5) 0 (0.0)
New Jersey 405 107 (26.4) 298 (73.6) 0 (0.0)
New Mexico 48 28 (58.3) 20 (41.7) 0 (0.0)
New York 1,006 252 (25.0) 750 (74.6) 4 (0.4)
North Carolina 251 160 (63.7) 91 (36.3) 0 (0.0)
North Dakota 5 1 (20.0) 4 (80.0) 0 (0.0)
Ohio 180 87 (48.3) 92 (51.1) 1 (0.6)
Oklahoma 102 82 (80.4) 20 (19.6) 0 (0.0)
Oregon 89 28 (31.5) 61 (68.5) 0 (0.0)
Pennsylvania 236 108 (45.8) 127 (53.8) 1 (0.4)
Rhode Island 24 5 (20.8) 19 (79.2) 0 (0.0)
South Carolina 164 111 (67.7) 53 (32.3) 0 (0.0)
South Dakota 18 14 (77.8) 4 (22.2) 0 (0.0)
Tennessee 202 133 (65.8) 69 (34.2) 0 (0.0)
Texas 1,501 705 (47.0) 796 (53.0) 0 (0.0)
Utah 37 11 (29.7) 26 (70.3) 0 (0.0)
Vermont 7 0 (0.0) 7 (100.0) 0 (0.0)
Virginia 273 83 (30.4) 190 (69.6) 0 (0.0)
Washington 256 62 (24.2) 194 (75.8) 0 (0.0)
West Virginia 19 10 (52.6) 9 (47.4) 0 (0.0)
Wisconsin 67 28 (41.8) 38 (56.7) 1 (1.5)
Wyoming 2 1 (50.0) 1 (50.0) 0 (0.0)
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Table 25. Tuberculosis Cases and Percentages in Foreign-born Persons1 by Number of Years 
in the United States: States, 2009
State
Total
Cases
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands.
                 
<1 Year 1–4 5–9 10–19 >20 Unknown or 
Missing
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
United States 6,854 1,019 (14.9) 1,405 (20.5) 1,072 (15.6) 1,240 (18.1) 1,408 (20.5) 710 (10.4)
Alabama 42 6 (14.3) 15 (35.7) 8 (19.0) 5 (11.9) 7 (16.7) 1 (2.4)
Alaska 9 2 (22.2) 2 (22.2) 1 (11.1) 3 (33.3) 1 (11.1) 0 (0.0)
Arizona 154 45 (29.2) 15 (9.7) 22 (14.3) 20 (13.0) 32 (20.8) 20 (13.0)
Arkansas 15 2 (13.3) 4 (26.7) 5 (33.3) 1 (6.7) 2 (13.3) 1 (6.7)
California 1,860 176 (9.5) 261 (14.0) 248 (13.3) 335 (18.0) 538 (28.9) 302 (16.2)
Colorado 60 14 (23.3) 4 (6.7) 9 (15.0) 12 (20.0) 12 (20.0) 9 (15.0)
Connecticut 72 8 (11.1) 14 (19.4) 22 (30.6) 16 (22.2) 10 (13.9) 2 (2.8)
Delaware 12 1 (8.3) 5 (41.7) 2 (16.7) 3 (25.0) 1 (8.3) 0 (0.0)
District of Columbia 20 3 (15.0) 4 (20.0) 5 (25.0) 3 (15.0) 4 (20.0) 1 (5.0)
Florida 392 57 (14.5) 62 (15.8) 59 (15.1) 61 (15.6) 74 (18.9) 79 (20.2)
Georgia 176 31 (17.6) 53 (30.1) 32 (18.2) 37 (21.0) 17 (9.7) 6 (3.4)
Hawaii 81 12 (14.8) 15 (18.5) 9 (11.1) 15 (18.5) 19 (23.5) 11 (13.6)
Idaho 5 1 (20.0) 1 (20.0) 1 (20.0) 1 (20.0) 1 (20.0) 0 (0.0)
Illinois 261 36 (13.8) 48 (18.4) 37 (14.2) 43 (16.5) 51 (19.5) 46 (17.6)
Indiana 55 12 (21.8) 7 (12.7) 3 (5.5) 2 (3.6) 0 (0.0) 31 (56.4)
Iowa 29 2 (6.9) 0 (0.0) 2 (6.9) 0 (0.0) 0 (0.0) 25 (86.2)
Kansas 40 15 (37.5) 10 (25.0) 3 (7.5) 7 (17.5) 5 (12.5) 0 (0.0)
Kentucky 27 4 (14.8) 9 (33.3) 8 (29.6) 6 (22.2) 0 (0.0) 0 (0.0)
Louisiana 30 5 (16.7) 4 (13.3) 5 (16.7) 8 (26.7) 7 (23.3) 1 (3.3)
Maine 4 3 (75.0) 1 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Maryland 165 21 (12.7) 56 (33.9) 37 (22.4) 24 (14.5) 27 (16.4) 0 (0.0)
Massachusetts 102 20 (19.6) 26 (25.5) 13 (12.7) 22 (21.6) 21 (20.6) 0 (0.0)
Michigan 71 12 (16.9) 24 (33.8) 7 (9.9) 7 (9.9) 12 (16.9) 9 (12.7)
Minnesota 129 16 (12.4) 40 (31.0) 33 (25.6) 29 (22.5) 10 (7.8) 1 (0.8)
Mississippi 10 2 (20.0) 4 (40.0) 1 (10.0) 2 (20.0) 1 (10.0) 0 (0.0)
Missouri 46 13 (28.3) 11 (23.9) 5 (10.9) 9 (19.6) 8 (17.4) 0 (0.0)
Montana 5 3 (60.0) 2 (40.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nebraska 28 6 (21.4) 9 (32.1) 4 (14.3) 3 (10.7) 6 (21.4) 0 (0.0)
Nevada 71 21 (29.6) 8 (11.3) 15 (21.1) 17 (23.9) 8 (11.3) 2 (2.8)
New Hampshire 14 7 (50.0) 2 (14.3) 0 (0.0) 1 (7.1) 1 (7.1) 3 (21.4)
New Jersey 298 43 (14.4) 77 (25.8) 39 (13.1) 33 (11.1) 29 (9.7) 77 (25.8)
New Mexico 20 8 (40.0) 3 (15.0) 1 (5.0) 3 (15.0) 4 (20.0) 1 (5.0)
New York 750 97 (12.9) 183 (24.4) 142 (18.9) 147 (19.6) 163 (21.7) 18 (2.4)
North Carolina 91 14 (15.4) 20 (22.0) 22 (24.2) 23 (25.3) 9 (9.9) 3 (3.3)
North Dakota 4 2 (50.0) 2 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ohio 92 17 (18.5) 28 (30.4) 17 (18.5) 20 (21.7) 10 (10.9) 0 (0.0)
Oklahoma 20 1 (5.0) 0 (0.0) 2 (10.0) 3 (15.0) 0 (0.0) 14 (70.0)
Oregon 61 10 (16.4) 7 (11.5) 6 (9.8) 6 (9.8) 4 (6.6) 28 (45.9)
Pennsylvania 127 20 (15.7) 31 (24.4) 20 (15.7) 27 (21.3) 17 (13.4) 12 (9.4)
Rhode Island 19 3 (15.8) 1 (5.3) 2 (10.5) 3 (15.8) 10 (52.6) 0 (0.0)
South Carolina 53 8 (15.1) 21 (39.6) 6 (11.3) 10 (18.9) 8 (15.1) 0 (0.0)
South Dakota 4 0 (0.0) 1 (25.0) 2 (50.0) 1 (25.0) 0 (0.0) 0 (0.0)
Tennessee 69 11 (15.9) 24 (34.8) 18 (26.1) 10 (14.5) 6 (8.7) 0 (0.0)
Texas 796 143 (18.0) 168 (21.1) 128 (16.1) 159 (20.0) 198 (24.9) 0 (0.0)
Utah 26 3 (11.5) 8 (30.8) 6 (23.1) 5 (19.2) 4 (15.4) 0 (0.0)
Vermont 7 2 (28.6) 0 (0.0) 1 (14.3) 4 (57.1) 0 (0.0) 0 (0.0)
Virginia 190 32 (16.8) 61 (32.1) 31 (16.3) 38 (20.0) 27 (14.2) 1 (0.5)
Washington 194 39 (20.1) 43 (22.2) 26 (13.4) 46 (23.7) 34 (17.5) 6 (3.1)
West Virginia 9 3 (33.3) 3 (33.3) 1 (11.1) 0 (0.0) 2 (22.2) 0 (0.0)
Wisconsin 38 7 (18.4) 7 (18.4) 6 (15.8) 10 (26.3) 8 (21.1) 0 (0.0)
Wyoming 1 0 (0.0) 1 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
47
United States 11,545 7,976 (69.1) 2,383 (20.6) 1,028 (8.9) 247
Alabama 168 129 (76.8) 22 (13.1) 12 (7.1) 5
Alaska 37 29 (78.4) 5 (13.5) 3 (8.1) 0
Arizona 232 170 (73.3) 39 (16.8) 17 (7.3) 11
Arkansas 82 66 (80.5) 10 (12.2) 4 (4.9) 1
California 2,470 1,678 (67.9) 557 (22.6) 234 (9.5) 28
Colorado 85 59 (69.4) 23 (27.1) 3 (3.5) 3
Connecticut 95 62 (65.3) 24 (25.3) 9 (9.5) 0
Delaware 19 11 (57.9) 6 (31.6) 2 (10.5) 1
District of Columbia 41 28 (68.3) 8 (19.5) 4 (9.8) 4
Florida 821 650 (79.2) 110 (13.4) 46 (5.6) 23
Georgia 415 297 (71.6) 72 (17.3) 35 (8.4) 10
Hawaii 117 91 (77.8) 16 (13.7) 8 (6.8) 2
Idaho 18 12 (66.7) 3 (16.7) 2 (11.1) 0
Illinois 418 271 (64.8) 107 (25.6) 40 (9.6) 1
Indiana 119 83 (69.7) 21 (17.6) 13 (10.9) 5
Iowa 42 25 (59.5) 14 (33.3) 1 (2.4) 1
Kansas 64 50 (78.1) 7 (10.9) 5 (7.8) 1
Kentucky 77 60 (77.9) 12 (15.6) 4 (5.2) 1
Louisiana 194 163 (84.0) 16 (8.2) 6 (3.1) 4
Maine 9 9 (100.0) 0 (0.0) 0 (0.0) 0
Maryland 218 142 (65.1) 47 (21.6) 24 (11.0) 7
Massachusetts 243 143 (58.8) 59 (24.3) 37 (15.2) 13
Michigan 144 94 (65.3) 44 (30.6) 6 (4.2) 6
Minnesota 161 82 (50.9) 58 (36.0) 18 (11.2) 3
Mississippi 122 96 (78.7) 17 (13.9) 9 (7.4) 0
Missouri 80 53 (66.3) 22 (27.5) 5 (6.3) 1
Montana 8 2 (25.0) 6 (75.0) 0 (0.0) 0
Nebraska 32 22 (68.8) 6 (18.8) 2 (6.3) 1
Nevada 106 83 (78.3) 17 (16.0) 5 (4.7) 2
New Hampshire 16 11 (68.8) 1 (6.3) 4 (25.0) 1
New Jersey 405 259 (64.0) 96 (23.7) 43 (10.6) 7
New Mexico 48 35 (72.9) 10 (20.8) 2 (4.2) 2
New York 1,006 641 (63.7) 250 (24.9) 109 (10.8) 11
North Carolina 251 171 (68.1) 57 (22.7) 23 (9.2) 2
North Dakota 5 2 (40.0) 3 (60.0) 0 (0.0) 0
Ohio 180 113 (62.8) 49 (27.2) 18 (10.0) 6
Oklahoma 102 57 (55.9) 28 (27.5) 9 (8.8) 2
Oregon 89 50 (56.2) 29 (32.6) 5 (5.6) 5
Pennsylvania 236 161 (68.2) 54 (22.9) 16 (6.8) 12
Rhode Island 24 11 (45.8) 11 (45.8) 1 (4.2) 1
South Carolina 164 97 (59.1) 24 (14.6) 41 (25.0) 13
South Dakota 18 12 (66.7) 5 (27.8) 1 (5.6) 0
Tennessee 202 150 (74.3) 31 (15.3) 18 (8.9) 4
Texas 1,501 1,126 (75.0) 247 (16.5) 102 (6.8) 29
Utah 37 19 (51.4) 14 (37.8) 4 (10.8) 0
Vermont 7 4 (57.1) 1 (14.3) 2 (28.6) 0
Virginia 273 184 (67.4) 45 (16.5) 42 (15.4) 6
Washington 256 156 (60.9) 63 (24.6) 23 (9.0) 7
West Virginia 19 12 (63.2) 3 (15.8) 3 (15.8) 2
Wisconsin 67 44 (65.7) 14 (20.9) 7 (10.4) 3
Wyoming 2 1 (50.0) 0 (0.0) 1 (50.0) 0
American Samoa4 4 2 (50.0) 1 (25.0) 0 (0.0) 0
Fed. States of Micronesia4 143 96 (67.1) 25 (17.5) 21 (14.7) 11
Guam4 102 83 (81.4) 9 (8.8) 8 (7.8) 5
Marshall Islands4 140 101 (72.1) 10 (7.1) 26 (18.6) 5
N. Mariana Islands4 32 27 (84.4) 3 (9.4) 0 (0.0) 0
Puerto Rico4 63 54 (85.7) 8 (12.7) 1 (1.6) 1
Republic of Palau4 18 15 (83.3) 3 (16.7) 0 (0.0) 0
U.S. Virgin Islands4 ... ... ... ... ... ... ... ...
Table 26. Tuberculosis Cases and Percentages by Pulmonary and Extrapulmonary Disease: 
Reporting Areas, 2009
Reporting Area
Total
Cases
Pulmonary1 Extrapulmonary2
Pulmonary and
Extrapulmonary Cases
Total3 Miliary
No. No. No. No.(%) (%) (%)
1Includes cases with pulmonary listed as the only site of disease.
2Includes cases with pleural, lymphatic, bone and/or joint, meningeal, peritoneal, genitourinary, or other site, excluding pulmonary, listed 
as site of disease.
3Includes cases with evidence of miliary disease.
4Not included in U.S. totals.
Note: 158 cases had missing and/or unknown site of disease.
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>= 500 cases in 2009
California 2,470 6.7 2,699 7.4 -8.5 -9.5 3
Texas 1,501 6.1 1,501 6.2 0.0 -1.6 4
New York1 1,006 5.1 1,197 6.1 -16.0 -16.4 6
Florida 821 4.4 957 5.2 -14.2 -15.4 8
100 - 499 cases in 2009
Illinois 418 3.2 466 3.6 -10.3 -11.1 20
Georgia 415 4.2 478 4.9 -13.2 -14.3 10
New Jersey 405 4.7 421 4.9 -3.8 -4.1 7
Virginia 273 3.5 292 3.7 -6.5 -5.4 19
Washington 256 3.8 228 3.5 12.3 8.6 13
North Carolina 251 2.7 335 3.6 -25.1 -25.0 26
Massachusetts 243 3.7 261 4.0 -6.9 -7.5 15
Pennsylvania 236 1.9 387 3.1 -39.0 -38.7 33
Arizona 232 3.5 227 3.5 2.2 0.0 18
Maryland 218 3.8 278 4.9 -21.6 -22.4 14
Tennessee 202 3.2 282 4.5 -28.4 -28.9 21
Louisiana 194 4.3 227 5.1 -14.5 -15.7 9
Ohio 180 1.6 213 1.8 -15.5 -11.1 38
Alabama 168 3.6 176 3.8 -4.5 -5.3 17
South Carolina 164 3.6 188 4.2 -12.8 -14.3 16
Minnesota 161 3.1 211 4.0 -23.7 -22.5 22
Michigan 144 1.4 189 1.9 -23.8 -26.3 39
Mississippi 122 4.1 117 4.0 4.3 2.5 11
Indiana 119 1.9 118 1.8 0.8 5.6 34
Hawaii 117 9.0 124 9.6 -5.6 -6.2 1
Nevada 106 4.0 102 3.9 3.9 2.6 12
Oklahoma 102 2.8 100 2.7 2.0 3.7 24
< 100 cases in 2009
Connecticut 95 2.7 98 2.8 -3.1 -3.6 25
Oregon 89 2.3 75 2.0 18.7 15.0 28
Colorado 85 1.7 103 2.1 -17.5 -19.0 37
Arkansas 82 2.8 85 3.0 -3.5 -6.7 23
Missouri 80 1.3 107 1.8 -25.2 -27.8 41
Kentucky 77 1.8 101 2.4 -23.8 -25.0 35
Wisconsin 67 1.2 68 1.2 -1.5 0.0 44
Kansas 64 2.3 57 2.0 12.3 15.0 30
New Mexico 48 2.4 60 3.0 -20.0 -20.0 27
Iowa 42 1.4 49 1.6 -14.3 -12.5 40
District of Columbia 41 6.8 54 9.2 -24.1 -26.1 2
Alaska 37 5.3 50 7.3 -26.0 -27.4 5
Utah 37 1.3 27 1.0 37.0 30.0 42
Nebraska 32 1.8 33 1.9 -3.0 -5.3 36
Rhode Island 24 2.3 36 3.4 -33.3 -32.4 29
Delaware 19 2.1 23 2.6 -17.4 -19.2 32
West Virginia 19 1.0 28 1.5 -32.1 -33.3 47
Idaho 18 1.2 11 0.7 63.6 71.4 45
South Dakota 18 2.2 16 2.0 12.5 10.0 31
New Hampshire 16 1.2 19 1.4 -15.8 -14.3 43
Maine 9 0.7 9 0.7 0.0 0.0 50
Montana 8 0.8 9 0.9 -11.1 -11.1 48
Vermont 7 1.1 6 1.0 16.7 10.0 46
North Dakota 5 0.8 3 0.5 66.7 60.0 49
Wyoming 2 0.4 5 0.9 -60.0 -55.6 51
Total 11,545 3.8 12,906 4.2 -10.5 -9.5
Table 28.  Tuberculosis Cases and Case Rates per 100,000 Population, Ranked and 
Grouped by Number of Cases: States and the District of Columbia, 2009 and 2008
State
2009 2008 2008–2009 % Change
No. Rate No. No.
Overall 
Rank by 
2009 RateRate Rate
1Includes New York City.
Note: Denominators for computing 2008 and 2009 rates for states and the District of Columbia were obtained from Annual Es-
timates of the Population for the United States and States, and for Puerto Rico: April 1, 2000–July 1, 2009 (http://www.census.
gov/popest/states/tables/NST-EST2009-01.xls) (accessed August 30, 2010).
See Table 20 for ranking of states without the District of Columbia.
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Morbidity Tables
Reporting Areas, 2009 and 2007
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United States 10,893 10,853 (99.6) 461 (4.2)
Alabama 159 159 (100.0) 2 (1.3)
Alaska 35 35 (100.0) 0 (0.0)
Arizona 216 216 (100.0) 37 (17.1)
Arkansas 73 73 (100.0) 3 (4.1)
California 2,347 2,342 (99.8) 67 (2.9)
Colorado 74 74 (100.0) 2 (2.7)
Connecticut 91 91 (100.0) 0 (0.0)
Delaware 18 18 (100.0) 0 (0.0)
District of Columbia 40 40 (100.0) 0 (0.0)
Florida 793 793 (100.0) 43 (5.4)
Georgia 391 390 (99.7) 25 (6.4)
Hawaii 115 114 (99.1) 0 (0.0)
Idaho 15 15 (100.0) 0 (0.0)
Illinois 402 400 (99.5) 6 (1.5)
Indiana 112 112 (100.0) 6 (5.4)
Iowa 40 40 (100.0) 0 (0.0)
Kansas 59 58 (98.3) 1 (1.7)
Kentucky 75 75 (100.0) 0 (0.0)
Louisiana 186 186 (100.0) 7 (3.8)
Maine 7 7 (100.0) 0 (0.0)
Maryland 206 205 (99.5) 0 (0.0)
Massachusetts 231 231 (100.0) 2 (0.9)
Michigan 141 139 (98.6) 5 (3.6)
Minnesota 142 142 (100.0) 3 (2.1)
Mississippi 116 116 (100.0) 4 (3.4)
Missouri 74 73 (98.6) 1 (1.4)
Montana 7 7 (100.0) 0 (0.0)
Nebraska 29 29 (100.0) 0 (0.0)
Nevada 90 87 (96.7) 1 (1.1)
New Hampshire 16 16 (100.0) 0 (0.0)
New Jersey 391 391 (100.0) 4 (1.0)
New Mexico 48 48 (100.0) 5 (10.4)
New York State2 223 217 (97.3) 7 (3.2)
New York City 734 734 (100.0) 10 (1.4)
North Carolina 233 233 (100.0) 6 (2.6)
North Dakota 5 5 (100.0) 0 (0.0)
Ohio 173 170 (98.3) 4 (2.4)
Oklahoma 85 72 (84.7) 2 (2.8)
Oregon 88 88 (100.0) 0 (0.0)
Pennsylvania 225 224 (99.6) 3 (1.3)
Rhode Island 23 23 (100.0) 0 (0.0)
South Carolina 147 147 (100.0) 5 (3.4)
South Dakota 18 18 (100.0) 1 (5.6)
Tennessee 191 191 (100.0) 6 (3.1)
Texas 1,395 1,395 (100.0) 174 (12.5)
Utah 33 33 (100.0) 0 (0.0)
Vermont 6 6 (100.0) 0 (0.0)
Virginia 250 250 (100.0) 3 (1.2)
Washington 239 239 (100.0) 11 (4.6)
West Virginia 18 18 (100.0) 3 (16.7)
Wisconsin 66 66 (100.0) 2 (3.0)
Wyoming 2 2 (100.0) 0 (0.0)
American Samoa3 4 4 (100.0) 0 (0.0)
Fed. States of Micronesia3 86 86 (100.0) 0 (0.0)
Guam3 74 74 (100.0) 0 (0.0)
Marshall Islands3 113 112 (99.1) 0 (0.0)
N. Mariana Islands3 32 32 (100.0) 0 (0.0)
Puerto Rico3 61 61 (100.0) 1 (1.6)
Republic of Palau3 18 18 (100.0) 0 (0.0)
U.S. Virgin Islands3 ... ... ... ... ...
Table 29. Tuberculosis Cases and Percentages by Residence in Correctional Facilities, 
Age > 15: Reporting Areas, 2009
Reporting Area
Total 
Cases
Cases with Information on Residence
 in Correctional Facilities
Cases Reported As Residents
 of Correctional Facilities1
No. No.(%) (%)
1Resident of correctional facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the Dis-
trict of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals.
Note: Ellipses indicate data not available.
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United States 10,893 10,729 (98.5) 567 (5.3)
Alabama 159 159 (100.0) 9 (5.7)
Alaska 35 35 (100.0) 4 (11.4)
Arizona 216 194 (89.8) 8 (4.1)
Arkansas 73 73 (100.0) 4 (5.5)
California 2,347 2,326 (99.1) 103 (4.4)
Colorado 74 74 (100.0) 5 (6.8)
Connecticut 91 91 (100.0) 1 (1.1)
Delaware 18 18 (100.0) 1 (5.6)
District of Columbia 40 40 (100.0) 1 (2.5)
Florida 793 747 (94.2) 61 (8.2)
Georgia 391 389 (99.5) 47 (12.1)
Hawaii 115 104 (90.4) 6 (5.8)
Idaho 15 15 (100.0) 0 (0.0)
Illinois 402 393 (97.8) 25 (6.4)
Indiana 112 111 (99.1) 16 (14.4)
Iowa 40 40 (100.0) 0 (0.0)
Kansas 59 58 (98.3) 6 (10.3)
Kentucky 75 75 (100.0) 5 (6.7)
Louisiana 186 186 (100.0) 13 (7.0)
Maine 7 7 (100.0) 1 (14.3)
Maryland 206 204 (99.0) 6 (2.9)
Massachusetts 231 231 (100.0) 16 (6.9)
Michigan 141 136 (96.5) 12 (8.8)
Minnesota 142 142 (100.0) 4 (2.8)
Mississippi 116 116 (100.0) 24 (20.7)
Missouri 74 69 (93.2) 3 (4.3)
Montana 7 7 (100.0) 1 (14.3)
Nebraska 29 29 (100.0) 1 (3.4)
Nevada 90 90 (100.0) 5 (5.6)
New Hampshire 16 16 (100.0) 0 (0.0)
New Jersey 391 391 (100.0) 8 (2.0)
New Mexico 48 48 (100.0) 2 (4.2)
New York State2 223 212 (95.1) 4 (1.9)
New York City 734 719 (98.0) 28 (3.9)
North Carolina 233 232 (99.6) 16 (6.9)
North Dakota 5 5 (100.0) 0 (0.0)
Ohio 173 169 (97.7) 10 (5.9)
Oklahoma 85 78 (91.8) 6 (7.7)
Oregon 88 88 (100.0) 9 (10.2)
Pennsylvania 225 225 (100.0) 10 (4.4)
Rhode Island 23 23 (100.0) 0 (0.0)
South Carolina 147 147 (100.0) 4 (2.7)
South Dakota 18 18 (100.0) 1 (5.6)
Tennessee 191 191 (100.0) 15 (7.9)
Texas 1,395 1,395 (100.0) 39 (2.8)
Utah 33 33 (100.0) 1 (3.0)
Vermont 6 6 (100.0) 0 (0.0)
Virginia 250 250 (100.0) 9 (3.6)
Washington 239 239 (100.0) 11 (4.6)
West Virginia 18 18 (100.0) 1 (5.6)
Wisconsin 66 65 (98.5) 5 (7.7)
Wyoming 2 2 (100.0) 0 (0.0)
American Samoa3 4 4 (100.0) 0 (0.0)
Fed. States of Micronesia3 86 86 (100.0) 0 (0.0)
Guam3 74 74 (100.0) 0 (0.0)
Marshall Islands3 113 111 (98.2) 1 (0.9)
N. Mariana Islands3 32 32 (100.0) 0 (0.0)
Puerto Rico3 61 61 (100.0) 0 (0.0)
Republic of Palau3 18 18 (100.0) 0 (0.0)
U.S. Virgin Islands3 ... ... ... ... ...
Reporting Area
Total 
Cases
Cases with Information
on Homeless Status
Cases Reported As
Being Homeless 
No. No.(%) (%)
Table 30. Tuberculosis Cases and Percentages by Homeless Status,1 Age >15: Reporting 
Areas, 2009
1Homeless within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 10,893 10,845 (99.6) 238 (2.2)
Alabama 159 159 (100.0) 4 (2.5)
Alaska 35 35 (100.0) 0 (0.0)
Arizona 216 213 (98.6) 2 (0.9)
Arkansas 73 73 (100.0) 3 (4.1)
California 2,347 2,344 (99.9) 48 (2.0)
Colorado 74 74 (100.0) 0 (0.0)
Connecticut 91 91 (100.0) 1 (1.1)
Delaware 18 18 (100.0) 1 (5.6)
District of Columbia 40 40 (100.0) 0 (0.0)
Florida 793 793 (100.0) 15 (1.9)
Georgia 391 389 (99.5) 7 (1.8)
Hawaii 115 112 (97.4) 3 (2.7)
Idaho 15 15 (100.0) 2 (13.3)
Illinois 402 396 (98.5) 13 (3.3)
Indiana 112 111 (99.1) 1 (0.9)
Iowa 40 40 (100.0) 0 (0.0)
Kansas 59 58 (98.3) 1 (1.7)
Kentucky 75 75 (100.0) 6 (8.0)
Louisiana 186 186 (100.0) 9 (4.8)
Maine 7 7 (100.0) 0 (0.0)
Maryland 206 204 (99.0) 6 (2.9)
Massachusetts 231 231 (100.0) 4 (1.7)
Michigan 141 139 (98.6) 7 (5.0)
Minnesota 142 142 (100.0) 1 (0.7)
Mississippi 116 116 (100.0) 10 (8.6)
Missouri 74 73 (98.6) 1 (1.4)
Montana 7 7 (100.0) 0 (0.0)
Nebraska 29 29 (100.0) 1 (3.4)
Nevada 90 88 (97.8) 1 (1.1)
New Hampshire 16 16 (100.0) 1 (6.3)
New Jersey 391 391 (100.0) 7 (1.8)
New Mexico 48 48 (100.0) 1 (2.1)
New York State2 223 217 (97.3) 7 (3.2)
New York City 734 734 (100.0) 14 (1.9)
North Carolina 233 233 (100.0) 7 (3.0)
North Dakota 5 5 (100.0) 0 (0.0)
Ohio 173 170 (98.3) 3 (1.8)
Oklahoma 85 72 (84.7) 4 (5.6)
Oregon 88 88 (100.0) 3 (3.4)
Pennsylvania 225 225 (100.0) 9 (4.0)
Rhode Island 23 23 (100.0) 1 (4.3)
South Carolina 147 147 (100.0) 3 (2.0)
South Dakota 18 18 (100.0) 0 (0.0)
Tennessee 191 191 (100.0) 3 (1.6)
Texas 1,395 1,395 (100.0) 15 (1.1)
Utah 33 33 (100.0) 0 (0.0)
Vermont 6 6 (100.0) 0 (0.0)
Virginia 250 250 (100.0) 1 (0.4)
Washington 239 239 (100.0) 9 (3.8)
West Virginia 18 18 (100.0) 0 (0.0)
Wisconsin 66 66 (100.0) 2 (3.0)
Wyoming 2 2 (100.0) 1 (50.0)
American Samoa3 4 4 (100.0) 0 (0.0)
Fed. States of Micronesia3 86 86 (100.0) 15 (17.4)
Guam3 74 73 (98.6) 0 (0.0)
Marshall Islands3 113 111 (98.2) 15 (13.5)
N. Mariana Islands3 32 32 (100.0) 0 (0.0)
Puerto Rico3 61 61 (100.0) 0 (0.0)
Republic of Palau3 18 18 (100.0) 0 (0.0)
U.S. Virgin Islands3 ... ... ... ... ...
Reporting Area
Total 
Cases
Cases with Information on
Residence in Long-term Care Facilities
Cases Reported As Residents of
Long-term Care Facilities
No. No.(%) (%)
Table 31. Tuberculosis Cases and Percentages by Residence in Long-term Care Facilities,1 
Age >15: Reporting Areas, 2009
1Resident of long-term care facility at time of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 10,893 10,590 (97.2) 152 (1.4)
Alabama 159 159 (100.0) 1 (0.6)
Alaska 35 35 (100.0) 0 (0.0)
Arizona 216 187 (86.6) 3 (1.6)
Arkansas 73 71 (97.3) 2 (2.8)
California 2,347 2,282 (97.2) 26 (1.1)
Colorado 74 73 (98.6) 1 (1.4)
Connecticut 91 91 (100.0) 0 (0.0)
Delaware 18 17 (94.4) 0 (0.0)
District of Columbia 40 40 (100.0) 0 (0.0)
Florida 793 773 (97.5) 5 (0.6)
Georgia 391 383 (98.0) 4 (1.0)
Hawaii 115 71 (61.7) -- --
Idaho 15 14 (93.3) 0 (0.0)
Illinois 402 380 (94.5) 7 (1.8)
Indiana 112 110 (98.2) 2 (1.8)
Iowa 40 40 (100.0) 1 (2.5)
Kansas 59 56 (94.9) 0 (0.0)
Kentucky 75 72 (96.0) 0 (0.0)
Louisiana 186 184 (98.9) 11 (6.0)
Maine 7 7 (100.0) 1 (14.3)
Maryland 206 199 (96.6) 2 (1.0)
Massachusetts 231 231 (100.0) 3 (1.3)
Michigan 141 133 (94.3) 6 (4.5)
Minnesota 142 142 (100.0) 0 (0.0)
Mississippi 116 116 (100.0) 0 (0.0)
Missouri 74 73 (98.6) 0 (0.0)
Montana 7 7 (100.0) 0 (0.0)
Nebraska 29 27 (93.1) 0 (0.0)
Nevada 90 86 (95.6) 0 (0.0)
New Hampshire 16 16 (100.0) 0 (0.0)
New Jersey 391 391 (100.0) 6 (1.5)
New Mexico 48 47 (97.9) 2 (4.3)
New York State2 223 202 (90.6) 1 (0.5)
New York City 734 717 (97.7) 11 (1.5)
North Carolina 233 233 (100.0) 4 (1.7)
North Dakota 5 5 (100.0) 0 (0.0)
Ohio 173 168 (97.1) 2 (1.2)
Oklahoma 85 74 (87.1) 4 (5.4)
Oregon 88 87 (98.9) 1 (1.1)
Pennsylvania 225 222 (98.7) 5 (2.3)
Rhode Island 23 23 (100.0) 0 (0.0)
South Carolina 147 145 (98.6) 1 (0.7)
South Dakota 18 18 (100.0) 0 (0.0)
Tennessee 191 191 (100.0) 2 (1.0)
Texas 1,395 1,391 (99.7) 32 (2.3)
Utah 33 33 (100.0) 0 (0.0)
Vermont 6 6 (100.0) 0 (0.0)
Virginia 250 250 (100.0) 4 (1.6)
Washington 239 226 (94.6) 1 (0.4)
West Virginia 18 18 (100.0) 0 (0.0)
Wisconsin 66 66 (100.0) 1 (1.5)
Wyoming 2 2 (100.0) 0 (0.0)
Amercian Samoa3 4 4 (100.0) 0 (0.0)
Fed. States of Micronesia3 86 85 (98.8) 0 (0.0)
Guam3 74 74 (100.0) 0 (0.0)
Marshall Islands3 113 112 (99.1) 0 (0.0)
N. Mariana Islands3 32 32 (100.0) 0 (0.0)
Puerto Rico3 61 61 (100.0) 7 (11.5)
Republic of Palau3 18 18 (100.0) 0 (0.0)
U.S. Virgin Islands3 ... ... ... ... ...
Reporting Area
Total 
Cases
Cases with Information on
Injecting Drug Use
Cases Reporting Injecting Drug Use
No. No.(%) (%)
Table 32. Tuberculosis Cases and Percentages by Injecting Drug Use,1 Age >15: 
Reporting Areas, 2009
1Injecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 10,893 10,571 (97.0) 828 (7.8)
Alabama 159 158 (99.4) 31 (19.6)
Alaska 35 34 (97.1) 0 (0.0)
Arizona 216 187 (86.6) 17 (9.1)
Arkansas 73 72 (98.6) 3 (4.2)
California 2,347 2,284 (97.3) 135 (5.9)
Colorado 74 73 (98.6) 6 (8.2)
Connecticut 91 91 (100.0) 4 (4.4)
Delaware 18 18 (100.0) 2 (11.1)
District of Columbia 40 40 (100.0) 2 (5.0)
Florida 793 775 (97.7) 89 (11.5)
Georgia 391 382 (97.7) 44 (11.5)
Hawaii 115 67 (58.3) -- --
Idaho 15 14 (93.3) 2 (14.3)
Illinois 402 378 (94.0) 37 (9.8)
Indiana 112 111 (99.1) 13 (11.7)
Iowa 40 40 (100.0) 1 (2.5)
Kansas 59 58 (98.3) 5 (8.6)
Kentucky 75 72 (96.0) 5 (6.9)
Louisiana 186 184 (98.9) 40 (21.7)
Maine 7 7 (100.0) 2 (28.6)
Maryland 206 197 (95.6) 10 (5.1)
Massachusetts 231 230 (99.6) 7 (3.0)
Michigan 141 132 (93.6) 20 (15.2)
Minnesota 142 142 (100.0) 6 (4.2)
Mississippi 116 116 (100.0) 19 (16.4)
Missouri 74 70 (94.6) 3 (4.3)
Montana 7 7 (100.0) 0 (0.0)
Nebraska 29 27 (93.1) 0 (0.0)
Nevada 90 85 (94.4) 3 (3.5)
New Hampshire 16 16 (100.0) 0 (0.0)
New Jersey 391 391 (100.0) 16 (4.1)
New Mexico 48 48 (100.0) 4 (8.3)
New York State2 223 199 (89.2) 10 (5.0)
New York City 734 717 (97.7) 40 (5.6)
North Carolina 233 233 (100.0) 40 (17.2)
North Dakota 5 5 (100.0) 0 (0.0)
Ohio 173 167 (96.5) 10 (6.0)
Oklahoma 85 74 (87.1) 10 (13.5)
Oregon 88 87 (98.9) 7 (8.0)
Pennsylvania 225 222 (98.7) 15 (6.8)
Rhode Island 23 23 (100.0) 0 (0.0)
South Carolina 147 145 (98.6) 18 (12.4)
South Dakota 18 18 (100.0) 0 (0.0)
Tennessee 191 191 (100.0) 25 (13.1)
Texas 1,395 1,386 (99.4) 107 (7.7)
Utah 33 33 (100.0) 1 (3.0)
Vermont 6 6 (100.0) 0 (0.0)
Virginia 250 249 (99.6) 6 (2.4)
Washington 239 225 (94.1) 8 (3.6)
West Virginia 18 18 (100.0) 0 (0.0)
Wisconsin 66 66 (100.0) 3 (4.5)
Wyoming 2 1 (50.0) -- --
American Samoa3 4 4 (100.0) 0 (0.0)
Fed. States of Micronesia3 86 85 (98.8) 0 (0.0)
Guam3 74 74 (100.0) 0 (0.0)
Marshall Islands3 113 112 (99.1) 0 (0.0)
N. Mariana Islands3 32 32 (100.0) 0 (0.0)
Puerto Rico3 61 61 (100.0) 10 (16.4)
Republic of Palau3 18 17 (94.4) 0 (0.0)
U.S. Virgin Islands3 ... ... ... ... ...
Reporting Area
Total 
Cases
Cases with Information on
Noninjecting Drug Use
Cases Reporting Noninjecting Drug Use
No. No.(%) (%)
Table 33. Tuberculosis Cases and Percentages by Noninjecting Drug Use,1 Age >15: 
Reporting Areas, 2009
1Noninjecting drug use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 10,893 10,609 (97.4) 1,382 (13.0)
Alabama 159 157 (98.7) 33 (21.0)
Alaska 35 35 (100.0) 2 (5.7)
Arizona 216 186 (86.1) 16 (8.6)
Arkansas 73 72 (98.6) 13 (18.1)
California 2,347 2,290 (97.6) 195 (8.5)
Colorado 74 74 (100.0) 8 (10.8)
Connecticut 91 91 (100.0) 4 (4.4)
Delaware 18 17 (94.4) 2 (11.8)
District of Columbia 40 40 (100.0) 1 (2.5)
Florida 793 779 (98.2) 156 (20.0)
Georgia 391 381 (97.4) 65 (17.1)
Hawaii 115 80 (69.6) -- --
Idaho 15 15 (100.0) 1 (6.7)
Illinois 402 379 (94.3) 55 (14.5)
Indiana 112 111 (99.1) 29 (26.1)
Iowa 40 40 (100.0) 5 (12.5)
Kansas 59 58 (98.3) 9 (15.5)
Kentucky 75 73 (97.3) 12 (16.4)
Louisiana 186 184 (98.9) 42 (22.8)
Maine 7 7 (100.0) 3 (42.9)
Maryland 206 195 (94.7) 14 (7.2)
Massachusetts 231 228 (98.7) 18 (7.9)
Michigan 141 132 (93.6) 23 (17.4)
Minnesota 142 142 (100.0) 7 (4.9)
Mississippi 116 116 (100.0) 11 (9.5)
Missouri 74 74 (100.0) 2 (2.7)
Montana 7 7 (100.0) 2 (28.6)
Nebraska 29 27 (93.1) 1 (3.7)
Nevada 90 86 (95.6) 11 (12.8)
New Hampshire 16 16 (100.0) 0 (0.0)
New Jersey 391 391 (100.0) 23 (5.9)
New Mexico 48 47 (97.9) 5 (10.6)
New York State2 223 203 (91.0) 23 (11.3)
New York City 734 719 (98.0) 89 (12.4)
North Carolina 233 233 (100.0) 42 (18.0)
North Dakota 5 5 (100.0) 0 (0.0)
Ohio 173 167 (96.5) 16 (9.6)
Oklahoma 85 76 (89.4) 14 (18.4)
Oregon 88 88 (100.0) 12 (13.6)
Pennsylvania 225 222 (98.7) 25 (11.3)
Rhode Island 23 23 (100.0) 0 (0.0)
South Carolina 147 146 (99.3) 31 (21.2)
South Dakota 18 18 (100.0) 5 (27.8)
Tennessee 191 189 (99.0) 36 (19.0)
Texas 1,395 1,392 (99.8) 263 (18.9)
Utah 33 33 (100.0) 2 (6.1)
Vermont 6 6 (100.0) 0 (0.0)
Virginia 250 249 (99.6) 22 (8.8)
Washington 239 225 (94.1) 17 (7.6)
West Virginia 18 18 (100.0) 2 (11.1)
Wisconsin 66 65 (98.5) 9 (13.8)
Wyoming 2 2 (100.0) 1 (50.0)
American Samoa3 4 4 (100.0) 0 (0.0)
Fed. States of Micronesia3 86 81 (94.2) 0 (0.0)
Guam3 74 74 (100.0) 0 (0.0)
Marshall Islands3 113 109 (96.5) 16 (14.7)
N. Mariana Islands3 32 32 (100.0) 4 (12.5)
Puerto Rico3 61 61 (100.0) 8 (13.1)
Republic of Palau3 18 17 (94.4) 2 (11.8)
U.S. Virgin Islands3 ... ... ... ... ...
Reporting Area
Total 
Cases
Cases with Information on
Excess Alcohol Use
Cases Reporting
Excess Alcohol Use
No. No.(%) (%)
Table 34. Tuberculosis Cases and Percentages by Excess Alcohol Use,1 Age >15: 
Reporting Areas, 2009
1Excess alcohol use within past 12 months of TB diagnosis. Percentage based on 52 reporting areas (50 states, New York City, and the 
District of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
2Excludes New York City.
3Not included in U.S. totals. 
Note: Ellipses indicate data not available.
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United States 11,545 11,304 11,212 (99.2) (1.0) (3.0) (84.0)
Alabama 168 164 164 (100.0) (0.0) (4.9) (75.0)
Alaska 37 36 36 (100.0) (0.0) (2.8) (91.7)
Arizona 232 227 223 (98.2) (0.9) (6.7) (65.0)
Arkansas 82 75 75 (100.0) (0.0) (2.7) (13.3)
California 2,470 2,428 2,427 (100.0) (0.5) (2.4) (87.0)
Colorado 85 84 84 (100.0) (0.0) (1.2) (81.0)
Connecticut 95 92 92 (100.0) (1.1) (3.3) (88.0)
Delaware 19 19 19 (100.0) (0.0) (5.3) (84.2)
District of Columbia 41 39 39 (100.0) (0.0) (0.0) (92.3)
Florida 821 799 799 (100.0) (0.3) (2.6) (82.6)
Georgia 415 409 409 (100.0) (2.0) (0.0) (87.8)
Hawaii 117 116 115 (99.1) (7.0) (8.7) (70.4)
Idaho 18 18 18 (100.0) (0.0) (11.1) (83.3)
Illinois 418 408 408 (100.0) (1.0) (2.9) (85.5)
Indiana 119 117 116 (99.1) (0.0) (4.3) (90.5)
Iowa 42 41 41 (100.0) (0.0) (4.9) (92.7)
Kansas 64 62 62 (100.0) (3.2) (6.5) (83.9)
Kentucky 77 76 76 (100.0) (0.0) (2.6) (81.6)
Louisiana 194 185 185 (100.0) (1.6) (2.2) (90.3)
Maine 9 9 9 (100.0) (0.0) (0.0) (55.6)
Maryland 218 212 212 (100.0) (0.9) (3.3) (84.9)
Massachusetts 243 240 240 (100.0) (1.7) (1.7) (73.8)
Michigan 144 135 131 (97.0) (0.8) (3.8) (79.4)
Minnesota 161 161 161 (100.0) (1.2) (1.9) (78.3)
Mississippi 122 118 118 (100.0) (0.0) (9.3) (83.9)
Missouri 80 80 80 (100.0) (0.0) (8.8) (81.3)
Montana 8 8 8 (100.0) (0.0) (0.0) (100.0)
Nebraska 32 31 31 (100.0) (0.0) (6.5) (71.0)
Nevada 106 103 103 (100.0) (0.0) (1.0) (95.1)
New Hampshire 16 16 16 (100.0) (0.0) (6.3) (75.0)
New Jersey 405 401 401 (100.0) (0.5) (4.2) (87.3)
New  Mexico 48 41 40 (97.6) (0.0) (0.0) (95.0)
New York State3 246 240 239 (99.6) (0.4) (4.2) (83.3)
New York City 760 747 747 (100.0) (0.9) (2.3) (87.0)
North Carolina 251 245 245 (100.0) (0.8) (2.4) (91.4)
North Dakota 5 5 5 (100.0) (0.0) (0.0) (60.0)
Ohio 180 174 174 (100.0) (1.7) (4.0) (79.3)
Oklahoma 102 98 84 (85.7) (29.8) (13.1) (45.2)
Oregon 89 89 89 (100.0) (0.0) (1.1) (86.5)
Pennsylvania 236 228 227 (99.6) (0.4) (0.9) (48.5)
Rhode Island 24 24 24 (100.0) (0.0) (4.2) (87.5)
South Carolina 164 158 158 (100.0) (0.0) (8.2) (88.0)
South Dakota 18 17 17 (100.0) (0.0) (17.6) (82.4)
Tennessee 202 199 199 (100.0) (0.5) (4.5) (76.4)
Texas 1,501 1,475 1,411 (95.7) (1.3) (2.7) (89.1)
Utah 37 36 36 (100.0) (0.0) (2.8) (88.9)
Vermont 7 7 7 (100.0) (0.0) (0.0) (85.7)
Virginia 273 271 271 (100.0) (0.0) (1.5) (95.6)
Washington 256 254 254 (100.0) (0.0) (2.8) (89.0)
West Virginia 19 19 19 (100.0) (0.0) (5.3) (78.9)
Wisconsin 67 66 66 (100.0) (0.0) (0.0) (92.4)
Wyoming 2 2 2 (100.0) (0.0) (0.0) (100.0)
American Samoa4 4 4 4 (100.0) (0.0) (0.0) (100.0)
Fed. States of Micronesia4 143 143 143 (100.0) (0.7) (0.0) (88.1)
Guam4 102 100 100 (100.0) (0.0) (17.0) (74.0)
Marshall Islands4 140 140 140 (100.0) (0.0) (0.0) (72.9)
N. Mariana Islands4 32 32 32 (100.0) (0.0) (0.0) (93.8)
Puerto Rico4 63 58 58 (100.0) (0.0) (1.7) (94.8)
Republic of Palau4 18 18 18 (100.0) (0.0) (0.0) (100.0)
U.S. Virgin Islands4 ... ... ... ... ... ... ...
Table 35. Tuberculosis Cases and Percentages by Initial Drug Regimen: 
Reporting Areas, 2009
1Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District of Columbia). Counts and percentages 
shown only for reporting areas with information reported for >75% of cases.
2I=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol.
3Excludes New York City.
4Not included in U.S. totals.
Note: Excluding cases with no information on drug regimen, 125 (1.11%) persons were not started on any drugs, 10 (0.09%) were 
started on one drug, and 1,206 (10.76%) had an initial multidrug regimen other than IR, IRZ, or IRZE.
Reporting Area
Total 
Cases
Cases with Information on
Initial Drug Regimen
Percentage of Cases in Persons with
Initial Drug Regimen1,2
No. (%) IRZ
Cases in 
Persons 
Alive at 
Diagnosis IR IRZE3
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United States 8,876 8,495 (95.7) 750 (8.8) 114 (1.3)
Alabama 134 128 (95.5) 10 (7.8) 1 (0.8)
Alaska 31 31 (100.0) 0 (0.0) 0 (0.0)
Arizona 181 177 (97.8) 13 (7.3) 0 (0.0)
Arkansas 70 66 (94.3) 2 (3.0) 1 (1.5)
California 1,967 1,924 (97.8) 192 (10.0) 33 (1.7)
Colorado 63 62 (98.4) 6 (9.7) 0 (0.0)
Connecticut 78 78 (100.0) 8 (10.3) 0 (0.0)
Delaware 14 11 (78.6) 1 (9.1) 0 (0.0)
District of Columbia 36 36 (100.0) 2 (5.6) 0 (0.0)
Florida 635 604 (95.1) 58 (9.6) 6 (1.0)
Georgia 296 285 (96.3) 39 (13.7) 2 (0.7)
Hawaii 95 95 (100.0) 12 (12.6) 3 (3.2)
Idaho 13 13 (100.0) 1 (7.7) 1 (7.7)
Illinois 330 310 (93.9) 30 (9.7) 4 (1.3)
Indiana 96 96 (100.0) 6 (6.3) 3 (3.1)
Iowa 33 22 (66.7) -- -- -- --
Kansas 44 38 (86.4) 3 (7.9) 1 (2.6)
Kentucky 58 55 (94.8) 3 (5.5) 0 (0.0)
Louisiana 157 143 (91.1) 7 (4.9) 0 (0.0)
Maine 6 5 (83.3) 0 (0.0) 0 (0.0)
Maryland 173 172 (99.4) 15 (8.7) 2 (1.2)
Massachusetts 182 179 (98.4) 19 (10.6) 3 (1.7)
Michigan 111 110 (99.1) 6 (5.5) 1 (0.9)
Minnesota 121 120 (99.2) 12 (10.0) 3 (2.5)
Mississippi 84 84 (100.0) 3 (3.6) 0 (0.0)
Missouri 67 60 (89.6) 4 (6.7) 1 (1.7)
Montana 3 3 (100.0) 0 (0.0) 0 (0.0)
Nebraska 21 21 (100.0) 2 (9.5) 1 (4.8)
Nevada 71 65 (91.5) 15 (23.1) 1 (1.5)
New Hampshire 14 14 (100.0) 1 (7.1) 0 (0.0)
New Jersey 305 298 (97.7) 25 (8.4) 9 (3.0)
New Mexico 45 45 (100.0) 3 (6.7) 0 (0.0)
New York State3 182 181 (99.5) 21 (11.6) 4 (2.2)
New York City 540 530 (98.1) 59 (11.1) 8 (1.5)
North Carolina 197 187 (94.9) 13 (7.0) 1 (0.5)
North Dakota 3 2 (66.7) -- -- -- --
Ohio 154 154 (100.0) 7 (4.5) 2 (1.3)
Oklahoma 60 44 (73.3) -- -- -- --
Oregon 67 67 (100.0) 6 (9.0) 1 (1.5)
Pennsylvania 181 136 (75.1) 8 (5.9) 2 (1.5)
Rhode Island 17 17 (100.0) 0 (0.0) 0 (0.0)
South Carolina 114 107 (93.9) 9 (8.4) 0 (0.0)
South Dakota 15 15 (100.0) 1 (6.7) 0 (0.0)
Tennessee 134 129 (96.3) 5 (3.9) 1 (0.8)
Texas 1,147 1,064 (92.8) 82 (7.7) 16 (1.5)
Utah 29 29 (100.0) 4 (13.8) 1 (3.4)
Vermont 4 2 (50.0) -- -- -- --
Virginia 210 196 (93.3) 17 (8.7) 2 (1.0)
Washington 207 204 (98.6) 11 (5.4) 0 (0.0)
West Virginia 18 18 (100.0) 2 (11.1) 0 (0.0)
Wisconsin 61 61 (100.0) 2 (3.3) 0 (0.0)
Wyoming 2 2 (100.0) 0 (0.0) 0 (0.0)
American Samoa4 ... ... ... ... ... ... ...
Fed. States of Micronesia4 50 37 (74.0) -- -- -- --
Guam4 51 46 (90.2) 3 (6.5) 1 (2.2)
Marshall Islands4 45 42 (93.3) 1 (2.4) 1 (2.4)
N. Mariana Islands4 19 18 (94.7) 2 (11.1) 1 (5.6)
Puerto Rico4 56 54 (96.4) 2 (3.7) 0 (0.0)
Republic of Palau4 7 6 (85.7) 0 (0.0) 0 (0.0)
U.S. Virgin Islands4 ... ... ... ... ... ... ...
1Patients tested to at least isoniazid and rifampin
2Isolates may be resistant to other drugs. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and the District 
of Columbia). Counts and percentages shown only for reporting areas with information reported for >75% of cases.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Table 36. Culture-Positive Tuberculosis Cases and Percentages with Drug-Susceptibility 
Results, by Resistance to INH or Multidrug Resistance: Reporting Areas, 2009
Reporting Area
Total 
Culture 
Positive 
Cases
Cases with Initial Drug-
Susceptibility Testing Performed1
Resistance2
No. (%)
Isoniazid1 Isoniazid and Rifampin1
No. No.(%) (%)
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United States 3,893 2,754 (70.7) -- --
Alabama 39 37 (94.9) 9 (24.3)
Alaska 9 7 (77.8) 0 (0.0)
Arizona 82 75 (91.5) 13 (17.3)
Arkansas 23 17 (73.9) -- --
California 739 0 (0.0) -- --
Colorado 33 32 (97.0) 1 (3.1)
Connecticut 37 26 (70.3) -- --
Delaware 9 9 (100.0) 1 (11.1)
District of Columbia 14 10 (71.4) -- --
Florida 286 248 (86.7) 59 (23.8)
Georgia 145 138 (95.2) 31 (22.5)
Hawaii 26 15 (57.7) -- --
Idaho 2 2 (100.0) 0 (0.0)
Illinois 145 132 (91.0) 11 (8.3)
Indiana 36 35 (97.2) 5 (14.3)
Iowa 18 17 (94.4) 1 (5.9)
Kansas 20 20 (100.0) 0 (0.0)
Kentucky 24 23 (95.8) 1 (4.3)
Louisiana 66 62 (93.9) 15 (24.2)
Maine 0 0 . -- --
Maryland 92 88 (95.7) 11 (12.5)
Massachusetts 73 53 (72.6) -- --
Michigan 51 41 (80.4) 4 (9.8)
Minnesota 68 63 (92.6) 5 (7.9)
Mississippi 37 37 (100.0) 10 (27.0)
Missouri 28 23 (82.1) 3 (13.0)
Montana 2 2 (100.0) 0 (0.0)
Nebraska 10 7 (70.0) -- --
Nevada 28 28 (100.0) 2 (7.1)
New Hampshire 2 2 (100.0) 1 (50.0)
New Jersey 168 143 (85.1) 18 (12.6)
New Mexico 10 10 (100.0) 0 (0.0)
New York State3 85 76 (89.4) 6 (7.9)
New York City 284 255 (89.8) 37 (14.5)
North Carolina 79 76 (96.2) 7 (9.2)
North Dakota 3 3 (100.0) 0 (0.0)
Ohio 66 55 (83.3) 7 (12.7)
Oklahoma 23 19 (82.6) 2 (10.5)
Oregon 29 29 (100.0) 5 (17.2)
Pennsylvania 68 57 (83.8) 4 (7.0)
Rhode Island 9 9 (100.0) 2 (22.2)
South Carolina 53 53 (100.0) 5 (9.4)
South Dakota 6 6 (100.0) 0 (0.0)
Tennessee 65 65 (100.0) 9 (13.8)
Texas 549 423 (77.0) 74 (17.5)
Utah 19 19 (100.0) 1 (5.3)
Vermont 2 0 (0.0) ... ...
Virginia 104 93 (89.4) 13 (14.0)
Washington 98 88 (89.8) 4 (4.5)
West Virginia 6 5 (83.3) 0 (0.0)
Wisconsin 23 21 (91.3) 3 (14.3)
Wyoming 0 0 . -- --
American Samoa4 1 1 (100.0) 0 (0.0)
Fed. States of Micronesia4 39 25 (64.1) -- --
Guam4 21 15 (71.4) -- --
Marshall Islands4 37 34 (91.9) 2 (5.9)
N. Mariana Islands4 7 7 (100.0) 0 (0.0)
Puerto Rico4 20 20 (100.0) 4 (20.0)
Republic of Palau4 6 5 (83.3) 0 (0.0)
U.S. Virgin Islands4 ... ... ... ... ...
Table 37. Tuberculosis Cases and Percentages Among Persons Aged 25–44 by HIV Status: 
Reporting Areas, 2009
1Includes only those cases in persons with negative, positive, or indeterminate HIV test results.
2Counts and percentages shown only for reporting areas with information reported for >75% of cases. All 2009 California and Vermont 
cases are missing HIV status because these HIV data were not available at time of publication.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses indicate data not available.
See Technical Notes (page 9).
Reporting Area
Total  
Cases
Cases with Information on HIV Status1 Cases in Persons with HIV-Positive Results2
No. (%) No. (%)
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United States 10,893 10,503 (96.4) (41.0) (3.8) (0.2) (1.2) (8.0) (8.3) (37.5)
Alabama 159 154 (96.9) (23.4) (2.6) (1.3) (0.6) (20.8) (13.6) (37.7)
Alaska2 35 35 (100.0) (65.7) (2.9) (0.0) (2.9) … … (28.6)
Arizona 216 192 (88.9) (33.3) (1.6) (0.0) (2.1) (14.6) (13.0) (35.4)
Arkansas 73 71 (97.3) (32.4) (2.8) (0.0) (0.0) (28.2) (9.9) (26.8)
California2 2,347 2,254 (96.0) (55.1) (4.1) (0.2) (1.9) … … (38.9)
Colorado 74 74 (100.0) (18.9) (4.1) (0.0) (1.4) (12.2) (17.6) (45.9)
Connecticut2 91 91 (100.0) (46.2) (8.8) (0.0) (2.2) … … (42.9)
Delaware 18 17 (94.4) (23.5) (0.0) (0.0) (5.9) (5.9) (11.8) (52.9)
District of Columbia 40 40 (100.0) (70.0) (0.0) (0.0) (0.0) (7.5) (0.0) (22.5)
Florida 793 768 (96.8) (61.6) (1.3) (0.3) (2.2) (3.9) (2.9) (27.9)
Georgia 391 352 (90.0) (41.5) (3.4) (0.0) (0.0) (9.4) (8.5) (37.2)
Hawaii 115 101 (87.8) (14.9) (5.9) (0.0) (1.0) (21.8) (11.9) (44.6)
Idaho 15 15 (100.0) (20.0) (0.0) (0.0) (13.3) (26.7) (13.3) (26.7)
Illinois2 402 363 (90.3) (56.2) (6.1) (0.3) (0.0) … … (37.5)
Indiana 112 111 (99.1) (30.6) (2.7) (0.0) (0.9) (12.6) (21.6) (31.5)
Iowa 40 39 (97.5) (20.5) (2.6) (0.0) (0.0) (5.1) (7.7) (64.1)
Kansas 59 57 (96.6) (26.3) (1.8) (0.0) (0.0) (7.0) (19.3) (45.6)
Kentucky 75 75 (100.0) (26.7) (2.7) (0.0) (5.3) (25.3) (20.0) (20.0)
Louisiana 186 181 (97.3) (35.9) (4.4) (0.6) (1.7) (15.5) (9.4) (32.6)
Maine 7 7 (100.0) (28.6) (0.0) (0.0) (0.0) (28.6) (0.0) (42.9)
Maryland 206 193 (93.7) (19.7) (7.3) (1.0) (0.5) (11.9) (14.0) (45.6)
Massachusetts 231 229 (99.1) (29.3) (4.4) (0.0) (0.0) (14.8) (8.7) (42.8)
Michigan 141 121 (85.8) (63.6) (4.1) (0.0) (5.0) (0.0) (0.0) (27.3)
Minnesota 142 142 (100.0) (33.8) (4.9) (0.7) (0.0) (8.5) (9.2) (43.0)
Mississippi2 116 115 (99.1) (65.2) (0.9) (0.0) (0.9) … … (33.0)
Missouri2 74 73 (98.6) (54.8) (8.2) (0.0) (0.0) … … (37.0)
Montana 7 7 (100.0) (14.3) (0.0) (0.0) (0.0) (42.9) (28.6) (14.3)
Nebraska 29 29 (100.0) (27.6) (3.4) (0.0) (0.0) (6.9) (17.2) (44.8)
Nevada 90 90 (100.0) (28.9) (7.8) (0.0) (1.1) (18.9) (7.8) (35.6)
New Hampshire 16 16 (100.0) (31.3) (0.0) (0.0) (0.0) (12.5) (25.0) (31.3)
New Jersey 391 390 (99.7) (28.2) (3.8) (0.0) (0.0) (13.1) (11.8) (43.1)
New Mexico 48 46 (95.8) (34.8) (4.3) (0.0) (0.0) (32.6) (6.5) (21.7)
New York State3 223 203 (91.0) (25.6) (3.9) (0.0) (1.0) (20.7) (8.9) (39.9)
New York City2 734 710 (96.7) (51.4) (4.6) (0.0) (0.1) … … (43.8)
North Carolina2 233 232 (99.6) (31.0) (3.9) (0.0) (3.0) … … (62.1)
North Dakota2 5 5 (100.0) (60.0) (0.0) (0.0) (0.0) … … (40.0)
Ohio 173 161 (93.1) (24.2) (5.0) (0.0) (1.2) (19.3) (13.0) (37.3)
Oklahoma 85 70 (82.4) (40.0) (5.7) (1.4) (0.0) (14.3) (0.0) (38.6)
Oregon 88 88 (100.0) (27.3) (1.1) (0.0) (4.5) (15.9) (21.6) (29.5)
Pennsylvania 225 222 (98.7) (23.4) (4.1) (0.0) (0.9) (24.3) (18.5) (28.8)
Rhode Island 23 23 (100.0) (21.7) (4.3) (0.0) (0.0) (43.5) (0.0) (30.4)
South Carolina 147 145 (98.6) (33.8) (2.8) (0.0) (2.8) (13.1) (8.3) (39.3)
South Dakota 18 18 (100.0) (22.2) (0.0) (0.0) (0.0) (5.6) (27.8) (44.4)
Tennessee 191 187 (97.9) (29.4) (2.1) (0.5) (0.0) (18.7) (12.3) (36.9)
Texas 1,395 1,395 (100.0) (36.3) (3.7) (0.4) (0.4) (8.6) (17.3) (33.3)
Utah2 33 33 (100.0) (48.5) (3.0) (0.0) (0.0) … … (48.5)
Vermont 6 6 (100.0) (0.0) (0.0) (0.0) (0.0) (0.0) (16.7) (83.3)
Virginia 250 250 (100.0) (0.4) (4.0) (0.0) (0.0) (17.6) (38.0) (40.0)
Washington 239 222 (92.9) (18.9) (4.1) (0.5) (3.6) (13.1) (22.1) (37.8)
West Virginia 18 18 (100.0) (11.1) (0.0) (0.0) (0.0) (16.7) (61.1) (11.1)
Wisconsin 66 65 (98.5) (33.8) (4.6) (0.0) (0.0) (20.0) (7.7) (33.8)
Wyoming 2 2 (100.0) (50.0) (0.0) (0.0) (0.0) (0.0) (0.0) (50.0)
American Samoa4 4 4 (100.0) (25.0) (0.0) (0.0) (0.0) (0.0) (0.0) (75.0)
Fed. States of Micronesia4 86 82 (95.3) (53.7) (0.0) (1.2) (1.2) (3.7) (17.1) (23.2)
Guam4 74 74 (100.0) (24.3) (2.7) (0.0) (0.0) (17.6) (13.5) (41.9)
Marshall Islands4 113 112 (99.1) (50.0) (0.9) (0.0) (3.6) (0.9) (11.6) (33.0)
N. Mariana Islands4 32 32 (100.0) (43.8) (0.0) (0.0) (0.0) (0.0) (3.1) (53.1)
Puerto Rico4 61 1 (1.6) -- -- -- -- -- -- --
Republic of Palau4 18 18 (100.0) (22.2) (5.6) (0.0) (11.1) (22.2) (0.0) (38.9)
U.S. Virgin Islands4 ... ... ... ... ... ... ... ... ... ...
Table 38. Tuberculosis Cases and Percentages by Primary Occupation, Age >15: 
Reporting Areas, 2009
1Occupation within past 24 months of TB diagnosis. Overall U.S. percentage based on 52 reporting areas (50 states, New York City, and 
the District of Columbia). Percentages shown only for reporting areas with information reported for >75% of cases.
2Data not collected for this variable in 2009.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area
Total 
Cases
Cases with
Information on 
Occupation
Percentage of Cases by Occupation1
No. (%)
Unemployed Health Care 
Worker
Correctional 
Employee
Migrant 
Worker
Not Seeking 
Employment
OtherRetired
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United States 13,280 12,989 12,813 (98.6) (59.1) (18.7) (22.1)
Alabama 176 168 168 (100.0) (69.0) (4.8) (26.2)
Alaska 50 50 50 (100.0) (40.0) (4.0) (56.0)
Arizona 302 288 249 (86.5) (73.1) (15.3) (11.6)
Arkansas 106 104 101 (97.1) (81.2) (18.8) (0.0)
California 2,726 2,677 2,664 (99.5) (53.0) (29.6) (17.5)
Colorado 111 103 102 (99.0) (79.4) (9.8) (10.8)
Connecticut 108 106 105 (99.1) (18.1) (41.0) (41.0)
Delaware 19 19 19 (100.0) (73.7) (0.0) (26.3)
District of Columbia 59 56 56 (100.0) (87.5) (10.7) (1.8)
Florida 988 965 964 (99.9) (66.4) (10.4) (23.2)
Georgia 475 466 410 (88.0) (68.0) (15.9) (16.1)
Hawaii 122 121 116 (95.9) (32.8) (11.2) (56.0)
Idaho 9 8 8 (100.0) (50.0) (25.0) (25.0)
Illinois 520 518 513 (99.0) (44.1) (23.2) (32.7)
Indiana 128 123 123 (100.0) (20.3) (4.9) (74.8)
Iowa 43 42 42 (100.0) (0.0) (0.0) (100.0)
Kansas 59 57 57 (100.0) (28.1) (7.0) (64.9)
Kentucky 120 118 117 (99.2) (68.4) (9.4) (22.2)
Louisiana 217 215 213 (99.1) (72.8) (7.0) (20.2)
Maine 19 19 19 (100.0) (100.0) (0.0) (0.0)
Maryland 271 267 267 (100.0) (92.1) (1.9) (6.0)
Massachusetts 224 222 220 (99.1) (38.6) (9.5) (51.8)
Michigan 225 214 209 (97.7) (55.5) (16.7) (27.8)
Minnesota 238 235 235 (100.0) (58.3) (37.0) (4.7)
Mississippi 137 132 130 (98.5) (91.5) (6.9) (1.5)
Missouri 118 111 108 (97.3) (30.6) (13.9) (55.6)
Montana 11 11 11 (100.0) (45.5) (0.0) (54.5)
Nebraska 25 25 24 (96.0) (0.0) (33.3) (66.7)
Nevada 102 96 94 (97.9) (83.0) (13.8) (3.2)
New Hampshire 11 10 10 (100.0) (10.0) (50.0) (40.0)
New Jersey 467 459 450 (98.0) (70.7) (24.0) (5.3)
New Mexico 51 51 51 (100.0) (52.9) (11.8) (35.3)
New York State3 261 252 241 (95.6) (56.8) (23.2) (19.9)
New York City 908 890 890 (100.0) (33.9) (20.0) (46.1)
North Carolina 345 337 337 (100.0) (61.4) (3.0) (35.6)
North Dakota 7 7 6 (85.7) (33.3) (33.3) (33.3)
Ohio 251 246 246 (100.0) (63.4) (20.7) (15.9)
Oklahoma 149 145 144 (99.3) (93.1) (2.8) (4.2)
Oregon 94 92 92 (100.0) (60.9) (6.5) (32.6)
Pennsylvania 276 271 267 (98.5) (85.0) (11.6) (3.4)
Rhode Island 45 45 45 (100.0) (95.6) (2.2) (2.2)
South Carolina 218 213 207 (97.2) (72.5) (4.8) (22.7)
South Dakota 13 13 13 (100.0) (84.6) (0.0) (15.4)
Tennessee 235 232 231 (99.6) (51.5) (6.5) (42.0)
Texas 1,504 1,465 1,465 (100.0) (62.9) (27.9) (9.1)
Utah 39 39 39 (100.0) (53.8) (10.3) (35.9)
Vermont 3 3 3 (100.0) (33.3) (0.0) (66.7)
Virginia 309 304 304 (100.0) (84.2) (8.2) (7.6)
Washington 291 288 288 (100.0) (67.4) (10.4) (22.2)
West Virginia 24 21 21 (100.0) (47.6) (19.0) (33.3)
Wisconsin 69 68 67 (98.5) (10.4) (3.0) (86.6)
Wyoming 2 2 2 (100.0) (0.0) (0.0) (100.0)
American Samoa4 3 3 0 ... ... ... ...
Fed. States of Micronesia4 142 136 17 (12.5) -- -- --
Guam4 93 91 84 (92.3) (94.0) (0.0) (6.0)
Marshall Islands4 125 120 15 (12.5) -- -- --
N. Mariana Islands4 42 41 34 (82.9) (100.0) (0.0) (0.0)
Puerto Rico4 98 93 93 (100.0) (88.2) (9.7) (2.2)
Republic of Palau4 12 12 6 (50.0) -- -- --
U.S. Virgin Islands4 ... ... 0 ... ... ... ...
1Most recent year for which data are available.
2Health Department: All outpatient care provided by the state or local health department; Private/Other: All care (except contact inves-
tigation and dispensing of medication) provided by non–health department providers; Both Health Department and Private/Other: Both 
sectors involved in the care of the patient. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of 
Columbia). Percentages shown only for reporting areas with information reported for >75% of cases.
3Excludes New York City.
4Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Table 39. Tuberculosis Cases and Percentages by Type of Health Care Provider: 
Reporting Areas, 20071
Reporting Area
Total  
Cases
Percentage of Cases by
Type of Health Care Provider2
No. (%)
Health 
Department
Private/
Other
Both Health 
Department and 
Private/Other
Cases in 
Persons 
Alive at 
Diagnosis
Cases with Information on
Type of Health Care Provider
64
United States 13,280 12,888 12,742 (98.9) (56.2) (33.0)
Alabama 176 168 168 (100.0) (42.9) (57.1)
Alaska 50 50 50 (100.0) (90.0) (6.0)
Arizona 302 273 244 (89.4) (82.0) (16.0)
Arkansas 106 104 104 (100.0) (6.7) (52.9)
California 2,726 2,659 2,645 (99.5) (58.7) (26.6)
Colorado 111 102 102 (100.0) (90.2) (6.9)
Connecticut 108 106 105 (99.1) (33.3) (42.9)
Delaware 19 19 19 (100.0) (73.7) (26.3)
District of Columbia 59 55 55 (100.0) (96.4) (0.0)
Florida 988 957 957 (100.0) (41.2) (53.8)
Georgia 475 455 409 (89.9) (81.9) (14.2)
Hawaii 122 120 119 (99.2) (1.7) (75.6)
Idaho 9 8 8 (100.0) (87.5) (0.0)
Illinois 520 508 496 (97.6) (57.5) (21.8)
Indiana 128 123 123 (100.0) (48.8) (49.6)
Iowa 43 42 42 (100.0) (69.0) (21.4)
Kansas 59 57 57 (100.0) (100.0) (0.0)
Kentucky 120 116 116 (100.0) (42.2) (53.4)
Louisiana 217 214 213 (99.5) (83.1) (12.2)
Maine 19 19 19 (100.0) (89.5) (10.5)
Maryland 271 267 267 (100.0) (92.1) (5.6)
Massachusetts 224 221 219 (99.1) (38.4) (40.2)
Michigan 225 212 204 (96.2) (47.5) (28.9)
Minnesota 238 234 234 (100.0) (81.2) (16.2)
Mississippi 137 132 132 (100.0) (38.6) (61.4)
Missouri 118 111 108 (97.3) (29.6) (53.7)
Montana 11 11 11 (100.0) (81.8) (9.1)
Nebraska 25 24 23 (95.8) (69.6) (4.3)
Nevada 102 96 92 (95.8) (91.3) (6.5)
New Hampshire 11 10 10 (100.0) (60.0) (40.0)
New Jersey 467 458 448 (97.8) (47.1) (23.9)
New Mexico 51 51 50 (98.0) (72.0) (26.0)
New York State4 261 252 252 (100.0) (21.4) (74.6)
New York City 908 880 880 (100.0) (0.9) (70.3)
North Carolina 345 336 336 (100.0) (99.7) (0.3)
North Dakota 7 5 5 (100.0) (40.0) (60.0)
Ohio 251 246 245 (99.6) (66.9) (15.1)
Oklahoma 149 144 144 (100.0) (97.2) (2.1)
Oregon 94 92 92 (100.0) (67.4) (28.3)
Pennsylvania 276 266 266 (100.0) (43.6) (46.2)
Rhode Island 45 44 44 (100.0) (6.8) (86.4)
South Carolina 218 213 207 (97.2) (91.8) (7.7)
South Dakota 13 13 13 (100.0) (76.9) (15.4)
Tennessee 235 232 231 (99.6) (97.0) (3.0)
Texas 1,504 1,464 1,464 (100.0) (55.5) (41.9)
Utah 39 39 39 (100.0) (92.3) (7.7)
Vermont 3 3 3 (100.0) (66.7) (33.3)
Virginia 309 302 298 (98.7) (64.4) (33.2)
Washington 291 284 284 (100.0) (72.9) (15.5)
West Virginia 24 21 21 (100.0) (81.0) (14.3)
Wisconsin 69 68 67 (98.5) (56.7) (35.8)
Wyoming 2 2 2 (100.0) (50.0) (0.0)
American Samoa5 3 3 ... ... ... ...
Fed. States of Micronesia5 142 132 19 (14.4) -- --
Guam5 93 91 83 (91.2) (2.4) (97.6)
Marshall Islands5 125 119 15 (12.6) -- --
N. Mariana Islands5 42 41 35 (85.4) (100.0) (0.0)
Puerto Rico5 98 93 92 (98.9) (66.3) (0.0)
Republic of Palau5 12 12 7 (58.3) -- --
U.S. Virgin Islands5 ... ... ... ... ... ...
Table 40. Tuberculosis Cases and Percentages by Directly Observed Therapy (DOT): 
Reporting Areas, 20071
1Most recent year for which data are available.
2Includes persons alive at diagnosis with an initial drug regimen of one or more drugs prescribed.
3Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for 
reporting areas with information reported for >75% of cases.
4Excludes New York City.
5Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area
Total  
Cases
Percentage of Cases by
Directly Observed Therapy3
No. (%) DOT Only
Both DOT and 
Self-Administered
Cases with 
Initial Drug 
Regimen 
Prescribed2
Cases with Information on
Directly Observed Therapy
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Table 41. Tuberculosis Cases and Percentages by Completion of Tuberculosis Therapy 
(COT): Reporting Areas, 20071
1Most recent year for which data are available.
2Initial isolate susceptible to rifampin (n=8,912) or susceptibility unknown (n=139); culture negative (n=2,234); culture status unknown (n=466); age unknown 
(n=0).
3Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. 
based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information reported 
for >90% of cases.
4Excludes initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.
5Initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or positive blood culture.
6Excludes New York City.
7Not included in U.S. totals. 
Note: Ellipses indicate data not available. See Technical Notes for description of Completion of Therapy calculation (page 9).
Reporting Area
Total  
Cases
All Drug Therapy3
No. COT(%) No. COT(%)
Therapy <1 Year Indicated2,3,4
COT <1 Year(%)
Therapy >1 Year Indicated3,5
No. COT(%)
United States 13,280 11750 (84.3) (93.2) 320 (87.2) 12075 (93.0)
Alabama 176 149 (91.9) (96.6) 4 (100.0) 153 (96.7)
Alaska 50 43 (88.4) (93.0) 0 ... 43 (93.0)
Arizona 302 242 (69.0) (76.0) 7 (57.1) 249 (75.5)
Arkansas 106 96 (92.7) (94.8) 3 (100.0) 99 (94.9)
California 2,726 2427 (78.9) (92.0) 68 (92.6) 2495 (92.1)
Colorado 111 91 (97.8) (100.0) 3 (100.0) 94 (100.0)
Connecticut 108 96 (76.0) (89.6) 5 (60.0) 101 (88.1)
Delaware 19 18 (94.4) (100.0) 1 (100.0) 19 (100.0)
District of Columbia 59 51 (70.6) (88.2) 1 (100.0) 52 (88.5)
Florida 988 884 (89.9) (96.9) 13 (92.3) 897 (96.9)
Georgia 475 414 (85.0) (91.3) 9 (77.8) 427 (90.2)
Hawaii 122 109 (76.1) (89.0) 1 (100.0) 110 (89.1)
Idaho 9 8 (75.0) (75.0) 0 ... 8 (75.0)
Illinois 520 457 (82.3) (94.1) 11 (81.8) 468 (93.8)
Indiana 128 118 (89.0) (96.6) 1 (100.0) 119 (96.6)
Iowa 43 36 (88.9) (91.7) 4 (75.0) 40 (90.0)
Kansas 59 53 (83.0) (96.2) 0 ... 53 (96.2)
Kentucky 120 108 (89.8) (93.5) 0 ... 108 (93.5)
Louisiana 217 196 (79.6) (92.9) 4 (100.0) 200 (93.0)
Maine 19 18 (88.9) (100.0) 1 (100.0) 19 (100.0)
Maryland 271 246 (89.4) (96.7) 9 (100.0) 255 (96.9)
Massachusetts 224 205 (81.5) (95.1) 5 (80.0) 210 (94.8)
Michigan 225 184 (82.1) (90.2) 6 (100.0) 190 (90.5)
Minnesota 238 225 (88.9) (94.7) 6 (66.7) 231 (93.9)
Mississippi 137 118 (95.8) (99.2) 7 (85.7) 125 (98.4)
Missouri 118 106 (75.5) (84.9) 3 (66.7) 109 (84.4)
Montana 11 11 (100.0) (100.0) 0 ... 11 (100.0)
Nebraska 25 24 (91.7) (91.7) 0 ... 24 (91.7)
Nevada 102 82 (86.6) (93.9) 3 (66.7) 85 (92.9)
New Hampshire 11 10 (90.0) (100.0) 0 ... 10 (100.0)
New Jersey 467 411 (83.5) (90.8) 19 (78.9) 430 (90.2)
New Mexico 51 43 (88.4) (95.3) 1 (0.0) 44 (93.2)
New York State6 261 228 (87.3) (95.2) 8 (87.5) 236 (94.9)
New York City 908 791 (90.8) (96.6) 28 (96.4) 819 (96.6)
North Carolina 345 312 (91.7) (98.1) 6 (100.0) 318 (98.1)
North Dakota 7 4 (100.0) (100.0) 0 ... 4 (100.0)
Ohio 251 221 (87.3) (93.7) 5 (80.0) 226 (93.4)
Oklahoma 149 131 (81.7) (93.1) 1 (0.0) 132 (92.4)
Oregon 94 88 (90.9) (95.5) 2 (100.0) 90 (95.6)
Pennsylvania 276 248 (81.0) (91.1) 3 (100.0) 251 (91.2)
Rhode Island 45 40 (90.0) (95.0) 1 (100.0) 41 (95.1)
South Carolina 218 188 (88.8) (94.1) 4 (25.0) 192 (92.7)
South Dakota 13 11 (100.0) (100.0) 0 ... 11 (100.0)
Tennessee 235 202 (86.6) (94.6) 7 (100.0) 209 (94.7)
Texas 1,504 1339 (81.9) (91.4) 37 (94.6) 1376 (91.5)
Utah 39 35 (94.3) (97.1) 2 (100.0) 37 (97.3)
Vermont 3 3 (33.3) (66.7) 0 ... 3 (66.7)
Virginia 309 291 (88.0) (95.2) 7 (71.4) 298 (94.6)
Washington 291 264 (88.6) (94.3) 9 (77.8) 273 (93.8)
West Virginia 24 16 (100.0) (100.0) 0 ... 16 (100.0)
Wisconsin 69 57 (77.2) (91.2) 5 (80.0) 63 (88.9)
Wyoming 2 2 (50.0) (50.0) 0 ... 2 (50.0)
American Samoa7 3 3 -- -- 0 ... 3 --
Fed. States of Micronesia7 142 131 -- -- 1 -- 132 --
Guam7 93 89 -- -- 0 ... 89 --
Marshall Islands7 125 115 -- -- 3 -- 118 --
N. Mariana Islands7 42 39 -- -- 0 ... 39 --
Puerto Rico7 98 81 (97.5) (98.8) 3 (0.0) 84 (95.2)
Republic of Palau7 12 12 -- -- 0 ... 12 --
U.S. Virgin Islands7 0 0 -- -- 0 ... 0 --
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United States 12,888 11,239 (87.2) 284 (2.2) 309 (2.4) 72 (0.6) 813 (6.3) 171 (1.3)
Alabama 168 148 (88.1) 2 (1.2) 2 (1.2) 1 (0.6) 15 (8.9) 0 (0.0)
Alaska 50 40 (80.0) 0 (0.0) 0 (0.0) 1 (2.0) 7 (14.0) 2 (4.0)
Arizona 273 188 (68.9) 16 (5.9) 18 (6.6) 4 (1.5) 24 (8.8) 23 (8.4)
Arkansas 104 94 (90.4) 1 (1.0) 1 (1.0) 0 (0.0) 5 (4.8) 3 (2.9)
California 2,659 2,297 (86.4) 105 (3.9) 52 (2.0) 15 (0.6) 164 (6.2) 26 (1.0)
Colorado 102 94 (92.2) 0 (0.0) 0 (0.0) 0 (0.0) 8 (7.8) 0 (0.0)
Connecticut 106 89 (84.0) 3 (2.8) 0 (0.0) 1 (0.9) 5 (4.7) 8 (7.5)
Delaware 19 19 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
District of Columbia 55 46 (83.6) 2 (3.6) 3 (5.5) 0 (0.0) 3 (5.5) 1 (1.8)
Florida 957 869 (90.8) 13 (1.4) 14 (1.5) 1 (0.1) 60 (6.3) 0 (0.0)
Georgia 455 389 (85.5) 10 (2.2) 5 (1.1) 6 (1.3) 28 (6.2) 17 (3.7)
Hawaii 120 98 (81.7) 10 (8.3) 1 (0.8) 0 (0.0) 10 (8.3) 1 (0.8)
Idaho 8 6 (75.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (25.0)
Illinois 508 439 (86.4) 15 (3.0) 8 (1.6) 2 (0.4) 40 (7.9) 4 (0.8)
Indiana 123 115 (93.5) 3 (2.4) 0 (0.0) 1 (0.8) 4 (3.3) 0 (0.0)
Iowa 42 36 (85.7) 2 (4.8) 0 (0.0) 1 (2.4) 2 (4.8) 1 (2.4)
Kansas 57 51 (89.5) 0 (0.0) 1 (1.8) 0 (0.0) 4 (7.0) 1 (1.8)
Kentucky 116 101 (87.1) 1 (0.9) 6 (5.2) 0 (0.0) 8 (6.9) 0 (0.0)
Louisiana 214 186 (86.9) 5 (2.3) 3 (1.4) 3 (1.4) 14 (6.5) 3 (1.4)
Maine 19 19 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Maryland 267 247 (92.5) 5 (1.9) 1 (0.4) 1 (0.4) 12 (4.5) 1 (0.4)
Massachusetts 221 199 (90.0) 9 (4.1) 1 (0.5) 0 (0.0) 11 (5.0) 1 (0.5)
Michigan 212 172 (81.1) 4 (1.9) 7 (3.3) 4 (1.9) 22 (10.4) 3 (1.4)
Minnesota 234 217 (92.7) 8 (3.4) 1 (0.4) 1 (0.4) 3 (1.3) 4 (1.7)
Mississippi 132 123 (93.2) 1 (0.8) 1 (0.8) 0 (0.0) 7 (5.3) 0 (0.0)
Missouri 111 92 (82.9) 9 (8.1) 3 (2.7) 2 (1.8) 2 (1.8) 3 (2.7)
Montana 11 11 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nebraska 24 22 (91.7) 1 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.2)
Nevada 96 79 (82.3) 3 (3.1) 1 (1.0) 0 (0.0) 11 (11.5) 2 (2.1)
New Hampshire 10 10 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
New Jersey 458 388 (84.7) 5 (1.1) 25 (5.5) 2 (0.4) 28 (6.1) 10 (2.2)
New Mexico 51 41 (80.4) 0 (0.0) 1 (2.0) 2 (3.9) 7 (13.7) 0 (0.0)
New York State5 252 224 (88.9) 0 (0.0) 8 (3.2) 2 (0.8) 16 (6.3) 2 (0.8)
New York City 880 791 (89.9) 11 (1.3) 10 (1.1) 6 (0.7) 61 (6.9) 1 (0.1)
North Carolina 336 312 (92.9) 3 (0.9) 3 (0.9) 0 (0.0) 18 (5.4) 0 (0.0)
North Dakota 5 4 (80.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (20.0) 0 (0.0)
Ohio 246 211 (85.8) 6 (2.4) 6 (2.4) 0 (0.0) 20 (8.1) 3 (1.2)
Oklahoma 144 122 (84.7) 5 (3.5) 1 (0.7) 0 (0.0) 12 (8.3) 4 (2.8)
Oregon 92 86 (93.5) 1 (1.1) 2 (2.2) 1 (1.1) 2 (2.2) 0 (0.0)
Pennsylvania 266 229 (86.1) 1 (0.4) 3 (1.1) 2 (0.8) 15 (5.6) 16 (6.0)
Rhode Island 44 39 (88.6) 0 (0.0) 0 (0.0) 2 (4.5) 3 (6.8) 0 (0.0)
South Carolina 213 178 (83.6) 1 (0.5) 5 (2.3) 2 (0.9) 21 (9.9) 6 (2.8)
South Dakota 13 11 (84.6) 0 (0.0) 0 (0.0) 0 (0.0) 2 (15.4) 0 (0.0)
Tennessee 232 198 (85.3) 1 (0.4) 6 (2.6) 0 (0.0) 23 (9.9) 4 (1.7)
Texas 1,464 1,259 (86.0) 0 (0.0) 99 (6.8) 8 (0.5) 88 (6.0) 10 (0.7)
Utah 39 36 (92.3) 0 (0.0) 1 (2.6) 0 (0.0) 2 (5.1) 0 (0.0)
Vermont 3 2 (66.7) 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Virginia 302 282 (93.4) 7 (2.3) 7 (2.3) 0 (0.0) 4 (1.3) 2 (0.7)
Washington 284 256 (90.1) 12 (4.2) 2 (0.7) 1 (0.4) 11 (3.9) 2 (0.7)
West Virginia 21 16 (76.2) 0 (0.0) 0 (0.0) 0 (0.0) 5 (23.8) 0 (0.0)
Wisconsin 68 57 (83.8) 2 (2.9) 1 (1.5) 0 (0.0) 5 (7.4) 3 (4.4)
Wyoming 2 1 (50.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (50.0)
American Samoa6 3 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (100.0)
Fed. States of Micronesia6 132 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 132 (100.0)
Guam6 91 74 (81.3) 1 (1.1) 1 (1.1) 0 (0.0) 2 (2.2) 13 (14.3)
Marshall Islands6 119 10 (8.4) 3 (2.5) 0 (0.0) 1 (0.8) 1 (0.8) 104 (87.4)
N. Mariana Islands6 41 29 (70.7) 4 (9.8) 0 (0.0) 0 (0.0) 2 (4.9) 6 (14.6)
Puerto Rico6 93 80 (86.0) 1 (1.1) 2 (2.2) 0 (0.0) 9 (9.7) 1 (1.1)
Republic of Palau6 12 5 (41.7) 1 (8.3) 0 (0.0) 0 (0.0) 0 (0.0) 6 (50.0)
U.S. Virgin Islands6 ... ... ... ... ... ... ... ... ... ... ... ... ...
Table 42. Tuberculosis Cases and Percentages by Reason Therapy Stopped: 
Reporting Areas, 20071
1Most recent year for which data are available.
2Number of cases in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed. Percentage for U.S. based on 52 
reporting areas (50 states, New York City, and the District of Columbia).
3Died = Died of any cause.
4Includes cases reported as Other, Missing, or Unknown.
5Excludes New York City.
6Not included in U.S. totals. 
Note: Ellipses indicate data not available.
Reporting Area
Completed Moved Lost Refused Died3 Unknown4
No. No. No. No. No. No.(%) (%) (%) (%) (%) (%)
Cases with 
Initial Drug 
Regimen 
Prescribed2
67
This page intentionally left blank
68
U
ni
te
d 
St
at
es
11
,7
50
34
84
(8
2.
5)
10
7
(8
9.
7)
31
31
(8
3.
6)
30
35
(8
6.
7)
89
(7
8.
7)
18
60
(8
4.
9)
22
(9
0.
9)
22
(7
7.
3)
A
la
ba
m
a
14
9
21
(8
5.
7)
0
--
13
(8
4.
6)
69
(9
1.
3)
1
(1
00
.0
)
45
(9
7.
8)
0
--
0
--
A
la
sk
a
43
1
24
(9
5.
8)
7
(8
5.
7)
0
--
0
--
7
(7
1.
4)
1
(1
00
.0
)
3
(6
6.
7)
A
riz
on
a
24
2
14
4
(6
5.
3)
12
(6
6.
7)
43
(7
6.
7)
17
(8
8.
2)
0
--
25
(6
4.
0)
1
(1
00
.0
)
0
--
A
rk
an
sa
s
96
17
(9
4.
1)
0
--
11
(1
00
.0
)
31
(1
00
.0
)
4
(7
5.
0)
33
(8
4.
8)
0
--
0
--
C
al
ifo
rn
ia
2,
42
7
88
8
(7
8.
3)
5
(8
0.
0)
11
26
(7
9.
1)
18
9
(8
5.
2)
16
(5
6.
3)
19
3
(7
4.
6)
3
(1
00
.0
)
7
(1
00
.0
)
C
ol
or
ad
o
91
43
(9
7.
7)
1
(1
00
.0
)
23
(1
00
.0
)
13
(1
00
.0
)
0
--
10
(9
0.
0)
0
--
1
(1
00
.0
)
C
on
ne
ct
ic
ut
96
26
(8
0.
8)
0
--
31
(8
0.
6)
17
(6
4.
7)
0
--
22
(7
2.
7)
0
--
0
--
D
el
aw
ar
e
18
6
(8
3.
3)
0
--
7
(1
00
.0
)
5
(1
00
.0
)
0
--
0
--
0
--
0
--
D
is
tri
ct
 o
f C
ol
um
bi
a
51
14
(7
8.
6)
0
--
4
(1
00
.0
)
33
(6
3.
6)
0
--
0
--
0
--
0
--
Fl
or
id
a
88
4
26
0
(8
9.
2)
2
(1
00
.0
)
97
(9
1.
8)
33
9
(8
8.
2)
1
(1
00
.0
)
18
3
(9
2.
9)
2
(1
00
.0
)
0
--
G
eo
rg
ia
41
4
89
(7
4.
2)
0
--
56
(8
9.
3)
20
7
(8
7.
0)
1
(1
00
.0
)
61
(9
0.
2)
0
--
0
--
H
aw
ai
i
10
9
1
0
--
76
(7
8.
9)
0
--
25
(7
6.
0)
7
(4
2.
9)
0
--
0
--
Id
ah
o
8
3
(6
6.
7)
0
--
1
(1
00
.0
)
0
--
0
--
4
(7
5.
0)
0
--
0
--
Ill
in
oi
s
45
7
11
8
(8
3.
9)
0
--
13
6
(8
1.
6)
12
9
(8
5.
3)
0
--
69
(7
6.
8)
1
(1
00
.0
)
4
(5
0.
0)
In
di
an
a
11
8
29
(9
3.
1)
0
--
18
(8
8.
9)
28
(7
8.
6)
0
--
43
(9
3.
0)
0
--
0
--
Io
w
a
36
8
0
--
13
(8
4.
6)
2
(1
00
.0
)
1
(1
00
.0
)
12
(8
3.
3)
0
--
0
--
K
an
sa
s
53
14
(7
8.
6)
1
(0
.0
)
16
(8
1.
3)
13
(9
2.
3)
1
(1
00
.0
)
8
(8
7.
5)
0
--
0
--
K
en
tu
ck
y
10
8
24
(7
5.
0)
0
--
4
(1
00
.0
)
23
(8
7.
0)
0
--
57
(9
6.
5)
0
--
0
--
Lo
ui
si
an
a
19
6
25
(6
4.
0)
0
--
13
(8
4.
6)
11
2
(8
3.
0)
0
--
46
(7
8.
3)
0
--
0
--
M
ai
ne
18
2
0
--
4
(7
5.
0)
6
(1
00
.0
)
0
--
6
(8
3.
3)
0
--
0
--
M
ar
yl
an
d
24
6
36
(8
8.
9)
0
--
73
(9
0.
4)
11
7
(8
8.
9)
0
--
20
(9
0.
0)
0
--
0
--
M
as
sa
ch
us
et
ts
20
5
31
(9
0.
3)
0
--
66
(7
7.
3)
66
(8
3.
3)
0
--
42
(7
8.
6)
0
--
0
--
M
ic
hi
ga
n
18
4
18
(7
7.
8)
0
--
37
(8
9.
2)
83
(7
9.
5)
0
--
44
(8
4.
1)
1
(1
00
.0
)
1
(0
.0
)
M
in
ne
so
ta
22
5
25
(9
2.
0)
2
(1
00
.0
)
44
(8
4.
1)
14
0
(9
0.
7)
0
--
14
(7
8.
6)
0
--
0
--
M
is
si
ss
ip
pi
11
8
11
(9
0.
9)
3
(1
00
.0
)
5
(1
00
.0
)
73
(9
7.
3)
0
--
26
(9
2.
3)
0
--
0
--
M
is
so
ur
i
10
6
9
(6
6.
7)
0
--
22
(7
2.
7)
36
(7
2.
2)
1
(1
00
.0
)
38
(8
1.
6)
0
--
0
--
M
on
ta
na
11
0
--
2
(1
00
.0
)
3
(1
00
.0
)
0
--
0
--
6
(1
00
.0
)
0
--
0
--
N
eb
ra
sk
a
24
11
(8
1.
8)
0
--
6
(1
00
.0
)
3
(1
00
.0
)
1
(1
00
.0
)
2
(1
00
.0
)
1
(1
00
.0
)
0
--
N
ev
ad
a
82
31
(8
0.
6)
0
--
27
(8
8.
9)
11
(9
0.
9)
1
(1
00
.0
)
12
(9
1.
7)
0
--
0
--
N
ew
 H
am
ps
hi
re
10
2
0
--
6
(8
3.
3)
0
--
0
--
2
(1
00
.0
)
0
--
0
--
N
ew
 J
er
se
y
41
1
14
9
(8
7.
2)
0
--
14
5
(8
2.
8)
66
(7
7.
3)
0
--
51
(8
2.
4)
0
--
0
--
Ta
bl
e 
43
. C
om
pl
et
io
n 
of
 T
ub
er
cu
lo
si
s 
Th
er
ap
y 
(C
O
T)
 C
as
es
 a
nd
 P
er
ce
nt
ag
es
1  b
y 
H
is
pa
ni
c 
Et
hn
ic
ity
 a
nd
 N
on
-H
is
pa
ni
c 
R
ac
e:
 
R
ep
or
tin
g 
A
re
as
, 2
00
72
R
ep
or
tin
g 
A
re
a
To
ta
l
C
as
es
3
U
nk
no
w
n 
or
 
M
is
si
ng
W
hi
te
A
si
an
H
is
pa
ni
c4
A
m
er
ic
an
 In
di
an
 
or
 A
la
sk
a 
N
at
iv
e
B
la
ck
N
on
-H
is
pa
ni
c
N
o.
(%
)
N
o.
N
o.
N
o.
N
o.
(%
)
(%
)
(%
)
(%
)
N
o.
(%
)
N
at
iv
e 
H
aw
ai
ia
n 
or
 O
th
er
 P
ac
ifi
c 
Is
la
nd
er
N
o.
(%
)
M
ul
tip
le
 R
ac
e2
N
o.
(%
)
69
1 P
er
ce
nt
ag
es
 s
ho
w
n 
on
ly
 fo
r r
ep
or
tin
g 
ar
ea
s 
w
ith
 in
fo
rm
at
io
n 
re
po
rte
d 
fo
r >
90
%
 o
f c
as
es
, a
nd
 in
di
ca
te
 th
e 
pe
rc
en
ta
ge
 o
f t
ho
se
 w
ho
 c
om
pl
et
ed
 th
er
ap
y 
w
ith
in
 1
 y
ea
r. 
2 M
os
t r
ec
en
t y
ea
r f
or
 w
hi
ch
 d
at
a 
ar
e 
av
ai
la
bl
e.
3 T
he
ra
py
 <
 1
 y
ea
r i
nd
ic
at
ed
 in
 p
er
so
ns
 a
liv
e 
at
 d
ia
gn
os
is
 w
ith
 a
n 
in
iti
al
 re
gi
m
en
 o
f o
ne
 o
r m
or
e 
dr
ug
s 
pr
es
cr
ib
ed
, w
ho
 d
id
 n
ot
 d
ie
 d
ur
in
g 
th
er
ap
y.
 E
xc
lu
de
s 
pe
rs
on
s 
w
ith
 in
iti
al
 is
ol
at
e 
rif
am
pi
n 
re
si
st
an
t, 
or
 p
at
ie
nt
 w
ith
 m
en
in
ge
al
 d
is
ea
se
, o
r p
ed
ia
tri
c 
pa
tie
nt
 (a
ge
d 
<1
5)
 w
ith
 m
ili
ar
y 
di
se
as
e 
or
 p
os
iti
ve
 b
lo
od
 c
ul
tu
re
. 
4 P
er
so
ns
 o
f H
is
pa
ni
c 
or
 L
at
in
o 
or
ig
in
 m
ay
 b
e 
of
 a
ny
 ra
ce
.
5 E
xc
lu
de
s 
N
ew
 Y
or
k 
C
ity
.
6 N
ot
 in
cl
ud
ed
 in
 U
.S
. t
ot
al
s.
 
N
ot
e:
 C
as
e 
co
un
ts
 a
nd
 p
er
ce
nt
ag
e 
fo
r r
ac
e 
ca
te
go
rie
s 
do
 n
ot
 in
cl
ud
e 
pe
rs
on
s 
of
 H
is
pa
ni
c 
et
hn
ic
ity
. E
lli
ps
es
 in
di
ca
te
 d
at
a 
no
t a
va
ila
bl
e.
 S
ee
 T
ec
hn
ic
al
 N
ot
es
 fo
r d
es
cr
ip
tio
n 
of
 C
om
pl
et
io
n 
of
 
Th
er
ap
y 
ca
lc
ul
at
io
n 
(p
ag
e 
9)
.
N
ew
 M
ex
ic
o
43
26
(8
4.
6)
8
(8
7.
5)
1
(1
00
.0
)
1
(1
00
.0
)
0
--
7
(1
00
.0
)
0
--
0
--
N
ew
 Y
or
k 
S
ta
te
5
22
8
81
(8
4.
0)
0
--
50
(9
2.
0)
49
(8
7.
8)
1
(1
00
.0
)
46
(8
7.
0)
0
--
1
(1
00
.0
)
N
ew
 Y
or
k 
C
ity
79
1
23
0
(9
0.
9)
0
--
26
7
(8
9.
9)
22
1
(9
0.
5)
2
(1
00
.0
)
67
(9
5.
5)
4
(7
5.
0)
0
--
N
or
th
 C
ar
ol
in
a
31
2
95
(8
6.
3)
8
(1
00
.0
)
46
(9
5.
7)
11
0
(9
4.
5)
1
(1
00
.0
)
47
(9
1.
5)
3
(6
6.
7)
2
(1
00
.0
)
N
or
th
 D
ak
ot
a
4
1
1
(1
00
.0
)
0
...
0
--
0
--
2
(1
00
.0
)
0
--
0
--
O
hi
o
22
1
18
(6
6.
7)
0
--
41
(9
5.
1)
10
1
(9
1.
1)
0
--
61
(8
2.
0)
0
--
0
--
O
kl
ah
om
a
13
1
23
(7
8.
3)
22
(9
0.
9)
8
(6
2.
5)
20
(8
5.
0)
5
(6
0.
0)
53
(8
3.
0)
0
--
0
--
O
re
go
n
88
37
(8
6.
5)
0
--
22
(9
0.
9)
7
(1
00
.0
)
2
(1
00
.0
)
20
(9
5.
0)
0
--
0
--
P
en
ns
yl
va
ni
a
24
8
16
(8
1.
3)
0
--
88
(8
5.
2)
79
(7
7.
2)
1
(1
00
.0
)
63
(7
9.
4)
1
(1
00
.0
)
0
--
R
ho
de
 Is
la
nd
40
13
(9
2.
3)
0
--
5
(1
00
.0
)
12
(9
1.
7)
0
--
10
(8
0.
0)
0
--
0
--
S
ou
th
 C
ar
ol
in
a
18
8
32
(7
8.
1)
3
(1
00
.0
)
16
(9
3.
8)
10
7
(9
2.
5)
2
(1
00
.0
)
26
(8
0.
8)
2
(1
00
.0
)
0
--
S
ou
th
 D
ak
ot
a
11
0
--
5
(1
00
.0
)
1
(1
00
.0
)
2
(1
00
.0
)
0
--
3
(1
00
.0
)
0
--
0
--
Te
nn
es
se
e
20
2
31
(8
0.
6)
0
--
18
(8
8.
9)
83
(8
6.
7)
1
(1
00
.0
)
67
(8
8.
1)
1
(1
00
.0
)
1
(1
00
.0
)
Te
xa
s
1,
33
9
65
0
(8
2.
6)
1
(0
.0
)
20
2
(7
8.
7)
27
4
(8
1.
8)
4
(5
0.
0)
20
8
(8
3.
7)
0
--
0
--
U
ta
h
35
15
0
--
9
(1
00
.0
)
4
(7
5.
0)
3
(6
6.
7)
4
(1
00
.0
)
0
--
0
--
Ve
rm
on
t
3
0
--
0
--
0
--
2
(0
.0
)
0
--
1
(1
00
.0
)
0
--
0
--
V
irg
in
ia
29
1
92
(8
9.
1)
0
--
97
(8
7.
6)
71
(8
8.
7)
0
--
30
(8
3.
3)
0
--
1
(1
00
.0
)
W
as
hi
ng
to
n
26
4
50
(8
2.
0)
7
(1
00
.0
)
11
0
(8
9.
1)
52
(8
6.
5)
14
(1
00
.0
)
30
(9
3.
3)
1
(1
00
.0
)
0
--
W
es
t V
irg
in
ia
16
0
--
0
--
4
(1
00
.0
)
2
(1
00
.0
)
0
--
10
(1
00
.0
)
0
--
0
--
W
is
co
ns
in
57
18
(8
3.
3)
0
--
12
(8
3.
3)
10
(8
0.
0)
0
--
16
(6
8.
8)
0
--
1
(0
.0
)
W
yo
m
in
g
2
0
--
0
--
1
(0
.0
)
0
--
0
--
1
(1
00
.0
)
0
--
0
--
A
m
er
ic
an
 S
am
oa
6
3
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Fe
d.
 S
ta
te
s 
of
 M
ic
ro
ne
si
a6
12
6
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
G
ua
m
6
89
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
M
ar
sh
al
l I
sl
an
ds
6
11
5
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
N
. M
ar
ia
na
 Is
la
nd
s6
39
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
P
ue
rto
 R
ic
o6
81
80
(9
7.
5)
0
--
0
--
1
(1
00
.0
)
0
--
0
--
0
--
0
--
R
ep
ub
lic
 o
f P
al
au
6
12
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
U
.S
. V
irg
in
 Is
la
nd
s6
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
Ta
bl
e 
43
. (
C
on
t’d
) C
om
pl
et
io
n 
of
 T
ub
er
cu
lo
si
s 
Th
er
ap
y 
(C
O
T)
 C
as
es
 a
nd
 P
er
ce
nt
ag
es
1  b
y 
H
is
pa
ni
c 
Et
hn
ic
ity
 a
nd
 N
on
-H
is
pa
ni
c 
R
ac
e:
 R
ep
or
tin
g 
A
re
as
, 2
00
72
R
ep
or
tin
g 
A
re
a
To
ta
l
C
as
es
3
U
nk
no
w
n 
or
 
M
is
si
ng
W
hi
te
A
si
an
H
is
pa
ni
c4
A
m
er
ic
an
 In
di
an
 
or
 A
la
sk
a 
N
at
iv
e
B
la
ck
N
on
-H
is
pa
ni
c
N
o.
(%
)
N
o.
N
o.
N
o.
N
o.
(%
)
(%
)
(%
)
(%
)
N
o.
(%
)
N
at
iv
e 
H
aw
ai
ia
n 
or
 O
th
er
 P
ac
ifi
c 
Is
la
nd
er
N
o.
(%
)
M
ul
tip
le
 R
ac
e2
N
o.
(%
)
70
United States 13,060 (82.8) 12,775 (83.6) 12,343 (83.2) 12,035 (83.9) 11,750 (84.3)
Alabama 232 (86.2) 179 (89.9) 194 (89.7) 166 (86.1) 149 (91.9)
Alaska 51 (92.2) 38 (84.2) 57 (93.0) 63 (88.9) 43 (88.4)
Arizona 260 (79.6) 246 (74.8) 245 (83.7) 273 (76.9) 242 (69.0)
Arkansas 116 (87.9) 115 (88.7) 103 ... 90 (90.0) 96 (92.7)
California 2,840 (81.5) 2,638 (81.8) 2,541 (81.3) 2,398 (80.9) 2,427 (78.9)
Colorado 102 (93.1) 116 (96.6) 85 (96.5) 108 (88.9) 91 (97.8)
Connecticut 100 (76.0) 85 (77.6) 87 (82.8) 77 (88.3) 96 (76.0)
Delaware 28 (85.7) 29 (93.1) 24 (87.5) 24 (83.3) 18 (94.4)
District of Columbia 68 (91.2) 66 (93.9) 49 (87.8) 64 (70.3) 51 (70.6)
Florida 916 (85.9) 928 (85.9) 968 (88.6) 919 (89.4) 884 (89.9)
Georgia 480 (79.6) 457 (83.6) 449 (82.0) 443 (82.6) 414 (85.0)
Hawaii 98 (79.6) 107 (80.4) 95 (74.7) 101 (79.2) 109 (76.1)
Idaho 13 (84.6) 10 (80.0) 21 (76.2) 18 (77.8) 8 (75.0)
Illinois 563 (80.8) 503 (79.9) 524 (80.0) 500 (82.2) 457 (82.3)
Indiana 118 (95.8) 111 (93.7) 133 (91.0) 116 (90.5) 118 (89.0)
Iowa 37 (91.9) 47 (76.6) 52 (84.6) 37 (86.5) 36 (88.9)
Kansas 64 (78.1) 57 (84.2) 57 (86.0) 73 (93.2) 53 (83.0)
Kentucky 120 (85.8) 110 (87.3) 104 (87.5) 75 (82.7) 108 (89.8)
Louisiana 219 (81.7) 231 (73.2) 218 ... 178 (77.0) 196 (79.6)
Maine 23 (69.6) 18 (66.7) 16 (75.0) 13 (100.0) 18 (88.9)
Maryland 239 (87.9) 279 (90.7) 249 (89.2) 226 (90.7) 246 (89.4)
Massachusetts 243 (80.2) 256 (77.7) 235 (78.7) 239 (85.8) 205 (81.5)
Michigan 205 (84.9) 239 (87.0) 201 (80.1) 200 (79.5) 184 (82.1)
Minnesota 200 (89.5) 188 (91.0) 183 (92.9) 200 (90.0) 225 (88.9)
Mississippi 108 (73.1) 101 (85.1) 84 (84.5) 97 (85.6) 118 (95.8)
Missouri 105 (73.3) 111 (82.0) 91 (85.7) 92 (76.1) 106 (75.5)
Montana 5 (100.0) 14 (92.9) 8 (87.5) 10 (90.0) 11 (100.0)
Nebraska 25 (68.0) 37 (86.5) 29 (75.9) 23 (100.0) 24 (91.7)
Nevada 96 (91.7) 88 (90.9) 106 ... 82 (90.2) 82 (86.6)
New Hampshire 13 (92.3) 21 (100.0) 4 (75.0) 15 (93.3) 10 (90.0)
New Jersey 450 (81.8) 429 (82.3) 420 (85.7) 463 (84.9) 411 (83.5)
New Mexico 37 (86.5) 33 (84.8) 26 (80.8) 37 (81.1) 43 (88.4)
New York State4 296 (83.4) 293 (86.3) 266 (87.6) 271 (85.6) 228 (87.3)
New York City 979 (86.7) 901 (84.5) 844 (82.0) 823 (84.4) 791 (90.8)
North Carolina 323 (90.4) 332 (92.8) 290 (85.9) 339 (87.3) 312 (91.7)
North Dakota 4 (50.0) 4 (100.0) 6 (50.0) 10 (60.0) 4 (100.0)
Ohio 193 (90.7) 190 (87.9) 231 (87.0) 205 (82.9) 221 (87.3)
Oklahoma 137 (69.3) 164 (80.5) 118 (85.6) 129 (81.4) 131 (81.7)
Oregon 96 (84.4) 97 (89.7) 95 (93.7) 71 (91.5) 88 (90.9)
Pennsylvania 288 (79.5) 280 ... 270 ... 295 (82.0) 248 (81.0)
Rhode Island 40 (90.0) 49 (85.7) 41 (82.9) 24 (79.2) 40 (90.0)
South Carolina 232 (86.6) 213 (82.2) 231 (87.4) 194 (86.6) 188 (88.8)
South Dakota 16 (68.8) 9 (44.4) 13 (53.8) 12 (50.0) 11 (100.0)
Tennessee 237 (81.0) 237 (86.1) 267 (88.8) 239 (88.3) 202 (86.6)
Texas 1,389 (77.3) 1,448 (82.9) 1,342 (82.3) 1,365 (83.0) 1,339 (81.9)
Utah 35 (97.1) 32 (96.9) 26 (96.2) 32 (84.4) 35 (94.3)
Vermont 8 (100.0) 6 (66.7) 7 (100.0) 6 (83.3) 3 (33.3)
Virginia 298 (87.6) 292 (88.4) 321 (83.2) 292 (85.3) 291 (88.0)
Washington 234 (82.5) 226 (88.5) 227 (83.3) 227 (81.9) 264 (88.6)
West Virginia 17 (70.6) 21 (81.0) 24 (58.3) 18 (77.8) 16 (100.0)
Wisconsin 61 (86.9) 89 (79.8) 66 (84.8) 59 (84.7) 57 (77.2)
Wyoming 3 (100.0) 5 (100.0) 0 ... 4 (100.0) 2 (50.0)
American Samoa5 0 ... 3 ... 5 ... 2 (100.0) 3 ...
Fed. States of Micronesia5 0 ... 5 ... 71 ... 76 ... 126 ...
Guam5 58 (87.9) 45 (84.4) 58 (79.3) 52 (86.5) 89 ...
Marshall Islands5 0 ... 38 ... 63 ... 26 ... 115 ...
N. Mariana Islands5 42 (78.6) 54 (87.0) 54 ... 44 ... 39 ...
Puerto Rico5 89 (70.8) 89 (79.8) 86 (87.2) 89 (96.6) 81 (97.5)
Republic of Palau5 7 (57.1) 5 (80.0) 10 (100.0) 9 (66.7) 12 ...
U.S. Virgin Islands5 0 ... 0 ... 0 ... 0 ... 0 ...
Reporting Area
2003 2004 2005 2006 2007
Year
No.2 No.2 No.2No.2(%)3 (%)3 (%)3 (%)3 (%)3
Table 44. Tuberculosis Cases and Percentages in Persons Completing Therapy for Whom 
Therapy Was Indicated for One Year or Less: Reporting Areas, 2003–20071
1Most recent year for which data are available.
2Total cases for which therapy less than 1 year indicated in persons alive at diagnosis, with an initial regimen of one or more drugs prescribed, who did not die 
during therapy. Excludes persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) with miliary disease or 
positive blood culture. 
3Percentage of total cases in persons who completed therapy within one year for whom therapy less than 1 year was indicated.
4Excludes New York City.
5Not included in U.S. totals. 
Note: Ellipses indicate data not available.
See Technical Notes for description of Completion of Therapy calculation (page 9).
No.2
71
Morbidity Tables
Cities and Metropolitan Statistical Areas, 2009
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Albuquerque, NM 12 14
Anaheim, CA 28 35
Arlington, TX 23 19
Atlanta, GA 23 19
Austin, TX 54 39
Baltimore, MD 24 32
Birmingham, AL 26 16
Boston, MA 56 61
Buffalo, NY 10 15
Charlotte, NC 26 20
Chicago, IL 200 212
Cincinnati, OH 20 10
Cleveland, OH 29 35
Colorado Springs, CO 6 10
Columbus, OH 27 55
Corpus Christi, TX 9 12
Dallas, TX 123 161
Denver, CO 30 30
Detroit, MI 32 54
El Paso, TX 49 59
Fort Worth, TX 56 48
Fresno, CA 53 52
Honolulu, HI 44 50
Houston, TX 260 264
Indianapolis, IN 46 33
Jacksonville, FL 85 100
Kansas City, MO 14 18
Las Vegas, NV 73 81
Long Beach, CA 44 47
Los Angeles, CA 275 327
Louisville, KY 25 26
Memphis, TN 61 81
Mesa, AZ 8 7
Miami, FL 111 129
Milwaukee, WI 25 24
Minneapolis, MN 33 56
Nashville, TN 50 68
Newark, NJ 27 36
New Orleans, LA 34 28
New York, NY 760 893
Norfolk, VA 3 5
Oakland, CA 57 49
Omaha, NE 16 17
Philadelphia, PA 96 162
Phoenix, AZ 82 64
Pittsburgh, PA 7 7
Portland, OR 29 26
Sacramento, CA 72 76
St. Louis, MO 10 20
St. Paul, MN 35 37
San Antonio, TX 91 80
San Diego, CA 128 155
San Francisco, CA 115 118
San Jose, CA 125 130
Santa Ana, CA 39 34
Seattle, WA 55 65
Tampa, FL 42 32
Toledo, OH 3 7
Tucson, AZ 27 26
Virginia Beach, VA 13 9
Washington, DC 41 54
Wichita, KS 10 16
TOTAL - 62 CITIES 3,987 4,465
San Juan, PR 4 10
Table 45. Tuberculosis Cases in Selected Cities1: 2009 and 2008
Cases2
2009 2008City
1Historical list of cities.
2Excludes cases known to not be within city limits. Residence within city limits was determined by the health department.
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Table 46. Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2009 and 2008
Metropolitan 
Statistical Area
Cases Case Rates Population 
Estimates 
20092009 20092008 2008
Akron, OH 10 5 1.4 0.7 699,935
Albany-Schenectady-Troy, NY 9 4 1 0.5 857,592
Albuquerque, NM 16 23 1.9 2.7 857,903
Allentown-Bethlehem-Easton, PA-NJ 13 17 1.6 2.1 816,012
Atlanta-Sandy Springs-Marietta, GA 257 298 4.7 5.5 5,475,213
Augusta-Richmond County, GA-SC 29 25 5.4 4.7 539,154
Austin-Round Rock, TX 70 56 4.1 3.4 1,705,075
Bakersfield, CA 41 50 5.1 6.3 807,407
Baltimore-Towson, MD 62 89 2.3 3.3 2,690,886
Baton Rouge, LA 24 30 3 3.8 786,947
Birmingham-Hoover, AL 49 32 4.3 2.8 1,131,070
Boise City-Nampa, ID 13 6 2.1 1 606,376
Boston-Cambridge-Quincy, MA-NH 194 207 4.2 4.6 4,588,680
Bridgeport-Stamford-Norwalk, CT 41 36 4.5 4 901,208
Buffalo-Niagara Falls, NY 16 18 1.4 1.6 1,123,804
Cape Coral-Fort Myers, FL 29 32 4.9 5.4 586,908
Charleston-North Charleston, SC 37 31 5.6 4.8 659,191
Charlotte-Gastonia-Concord, NC-SC 44 77 2.5 4.5 1,745,524
Chattanooga, TN-GA 13 16 2.5 3.1 524,303
Chicago-Naperville-Joliet, IL 377 434 3.9 4.6 9,580,567
Cincinnati-Middleton, OH-KY-IN 33 42 1.5 1.9 2,171,896
Cleveland-Elyria-Mentor, OH 45 59 2.2 2.8 2,091,286
Colorado Springs, CO 8 10 1.3 1.6 626,227
Columbia, SC 26 24 3.5 3.3 744,730
Columbus, OH 44 66 2.4 3.7 1,801,848
Dallas-Fort Worth-Arlington, TX 382 372 5.9 5.9 6,447,615
Dayton, OH 15 10 1.8 1.2 835,063
Denver-Aurora, CO 57 67 2.2 2.7 2,552,195
Des Moines-West Des Moines, IA 12 7 2.1 1.3 562,906
Detroit-Warren-Livonia, MI 84 119 1.9 2.7 4,403,437
Durham-Chapel Hill, NC 17 ... 3.4 ... 501,228
El Paso, TX 57 68 7.6 9.2 751,296
Fresno, CA 67 75 7.3 8.3 915,267
Grand Rapids-Wyoming, MI 19 14 2.4 1.8 778,009
Greensboro-High Point, NC 22 24 3.1 3.4 714,765
Greenville, SC 15 19 2.3 3 639,617
Harrisburg-Carlisle, PA 15 17 2.8 3.2 536,919
Hartford-West Hartford-East Hartford, CT 19 24 1.6 2 1,195,998
Honolulu, HI 83 101 9.1 11.2 907,574
Houston-Sugar Land-Baytown, TX 485 457 8.3 8 5,867,489
Indianapolis-Carmel, IN 58 40 3.3 2.3 1,743,658
Jackson, MS 57 34 10.5 6.3 540,866
Jacksonville, FL 99 107 7.5 8.1 1,328,144
Kansas City, MO-KS 39 46 1.9 2.2 2,067,585
Knoxville, TN 11 17 1.6 2.5 699,247
Lakeland, FL 9 21 1.5 3.6 583,403
Lancaster, PA 3 19 0.6 3.8 507,766
Las Vegas-Paradise, NV 84 91 4.4 4.8 1,902,834
Little Rock-North Little Rock-Conway, AR 17 16 2.5 2.4 685,488
Los Angeles-Long Beach-Santa Ana, CA 948 1,053 7.4 8.2 12,874,797
Louisville-Jefferson County, KY-IN 29 34 2.3 2.7 1,258,577
Madison, WI 13 8 2.3 1.4 570,025
McAllen-Edinburg-Mission, TX 75 90 10.1 12.5 741,152
Memphis, TN-MS-AR 72 96 5.5 7.4 1,304,926
Miami-Fort Lauderdale-Pompano Beach, FL 295 351 5.3 6.4 5,547,051
Milwaukee-Waukesha-West Allis, WI 34 35 2.2 2.3 1,559,667
Minneapolis-St. Paul-Bloomington, MN-WI 133 165 4.1 5.1 3,269,814
75
Modesto, CA 20 20 3.9 3.9 510,385
Nashville-Davidson-Murfreesboro-Franklin, TN 75 98 4.7 6.3 1,582,264
New Haven-Milford, CT 27 26 3.2 3.1 848,006
New Orleans-Metairie-Kenner, LA 71 72 6 6.2 1,189,981
New York-Northern New Jersey-Long Island, NY-NJ-PA 1,240 1,443 6.5 7.6 19,069,796
Ogden-Clearfield, UT 7 4 1.3 0.8 541,569
Oklahoma City, OK 33 35 2.7 2.9 1,227,278
Omaha-Council Bluffs, NE-IA 17 25 2 3 849,517
Orlando-Kissimmee, FL 66 106 3.2 5.1 2,082,421
Oxnard-Thousand Oaks-Ventura, CA 48 65 6 8.2 802,983
Palm Bay-Melbourne-Titusville, FL 8 10 1.5 1.9 536,357
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 195 287 3.3 4.8 5,968,252
Phoenix-Mesa-Scottsdale, AZ 164 150 3.8 3.5 4,364,094
Pittsburgh, PA 21 27 0.9 1.1 2,354,957
Portland-South Portland-Biddeford, ME 4 4 0.8 0.8 516,826
Portland-Vancouver-Beaverton, OR-WA 72 61 3.2 2.8 2,241,841
Poughkeepsie-Newburgh-Middletown, NY 6 15 0.9 2.2 677,094
Providence-New Bedford-Fall River, RI-MA 37 56 2.3 3.5 1,600,642
Provo-Orem, UT 4 1 0.7 0.2 555,551
Raleigh-Cary, NC 30 50 2.7 4.6 1,125,827
Richmond, VA 30 38 2.4 3.1 1,238,187
Riverside-San Bernardino-Ontario, CA 145 153 3.5 3.7 4,143,113
Rochester, NY 22 17 2.1 1.6 1,035,566
Sacramento-Arden Arcade-Roseville, CA 118 124 5.5 5.9 2,127,355
St. Louis, MO-IL 46 58 1.6 2.1 2,828,990
Salt Lake City, UT 20 16 1.8 1.4 1,130,293
San Antonio, TX 99 92 4.8 4.5 2,072,128
San Diego-Carlsbad-San Marcos, CA 223 264 7.3 8.7 3,053,793
San Francisco-Oakland-Fremont, CA 402 405 9.3 9.5 4,317,853
San Jose-Sunnyvale-Santa Clara, CA 197 198 10.7 10.9 1,839,700
Sarasota-Bradenton-Venice, FL 35 31 5.1 4.5 688,126
Scranton-Wilkes-Barre, PA 7 12 1.3 2.2 549,454
Seattle-Tacoma-Bellevue, WA 191 164 5.6 4.9 3,407,848
Springfield, MA 19 6 2.7 0.9 698,903
Stockton, CA 76 66 11.3 9.9 674,860
Syracuse, NY 19 22 2.9 3.4 646,084
Tampa-St. Petersburg-Clearwater, FL 111 111 4 4.1 2,747,272
Toledo, OH 3 8 0.4 1.2 672,220
Tucson, AZ 26 26 2.5 2.6 1,020,200
Tulsa, OK 16 22 1.7 2.4 929,015
Virginia Beach-Norfolk-Newport News, VA-NC 37 42 2.2 2.5 1,674,498
Washington-Arlington-Alexandria, DC-VA-MD-WV 344 401 6.3 7.5 5,476,241
Wichita, KS 11 17 1.8 2.8 612,683
Worchester, MA 17 29 2.1 3.6 803,701
Youngstown-Warren-Boardman, OH-PA 5 6 0.9 1.1 562,963
Total - 102 Areas 9,189 10,167 4.5 5.1 202,510,807
San Juan-Caguas-Guaynabo, PR 46 80 1.8 3.1 2,617,089
Table 46. (Cont’d) Tuberculosis Cases and Case Rates per 100,000 Population: Metropolitan 
Statistical Areas with >500,000 Population, 2009 and 2008
Metropolitan 
Statistical Area
Cases Case Rates Population 
Estimates 
20092009 20092008 2008
Note: In 2009, there was 1 metropolitan statistical area with a 2008 population of less than 500,000. Ellipses indicate that data not shown 
for those populations less than 500,000.  
2009 and 2008 population case counts and rates updated using U.S. Census Metropolitan Statistical Areas and Components, November 
2008, with Codes (http://www.whitehouse.gov/sites/default/files/omb/assets/omb/bulletins/fy2009/09-01.pdf) (accessed August 30, 2010).
See Technical Notes for definition of MSA (page 9).
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Akron, OH 10 6 (60.0) 1 (10.0) 3 (30.0) 0
Albany-Schenectady-Troy, NY 9 4 (44.4) 2 (22.2) 2 (22.2) 2
Albuquerque, NM 16 11 (68.8) 3 (18.8) 1 (6.3) 1
Allentown-Bethlehem-Easton, PA-NJ 13 9 (69.2) 2 (15.4) 2 (15.4) 1
Atlanta-Sandy Springs-Marietta, GA 257 169 (65.8) 55 (21.4) 23 (8.9) 7
Augusta-Richmond County, GA-SC 29 23 (79.3) 3 (10.3) 3 (10.3) 0
Austin-Round Rock, TX 70 43 (61.4) 15 (21.4) 9 (12.9) 1
Bakersfield, CA 41 32 (78.0) 7 (17.1) 2 (4.9) 0
Baltimore-Towson, MD 62 41 (66.1) 13 (21.0) 8 (12.9) 0
Baton Rouge, LA 24 19 (79.2) 1 (4.2) 1 (4.2) 0
Birmingham-Hoover, AL 49 41 (83.7) 7 (14.3) 1 (2.0) 0
Boise City-Nampa, ID 13 8 (61.5) 2 (15.4) 2 (15.4) 0
Boston-Cambridge-Quincy, MA-NH 194 110 (56.7) 52 (26.8) 29 (14.9) 11
Bridgeport-Stamford-Norwalk, CT 41 26 (63.4) 9 (22.0) 6 (14.6) 0
Buffalo-Niagara Falls, NY 16 12 (75.0) 4 (25.0) 0 (0.0) 0
Cape Coral-Fort Myers, FL 29 25 (86.2) 2 (6.9) 1 (3.4) 0
Charleston-North Charleston, SC 37 23 (62.2) 8 (21.6) 6 (16.2) 4
Charlotte-Gastonia-Concord, NC-SC 44 26 (59.1) 10 (22.7) 8 (18.2) 1
Chattanooga, TN-GA 13 9 (69.2) 4 (30.8) 0 (0.0) 0
Chicago-Naperville-Joliet, IL 377 244 (64.7) 95 (25.2) 37 (9.8) 0
Cincinnati-Middleton, OH-KY-IN 33 20 (60.6) 7 (21.2) 6 (18.2) 3
Cleveland-Elyria-Mentor, OH 45 26 (57.8) 16 (35.6) 3 (6.7) 1
Colorado Springs, CO 8 5 (62.5) 3 (37.5) 0 (0.0) 0
Columbia, SC 26 17 (65.4) 3 (11.5) 6 (23.1) 3
Columbus, OH 44 25 (56.8) 14 (31.8) 5 (11.4) 2
Dallas-Fort Worth-Arlington, TX 382 268 (70.2) 80 (20.9) 27 (7.1) 10
Dayton, OH 15 9 (60.0) 6 (40.0) 0 (0.0) 0
Denver-Aurora, CO 57 41 (71.9) 14 (24.6) 2 (3.5) 2
Des Moines-West Des Moines, IA 12 4 (33.3) 7 (58.3) 0 (0.0) 0
Detroit-Warren-Livonia, MI 84 55 (65.5) 25 (29.8) 4 (4.8) 4
Durham-Chapel Hill, NC 17 11 (64.7) 4 (23.5) 2 (11.8) 0
El Paso, TX 57 42 (73.7) 10 (17.5) 5 (8.8) 2
Fresno, CA 67 51 (76.1) 13 (19.4) 3 (4.5) 0
Grand Rapids-Wyoming, MI 19 11 (57.9) 8 (42.1) 0 (0.0) 0
Greensboro-High Point, NC 22 16 (72.7) 6 (27.3) 0 (0.0) 0
Greenville, SC 15 11 (73.3) 2 (13.3) 2 (13.3) 0
Harrisburg-Carlisle, PA 15 11 (73.3) 3 (20.0) 1 (6.7) 1
Hartford-West Hartford-East Hartford, CT 19 10 (52.6) 6 (31.6) 3 (15.8) 0
Honolulu, HI 83 66 (79.5) 12 (14.5) 5 (6.0) 1
Houston-Sugar Land-Baytown, TX 485 359 (74.0) 78 (16.1) 39 (8.0) 9
Indianapolis-Carmel, IN 58 42 (72.4) 12 (20.7) 3 (5.2) 1
Jackson, MS 57 45 (78.9) 5 (8.8) 7 (12.3) 0
Jacksonville, FL 99 87 (87.9) 9 (9.1) 3 (3.0) 1
Kansas City, MO-KS 39 28 (71.8) 5 (12.8) 5 (12.8) 2
Knoxville, TN 11 7 (63.6) 4 (36.4) 0 (0.0) 0
Lakeland, FL 9 7 (77.8) 1 (11.1) 1 (11.1) 1
Lancaster, PA 3 3 (100.0) 0 (0.0) 0 (0.0) 0
Las Vegas-Paradise, NV 84 67 (79.8) 14 (16.7) 3 (3.6) 2
Little Rock-North Little Rock-Conway, AR 17 10 (58.8) 5 (29.4) 0 (0.0) 0
Los Angeles-Long Beach-Santa Ana, CA 948 622 (65.6) 233 (24.6) 93 (9.8) 10
Louisville-Jefferson County, KY-IN 29 24 (82.8) 1 (3.4) 4 (13.8) 1
Madison, WI 13 8 (61.5) 3 (23.1) 1 (7.7) 1
McAllen-Edinburg-Mission, TX 75 57 (76.0) 11 (14.7) 5 (6.7) 1
Memphis, TN-MS-AR 72 45 (62.5) 13 (18.1) 13 (18.1) 2
Miami-Fort Lauderdale-Pompano Beach, FL 295 221 (74.9) 54 (18.3) 12 (4.1) 7
Milwaukee-Waukesha-West Allis, WI 34 24 (70.6) 8 (23.5) 2 (5.9) 2
Table 47. Tuberculosis Cases by Pulmonary and Extrapulmonary Disease: Metropolitan 
Statistical Areas with >500,000 Population, 2009
Metropolitan 
Statistical Area
Pulmonary1 Extrapulmonary2
No. (%)
Total
Cases
Total3
No. (%) No.
Cases in Persons with Both Pul-
monary and Extrapulm. Disease
Miliary
No. (%)
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Minneapolis-St. Paul-Bloomington, MN-WI 133 69 (51.9) 46 (34.6) 16 (12.0) 3
Modesto, CA 20 13 (65.0) 7 (35.0) 0 (0.0) 0
Nashville-Davidson-Murfreesboro-Franklin, TN 75 57 (76.0) 11 (14.7) 6 (8.0) 2
New Haven-Milford, CT 27 18 (66.7) 9 (33.3) 0 (0.0) 0
New Orleans-Metairie-Kenner, LA 71 59 (83.1) 5 (7.0) 2 (2.8) 2
New York-Northern New Jersey-Long Island, NY-NJ-PA 1,240 801 (64.6) 298 (24.0) 132 (10.6) 13
Ogden-Clearfield, UT 7 5 (71.4) 2 (28.6) 0 (0.0) 0
Oklahoma City, OK 33 22 (66.7) 8 (24.2) 0 (0.0) 0
Omaha-Council Bluffs, NE-IA 17 14 (82.4) 2 (11.8) 1 (5.9) 0
Orlando-Kissimmee, FL 66 54 (81.8) 6 (9.1) 6 (9.1) 2
Oxnard-Thousand Oaks-Ventura, CA 48 32 (66.7) 9 (18.8) 7 (14.6) 0
Palm Bay-Melbourne-Titusville, FL 8 4 (50.0) 2 (25.0) 2 (25.0) 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 195 118 (60.5) 56 (28.7) 17 (8.7) 10
Phoenix-Mesa-Scottsdale, AZ 164 120 (73.2) 26 (15.9) 15 (9.1) 10
Pittsburgh, PA 21 18 (85.7) 2 (9.5) 0 (0.0) 0
Portland-South Portland-Biddeford, ME 4 4 (100.0) 0 (0.0) 0 (0.0) 0
Portland-Vancouver-Beaverton, OR-WA 72 36 (50.0) 29 (40.3) 3 (4.2) 3
Poughkeepsie-Newburgh-Middletown, NY 6 2 (33.3) 3 (50.0) 0 (0.0) 0
Providence-New Bedford-Fall River, RI-MA 37 20 (54.1) 11 (29.7) 5 (13.5) 3
Provo-Orem, UT 4 3 (75.0) 1 (25.0) 0 (0.0) 0
Raleigh-Cary, NC 30 16 (53.3) 10 (33.3) 4 (13.3) 0
Richmond, VA 30 22 (73.3) 4 (13.3) 4 (13.3) 0
Riverside-San Bernardino-Ontario, CA 145 99 (68.3) 41 (28.3) 5 (3.4) 0
Rochester, NY 22 9 (40.9) 8 (36.4) 4 (18.2) 1
Sacramento-Arden Arcade-Roseville, CA 118 94 (79.7) 15 (12.7) 9 (7.6) 1
St. Louis, MO-IL 46 27 (58.7) 18 (39.1) 1 (2.2) 1
Salt Lake City, UT 20 7 (35.0) 9 (45.0) 4 (20.0) 0
San Antonio, TX 99 77 (77.8) 14 (14.1) 5 (5.1) 0
San Diego-Carlsbad-San Marcos, CA 223 141 (63.2) 44 (19.7) 38 (17.0) 8
San Francisco-Oakland-Fremont, CA 402 269 (66.9) 96 (23.9) 37 (9.2) 2
San Jose-Sunnyvale-Santa Clara, CA 197 136 (69.0) 45 (22.8) 16 (8.1) 5
Sarasota-Bradenton-Venice, FL 35 25 (71.4) 7 (20.0) 2 (5.7) 1
Scranton-Wilkes-Barre, PA 7 6 (85.7) 1 (14.3) 0 (0.0) 0
Seattle-Tacoma-Bellevue, WA 191 111 (58.1) 47 (24.6) 22 (11.5) 6
Springfield, MA 19 13 (68.4) 3 (15.8) 2 (10.5) 0
Stockton, CA 76 59 (77.6) 12 (15.8) 5 (6.6) 0
Syracuse, NY 19 12 (63.2) 6 (31.6) 1 (5.3) 0
Tampa-St. Petersburg-Clearwater, FL 111 95 (85.6) 7 (6.3) 7 (6.3) 3
Toledo, OH 3 3 (100.0) 0 (0.0) 0 (0.0) 0
Tucson, AZ 26 17 (65.4) 6 (23.1) 1 (3.8) 0
Tulsa, OK 16 9 (56.3) 4 (25.0) 1 (6.3) 0
Virginia Beach-Norfolk-Newport News, VA-NC 37 26 (70.3) 5 (13.5) 5 (13.5) 2
Washington-Arlington-Alexandria, DC-VA-MD-WV 344 220 (64.0) 70 (20.3) 49 (14.2) 14
Wichita, KS 11 8 (72.7) 1 (9.1) 2 (18.2) 0
Worcester, MA 17 10 (58.8) 4 (23.5) 3 (17.6) 0
Youngstown-Warren-Boardman, OH-PA 5 5 (100.0) 0 (0.0) 0 (0.0) 0
Total - 102 Areas 9,189 6,221 (67.7) 2,000 (21.8) 848 (9.2) 189
San Juan-Caguas-Guaynabo, PR 46 38 (82.6) 7 (15.2) 1 (2.2) 1
Table 47. (Cont’d) Tuberculosis Cases by Pulmonary and Extrapulmonary Disease: 
Metropolitan Statistical Areas with >500,000 Population, 2009
Metropolitan 
Statistical Area
Total
Cases
1Includes cases in persons with pulmonary listed as the only site of disease.
2Includes cases in persons with pleural, lymphatic, bone and/or joint, meningeal, peritoneal, genitourinary, or other site, excluding pulmo-
nary, listed as site of disease.
3Includes cases with evidence of miliary disease.
Note: 120 cases had missing and/or unknown site of disease. 
See Technical Notes for definition of MSA (page 9).
Pulmonary1 Extrapulmonary2
No. (%)
Total3
No. (%) No.
Cases in Persons with Both Pul-
monary and Extrapulm. Disease
Miliary
No. (%)
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Table 48. Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with 
>500,000 Population, 2009
Akron, OH 10 0 1 3 1 2 3 0
Albany-Schenectady-Troy, NY 9 0 0 2 2 2 3 0
Albuquerque, NM 16 0 0 1 3 3 9 0
Allentown-Bethlehem-Easton, PA-NJ 13 0 0 2 3 4 4 0
Atlanta-Sandy Springs-Marietta, GA 257 14 3 34 101 79 26 0
Augusta-Richmond County, GA-SC 29 0 1 2 16 6 4 0
Austin-Round Rock, TX 70 3 3 5 30 22 7 0
Bakersfield, CA 41 1 0 8 11 14 7 0
Baltimore-Towson, MD 62 0 5 4 28 17 8 0
Baton Rouge, LA 24 0 0 2 11 9 2 0
Birmingham-Hoover, AL 49 1 1 2 15 22 8 0
Boise City-Nampa, ID 13 2 0 1 1 6 3 0
Boston-Cambridge-Quincy, MA-NH 194 5 4 20 63 66 36 0
Bridgeport-Stamford-Norwalk, CT 41 3 0 7 17 7 7 0
Buffalo-Niagara Falls, NY 16 1 1 3 2 5 4 0
Cape Coral-Fort Myers, FL 29 2 1 4 4 9 9 0
Charleston-North Charleston, SC 37 3 2 3 12 12 5 0
Charlotte-Gastonia-Concord, NC-SC 44 1 3 5 14 17 4 0
Chattanooga, TN-GA 13 0 0 0 4 5 4 0
Chicago-Naperville-Joliet, IL 377 12 2 45 137 112 69 0
Cincinnati-Middleton, OH-KY-IN 33 0 0 1 10 11 11 0
Cleveland-Elyria-Mentor, OH 45 3 3 2 13 14 10 0
Colorado Springs, CO 8 2 0 0 3 3 0 0
Columbia, SC 26 2 1 6 10 3 4 0
Columbus, OH 44 0 0 9 25 5 5 0
Dallas-Fort Worth-Arlington, TX 382 19 6 39 154 122 42 0
Dayton, OH 15 0 0 2 6 4 3 0
Denver-Aurora, CO 57 2 3 7 22 17 6 0
Des Moines-West Des Moines, IA 12 0 1 1 6 4 0 0
Detroit-Warren-Livonia, MI 84 2 0 11 26 29 16 0
Durham-Chapel Hill, NC 17 1 0 4 6 2 4 0
El Paso, TX 57 1 0 7 15 19 15 0
Fresno, CA 67 3 3 7 13 25 16 0
Grand Rapids-Wyoming, MI 19 0 0 7 9 3 0 0
Greensboro-High Point, NC 22 0 1 4 6 9 2 0
Greenville, SC 15 3 1 2 4 3 2 0
Harrisburg-Carlisle, PA 15 0 1 2 6 5 1 0
Hartford-West Hartford-East Hartford, CT 19 0 0 2 7 4 6 0
Honolulu, HI 83 2 0 7 17 31 26 0
Houston-Sugar Land-Baytown, TX 485 25 13 48 185 158 56 0
Indianapolis-Carmel, IN 58 1 1 2 22 23 9 0
Jackson, MS 57 1 2 2 19 28 5 0
Jacksonville, FL 99 0 2 7 33 43 14 0
Kansas City, MO-KS 39 4 1 8 12 7 7 0
Knoxville, TN 11 1 0 0 4 1 5 0
Lakeland, FL 9 0 0 2 1 4 2 0
Lancaster, PA 3 0 0 0 1 1 1 0
Las Vegas-Paradise, NV 84 7 6 6 25 16 24 0
Little Rock-North Little Rock-Conway, AR 17 0 0 2 6 4 5 0
Los Angeles-Long Beach-Santa Ana, CA 948 19 15 81 286 309 238 0
Louisville-Jefferson County, KY-IN 29 0 0 2 12 10 5 0
Madison, WI 13 0 0 4 4 5 0 0
McAllen-Edinburg-Mission, TX 75 5 2 16 26 18 8 0
Memphis, TN-MS-AR 72 8 2 15 21 20 6 0
Miami-Fort Lauderdale-Pompano Beach, FL 295 10 5 21 118 76 65 0
Metropolitan 
Statistical Area
Total
Cases Under 5 15 –24
Unknown 
or 
Missing5–14 25–44 45–64 >65
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Table 48. (Cont’d) Tuberculosis Cases by Age Group: Metropolitan Statistical Areas with 
>500,000 Population, 2009
Metropolitan 
Statistical Area Under 5
Total
Cases 15 –24
Unknown 
or 
Missing
Note: See Technical Notes for definition of MSA (page 9).
5–14 25–44 45–64 >65
Milwaukee-Waukesha-West Allis, WI 34 0 1 3 8 10 12 0
Minneapolis-St. Paul-Bloomington, MN-WI 133 8 8 21 56 24 16 0
Modesto, CA 20 0 1 1 4 6 8 0
Nashville-Davidson-Murfreesboro-Franklin, TN 75 1 2 6 31 31 4 0
New Haven-Milford, CT 27 0 1 6 10 5 5 0
New Orleans-Metairie-Kenner, LA 71 5 0 9 22 22 13 0
New York-Northern New Jersey-Long Island, NY-NJ-PA 1,240 31 17 162 475 321 228 6
Ogden-Clearfield, UT 7 2 1 1 2 0 1 0
Oklahoma City, OK 33 1 2 1 11 16 2 0
Omaha-Council Bluffs, NE-IA 17 0 2 5 4 4 2 0
Orlando-Kissimmee, FL 66 1 0 8 18 28 11 0
Oxnard-Thousand Oaks-Ventura, CA 48 3 1 9 15 11 9 0
Palm Bay-Melbourne-Titusville, FL 8 0 0 0 5 1 2 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 195 6 5 26 63 54 41 0
Phoenix-Mesa-Scottsdale, AZ 164 11 1 19 61 41 31 0
Pittsburgh, PA 21 1 0 1 9 1 9 0
Portland-South Portland-Biddeford, ME 4 0 0 0 0 3 1 0
Portland-Vancouver-Beaverton, OR-WA 72 1 1 9 20 25 16 0
Poughkeepsie-Newburgh-Middletown, NY 6 0 0 2 2 1 1 0
Providence-New Bedford-Fall River, RI-MA 37 1 1 1 9 11 14 0
Provo-Orem, UT 4 0 0 2 1 1 0 0
Raleigh-Cary, NC 30 0 2 2 12 11 3 0
Richmond, VA 30 2 3 3 9 6 7 0
Riverside-San Bernardino-Ontario, CA 145 7 2 14 57 32 33 0
Rochester, NY 22 0 0 0 8 7 7 0
Sacramento-Arden Arcade-Roseville, CA 118 1 3 13 28 34 39 0
St. Louis, MO-IL 46 2 0 4 14 17 9 0
Salt Lake City, UT 20 0 0 1 12 4 3 0
San Antonio, TX 99 7 5 10 27 33 17 0
San Diego-Carlsbad-San Marcos, CA 223 9 9 21 77 55 52 0
San Francisco-Oakland-Fremont, CA 402 7 8 39 110 123 115 0
San Jose-Sunnyvale-Santa Clara, CA 197 6 1 11 75 51 53 0
Sarasota-Bradenton-Venice, FL 35 1 0 4 12 13 5 0
Scranton-Wilkes-Barre, PA 7 0 0 2 1 0 4 0
Seattle-Tacoma-Bellevue, WA 191 8 2 22 86 43 30 0
Springfield, MA 19 0 0 3 6 6 4 0
Stockton, CA 76 7 5 8 14 23 19 0
Syracuse, NY 19 1 1 1 7 3 6 0
Tampa-St. Petersburg-Clearwater, FL 111 1 1 7 37 45 20 0
Toledo, OH 3 0 0 2 1 0 0 0
Tucson, AZ 26 1 0 2 10 10 3 0
Tulsa, OK 16 1 0 3 4 6 2 0
Virginia Beach-Norfolk-Newport News, VA-NC 37 2 3 1 11 10 10 0
Washington-Arlington-Alexandria, DC-VA-MD-WV 344 6 9 47 144 81 57 0
Wichita, KS 11 0 0 4 3 2 2 0
Worcester, MA 17 1 1 4 5 5 1 0
Youngstown-Warren-Boardman, OH-PA 5 0 0 0 1 2 2 0
Total - 102 Areas 9,189 311 195 1,009 3,205 2,693 1,770 6
San Juan-Caguas-Guaynabo, PR 46 1 0 3 14 16 12 0
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Akron, OH 10 1 0 2 4 0 3 0 0
Albany-Schenectady-Troy, NY 9 0 0 3 2 0 4 0 0
Albuquerque, NM 16 8 3 3 1 0 1 0 0
Allentown-Bethlehem-Easton, PA-NJ 13 2 0 4 1 0 4 2 0
Atlanta-Sandy Springs-Marietta, GA 257 59 0 54 109 0 34 0 1
Augusta-Richmond County, GA-SC 29 7 0 4 10 0 8 0 0
Austin-Round Rock, TX 70 33 0 16 12 0 9 0 0
Bakersfield, CA 41 31 1 5 2 0 1 1 0
Baltimore-Towson, MD 62 7 0 24 24 0 7 0 0
Baton Rouge, LA 24 0 0 3 13 0 8 0 0
Birmingham-Hoover, AL 49 7 0 2 29 0 11 0 0
Boise City-Nampa, ID 13 5 0 2 1 0 5 0 0
Boston-Cambridge-Quincy, MA-NH 194 34 0 58 61 0 40 0 1
Bridgeport-Stamford-Norwalk, CT 41 16 0 5 13 0 7 0 0
Buffalo-Niagara Falls, NY 16 2 0 3 4 0 7 0 0
Cape Coral-Fort Myers, FL 29 13 0 1 6 0 9 0 0
Charleston-North Charleston, SC 37 6 0 3 25 0 3 0 0
Charlotte-Gastonia-Concord, NC-SC 44 5 0 13 20 0 6 0 0
Chattanooga, TN-GA 13 4 0 1 1 0 6 0 1
Chicago-Naperville-Joliet, IL 377 95 1 118 110 1 41 0 11
Cincinnati-Middleton, OH-KY-IN 33 5 0 6 9 0 12 1 0
Cleveland-Elyria-Mentor, OH 45 7 0 8 21 0 9 0 0
Colorado Springs, CO 8 3 0 1 1 0 3 0 0
Columbia, SC 26 8 0 4 13 0 1 0 0
Columbus, OH 44 5 0 6 22 0 11 0 0
Dallas-Fort Worth-Arlington, TX 382 97 0 92 132 0 61 0 0
Dayton, OH 15 2 0 4 3 0 6 0 0
Denver-Aurora, CO 57 26 1 14 10 0 6 0 0
Des Moines-West Des Moines, IA 12 0 0 6 1 0 4 0 1
Detroit-Warren-Livonia, MI 84 8 0 19 43 0 12 0 2
Durham-Chapel Hill, NC 17 3 0 3 7 0 4 0 0
El Paso, TX 57 51 0 1 2 0 3 0 0
Fresno, CA 67 32 0 28 3 0 3 0 1
Grand Rapids-Wyoming, MI 19 7 0 6 3 0 3 0 0
Greensboro-High Point, NC 22 3 0 9 9 0 1 0 0
Greenville, SC 15 10 0 1 1 0 3 0 0
Harrisburg-Carlisle, PA 15 0 0 4 5 0 5 1 0
Hartford-West Hartford-East Hartford, CT 19 4 0 6 3 0 6 0 0
Honolulu, HI 83 1 0 62 2 16 2 0 0
Houston-Sugar Land-Baytown, TX 485 216 0 95 112 0 61 1 0
Indianapolis-Carmel, IN 58 12 0 10 25 0 11 0 0
Jackson, MS 57 3 0 1 45 0 8 0 0
Jacksonville, FL 99 2 0 13 53 1 30 0 0
Kansas City, MO-KS 39 5 0 12 11 0 10 1 0
Knoxville, TN 11 0 0 2 1 0 8 0 0
Lakeland, FL 9 2 0 0 3 0 4 0 0
Lancaster, PA 3 1 0 1 0 0 1 0 0
Las Vegas-Paradise, NV 84 20 1 39 10 1 13 0 0
Little Rock-North Little Rock-Conway, AR 17 2 0 0 8 1 6 0 0
Los Angeles-Long Beach-Santa Ana, CA 948 405 0 412 66 2 61 1 1
Louisville-Jefferson County, KY-IN 29 1 0 1 9 0 18 0 0
Madison, WI 13 3 0 6 1 0 3 0 0
McAllen-Edinburg-Mission, TX 75 75 0 0 0 0 0 0 0
Memphis, TN-MS-AR 72 10 1 6 52 1 1 1 0
Miami-Fort Lauderdale-Pompano Beach, FL 295 105 0 19 143 0 28 0 0
Milwaukee-Waukesha-West Allis, WI 34 3 0 10 12 0 9 0 0
Minneapolis-St. Paul-Bloomington, MN-WI 133 11 2 39 68 0 13 0 0
Table 49. Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 
Statistical Areas with >500,000 Population, 2009
Metropolitan 
Statistical Area Asian
American 
Indian or 
Alaska 
Native
Total
Cases
Black 
or 
African 
American
Native 
Hawaiian or 
Other Pacific 
Islander White
Multiple 
Race2
Unknown
or 
Missing
Hispanic 
or 
Latino1
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Modesto, CA 20 8 1 5 1 0 5 0 0
Nashville-Davidson-Murfreesboro-Franklin, TN 75 16 1 11 24 0 23 0 0
New Haven-Milford, CT 27 7 0 10 4 0 6 0 0
New Orleans-Metairie-Kenner, LA 71 7 0 10 35 1 17 1 0
New York-Northern New Jersey-Long Island, NY-NJ-PA 1,240 404 1 419 273 1 119 3 20
Ogden-Clearfield, UT 7 4 0 1 1 0 1 0 0
Oklahoma City, OK 33 7 4 7 9 0 5 1 0
Omaha-Council Bluffs, NE-IA 17 8 0 3 5 0 0 1 0
Orlando-Kissimmee, FL 66 10 0 6 33 0 17 0 0
Oxnard-Thousand Oaks-Ventura, CA 48 32 0 9 0 0 7 0 0
Palm Bay-Melbourne-Titusville, FL 8 1 0 2 1 0 4 0 0
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 195 37 0 58 67 0 30 2 1
Phoenix-Mesa-Scottsdale, AZ 164 78 4 44 16 1 21 0 0
Pittsburgh, PA 21 1 0 7 3 0 10 0 0
Portland-South Portland-Biddeford, ME 4 0 0 0 1 0 3 0 0
Portland-Vancouver-Beaverton, OR-WA 72 20 0 24 5 2 20 1 0
Poughkeepsie-Newburgh-Middletown, NY 6 1 0 3 0 0 2 0 0
Providence-New Bedford-Fall River, RI-MA 37 8 0 12 4 0 13 0 0
Provo-Orem, UT 4 2 0 2 0 0 0 0 0
Raleigh-Cary, NC 30 9 0 2 11 0 8 0 0
Richmond, VA 30 2 0 4 21 0 3 0 0
Riverside-San Bernardino-Ontario, CA 145 58 1 50 8 2 24 2 0
Rochester, NY 22 2 0 3 7 0 9 0 1
Sacramento-Arden Arcade-Roseville, CA 118 16 0 71 6 0 20 0 5
St. Louis, MO-IL 46 3 0 19 17 0 7 0 0
Salt Lake City, UT 20 7 0 6 2 2 3 0 0
San Antonio, TX 99 68 0 14 7 0 10 0 0
San Diego-Carlsbad-San Marcos, CA 223 107 0 73 21 2 20 0 0
San Francisco-Oakland-Fremont, CA 402 64 1 238 55 7 35 1 1
San Jose-Sunnyvale-Santa Clara, CA 197 30 0 145 10 0 11 0 1
Sarasota-Bradenton-Venice, FL 35 9 0 3 10 0 13 0 0
Scranton-Wilkes-Barre, PA 7 1 0 1 0 0 5 0 0
Seattle-Tacoma-Bellevue, WA 191 23 3 86 46 7 22 1 3
Springfield, MA 19 6 0 4 6 0 3 0 0
Stockton, CA 76 26 0 41 4 0 4 1 0
Syracuse, NY 19 1 0 10 6 0 2 0 0
Tampa-St. Petersburg-Clearwater, FL 111 32 0 19 34 1 24 0 1
Toledo, OH 3 0 0 3 0 0 0 0 0
Tucson, AZ 26 10 4 7 5 0 0 0 0
Tulsa, OK 16 4 0 2 2 0 7 1 0
Virginia Beach-Norfolk-Newport News, VA-NC 37 4 0 11 16 0 6 0 0
Washington-Arlington-Alexandria, DC-VA-MD-WV 344 60 0 136 130 0 17 1 0
Wichita, KS 11 4 0 4 2 1 0 0 0
Worcester, MA 17 1 0 9 7 0 0 0 0
Youngstown-Warren-Boardman, OH-PA 5 0 0 1 3 0 1 0 0
Total - 102 Areas 9,189 2,681 30 2,865 2,275 50 1,211 25 52
San Juan-Caguas-Guaynabo, PR 46 46 0 0 0 0 0 0 0
Table 49. (Cont’d) Tuberculosis Cases by Hispanic Ethnicity and Non-Hispanic Race: Metropolitan 
Statistical Areas with >500,000 Population, 2009
1Persons of Hispanic or Latino origin may be of any race or multiple race.
2Indicates two or more races reported for a person.
Note: Case counts for race categories (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian or Other 
Pacific Islander, and White) are mutually exclusive and do not include persons of Hispanic ethnicity or multiple race. Multiple Race does 
not include persons of Hispanic ethnicity.
See Technical Notes for definition of MSA and Hispanic ethnicity and non-Hispanic race (page 9).
Metropolitan 
Statistical Area Asian
American 
Indian or 
Alaska 
Native
Total
Cases
Black 
or 
African 
American
Native 
Hawaiian or 
Other Pacific 
Islander White
Multiple 
Race2
Unknown
or 
Missing
Hispanic 
or 
Latino1
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Akron, OH 10 6 (60.0) 4 (40.0) 0 (0.0)
Albany-Schenectady-Troy, NY 9 3 (33.3) 6 (66.7) 0 (0.0)
Albuquerque, NM 16 7 (43.8) 9 (56.3) 0 (0.0)
Allentown-Bethlehem-Easton, PA-NJ 13 4 (30.8) 9 (69.2) 0 (0.0)
Atlanta-Sandy Springs-Marietta, GA 257 123 (47.9) 134 (52.1) 0 (0.0)
Augusta-Richmond County, GA-SC 29 18 (62.1) 11 (37.9) 0 (0.0)
Austin-Round Rock, TX 70 31 (44.3) 39 (55.7) 0 (0.0)
Bakersfield, CA 41 10 (24.4) 31 (75.6) 0 (0.0)
Baltimore-Towson, MD 62 22 (35.5) 40 (64.5) 0 (0.0)
Baton Rouge, LA 24 21 (87.5) 3 (12.5) 0 (0.0)
Birmingham-Hoover, AL 49 38 (77.6) 11 (22.4) 0 (0.0)
Boise City-Nampa, ID 13 8 (61.5) 5 (38.5) 0 (0.0)
Boston-Cambridge-Quincy, MA-NH 194 40 (20.6) 73 (37.6) 81 (41.8)
Bridgeport-Stamford-Norwalk, CT 41 9 (22.0) 32 (78.0) 0 (0.0)
Buffalo-Niagara Falls, NY 16 10 (62.5) 6 (37.5) 0 (0.0)
Cape Coral-Fort Myers, FL 29 19 (65.5) 10 (34.5) 0 (0.0)
Charleston-North Charleston, SC 37 27 (73.0) 10 (27.0) 0 (0.0)
Charlotte-Gastonia-Concord, NC-SC 44 28 (63.6) 16 (36.4) 0 (0.0)
Chattanooga, TN-GA 13 7 (53.8) 5 (38.5) 1 (7.7)
Chicago-Naperville-Joliet, IL 377 133 (35.3) 244 (64.7) 0 (0.0)
Cincinnati-Middleton, OH-KY-IN 33 20 (60.6) 13 (39.4) 0 (0.0)
Cleveland-Elyria-Mentor, OH 45 24 (53.3) 21 (46.7) 0 (0.0)
Colorado Springs, CO 8 5 (62.5) 3 (37.5) 0 (0.0)
Columbia, SC 26 15 (57.7) 11 (42.3) 0 (0.0)
Columbus, OH 44 14 (31.8) 30 (68.2) 0 (0.0)
Dallas-Fort Worth-Arlington, TX 382 181 (47.4) 201 (52.6) 0 (0.0)
Dayton, OH 15 7 (46.7) 8 (53.3) 0 (0.0)
Denver-Aurora, CO 57 13 (22.8) 44 (77.2) 0 (0.0)
Des Moines-West Des Moines, IA 12 2 (16.7) 10 (83.3) 0 (0.0)
Detroit-Warren-Livonia, MI 84 47 (56.0) 37 (44.0) 0 (0.0)
Durham-Chapel Hill, NC 17 8 (47.1) 9 (52.9) 0 (0.0)
El Paso, TX 57 16 (28.1) 41 (71.9) 0 (0.0)
Fresno, CA 67 22 (32.8) 44 (65.7) 1 (1.5)
Grand Rapids-Wyoming, MI 19 4 (21.1) 15 (78.9) 0 (0.0)
Greensboro-High Point, NC 22 7 (31.8) 15 (68.2) 0 (0.0)
Greenville, SC 15 8 (53.3) 7 (46.7) 0 (0.0)
Harrisburg-Carlisle, PA 15 5 (33.3) 10 (66.7) 0 (0.0)
Hartford-West Hartford-East Hartford, CT 19 6 (31.6) 13 (68.4) 0 (0.0)
Honolulu, HI 83 26 (31.3) 56 (67.5) 1 (1.2)
Houston-Sugar Land-Baytown, TX 485 230 (47.4) 255 (52.6) 0 (0.0)
Indianapolis-Carmel, IN 58 30 (51.7) 28 (48.3) 0 (0.0)
Jackson, MS 57 54 (94.7) 3 (5.3) 0 (0.0)
Jacksonville, FL 99 75 (75.8) 24 (24.2) 0 (0.0)
Kansas City, MO-KS 39 17 (43.6) 22 (56.4) 0 (0.0)
Knoxville, TN 11 7 (63.6) 4 (36.4) 0 (0.0)
Lakeland, FL 9 7 (77.8) 2 (22.2) 0 (0.0)
Lancaster, PA 3 2 (66.7) 1 (33.3) 0 (0.0)
Las Vegas-Paradise, NV 84 24 (28.6) 60 (71.4) 0 (0.0)
Little Rock-North Little Rock-Conway, AR 17 14 (82.4) 3 (17.6) 0 (0.0)
Los Angeles-Long Beach-Santa Ana, CA 948 189 (19.9) 749 (79.0) 10 (1.1)
Louisville-Jefferson County, KY-IN 29 17 (58.6) 12 (41.4) 0 (0.0)
Madison, WI 13 1 (7.7) 12 (92.3) 0 (0.0)
McAllen-Edinburg-Mission, TX 75 23 (30.7) 52 (69.3) 0 (0.0)
Memphis, TN-MS-AR 72 53 (73.6) 19 (26.4) 0 (0.0)
Miami-Fort Lauderdale-Pompano Beach, FL 295 96 (32.5) 199 (67.5) 0 (0.0)
Milwaukee-Waukesha-West Allis, WI 34 20 (58.8) 13 (38.2) 1 (2.9)
Table 50. Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born 
Persons: Metropolitan Statistical Areas with >500,000 Population, 2009
Metropolitan 
Statistical Area
U.S.-born Persons
Foreign-born 
Persons1 Unknown
No. No.(%) (%)
Total
Cases No. (%)
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Minneapolis-St. Paul-Bloomington, MN-WI 133 24 (18.0) 109 (82.0) 0 (0.0)
Modesto, CA 20 7 (35.0) 13 (65.0) 0 (0.0)
Nashville-Davidson-Murfreesboro-Franklin, TN 75 39 (52.0) 36 (48.0) 0 (0.0)
New Haven-Milford, CT 27 5 (18.5) 22 (81.5) 0 (0.0)
New Orleans-Metairie-Kenner, LA 71 54 (76.1) 17 (23.9) 0 (0.0)
New York-Northern New Jersey-Long Island, NY-NJ-PA 1,240 283 (22.8) 953 (76.9) 4 (0.3)
Ogden-Clearfield, UT 7 4 (57.1) 3 (42.9) 0 (0.0)
Oklahoma City, OK 33 21 (63.6) 12 (36.4) 0 (0.0)
Omaha-Council Bluffs, NE-IA 17 2 (11.8) 15 (88.2) 0 (0.0)
Orlando-Kissimmee, FL 66 32 (48.5) 34 (51.5) 0 (0.0)
Oxnard-Thousand Oaks-Ventura, CA 48 14 (29.2) 34 (70.8) 0 (0.0)
Palm Bay-Melbourne-Titusville, FL 8 4 (50.0) 4 (50.0) 0 (0.0)
Philadelphia-Camden-Wilmington, PA-NJ-DE-MD 195 80 (41.0) 115 (59.0) 0 (0.0)
Phoenix-Mesa-Scottsdale, AZ 164 45 (27.4) 119 (72.6) 0 (0.0)
Pittsburgh, PA 21 11 (52.4) 9 (42.9) 1 (4.8)
Portland-South Portland-Biddeford, ME 4 4 (100.0) 0 (0.0) 0 (0.0)
Portland-Vancouver-Beaverton, OR-WA 72 22 (30.6) 50 (69.4) 0 (0.0)
Poughkeepsie-Newburgh-Middletown, NY 6 2 (33.3) 4 (66.7) 0 (0.0)
Providence-New Bedford-Fall River, RI-MA 37 9 (24.3) 28 (75.7) 0 (0.0)
Provo-Orem, UT 4 0 (0.0) 4 (100.0) 0 (0.0)
Raleigh-Cary, NC 30 13 (43.3) 17 (56.7) 0 (0.0)
Richmond, VA 30 23 (76.7) 7 (23.3) 0 (0.0)
Riverside-San Bernardino-Ontario, CA 145 45 (31.0) 100 (69.0) 0 (0.0)
Rochester, NY 22 14 (63.6) 8 (36.4) 0 (0.0)
Sacramento-Arden Arcade-Roseville, CA 118 31 (26.3) 82 (69.5) 5 (4.2)
St. Louis, MO-IL 46 20 (43.5) 26 (56.5) 0 (0.0)
Salt Lake City, UT 20 3 (15.0) 17 (85.0) 0 (0.0)
San Antonio, TX 99 57 (57.6) 42 (42.4) 0 (0.0)
San Diego-Carlsbad-San Marcos, CA 223 75 (33.6) 148 (66.4) 0 (0.0)
San Francisco-Oakland-Fremont, CA 402 89 (22.1) 312 (77.6) 1 (0.2)
San Jose-Sunnyvale-Santa Clara, CA 197 20 (10.2) 174 (88.3) 3 (1.5)
Sarasota-Bradenton-Venice, FL 35 18 (51.4) 15 (42.9) 2 (5.7)
Scranton-Wilkes-Barre, PA 7 5 (71.4) 2 (28.6) 0 (0.0)
Seattle-Tacoma-Bellevue, WA 191 36 (18.8) 155 (81.2) 0 (0.0)
Springfield, MA 19 11 (57.9) 5 (26.3) 3 (15.8)
Stockton, CA 76 25 (32.9) 51 (67.1) 0 (0.0)
Syracuse, NY 19 4 (21.1) 15 (78.9) 0 (0.0)
Tampa-St. Petersburg-Clearwater, FL 111 59 (53.2) 50 (45.0) 2 (1.8)
Toledo, OH 3 0 (0.0) 3 (100.0) 0 (0.0)
Tucson, AZ 26 8 (30.8) 18 (69.2) 0 (0.0)
Tulsa, OK 16 12 (75.0) 4 (25.0) 0 (0.0)
Virginia Beach-Norfolk-Newport News, VA-NC 37 23 (62.2) 14 (37.8) 0 (0.0)
Washington-Arlington-Alexandria, DC-VA-MD-WV 344 61 (17.7) 283 (82.3) 0 (0.0)
Wichita, KS 11 2 (18.2) 9 (81.8) 0 (0.0)
Worcester, MA 17 2 (11.8) 15 (88.2) 0 (0.0)
Youngstown-Warren-Boardman, OH-PA 5 2 (40.0) 3 (60.0) 0 (0.0)
Total - 102 Areas 9,189 3,173 (34.5) 5,900 (64.2) 116 (1.3)
San Juan-Caguas-Guaynabo, PR 46 43 (93.5) 3 (6.5) 0 (0.0)
Table 50. (Cont’d) Tuberculosis Cases and Percentages, U.S.-born Persons and Foreign-born 
Persons: Metropolitan Statistical Areas with >500,000 Population, 2009
1Includes persons born outside the United States, American Samoa, the Federated States of Micronesia, Guam, the Republic of the 
Marshall Islands, Midway Island, the Commonwealth of the Northern Mariana Islands, Puerto Rico, the Republic of Palau, the U.S. Virgin 
Islands, and U.S. minor and outlying Pacific islands. 
Note: See Technical Notes for definition of MSA (page 9).
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Tuberculosis in the United States
National Tuberculosis Surveillance System Highlights from 2009
Slide 1 (title slide). Tuberculosis in the United States—National Tuberculosis Surveillance System, High-
lights from 2009.  This slide set was prepared by the Division of Tuberculosis Elimination, Centers for Dis-
ease Control and Prevention (CDC), Department of Health and Human Services (DHHS).  It provides trends 
for the recent past and highlights from data collected through the National Tuberculosis Surveillance System 
for 2009.  Since 1953, through the cooperation of state and local health departments, CDC has collected infor-
mation on the newly reported cases of tuberculosis (TB) disease in the United States.  The data presented here 
were collected via the revised TB case report introduced in 2009.  Currently, each individual TB case report 
(Report of Verified Case of Tuberculosis or RVCT) is submitted electronically to CDC.  The data for this slide 
set are based on updates received by CDC as of July 1, 2010.  All case counts and rates for years 1993–2009 
have been updated.
Slide 2. Reported TB Cases, United States, 1982–2009.  The resurgence of TB in the mid-1980s was 
marked by several years of increasing case counts until its peak in 1992.  Case counts began decreasing again 
in 1993, and 2009 marked the seventeenth year of decline in the total number of TB cases reported in the 
United States since the peak of the resurgence.  From 1992 until 2002, the total number of TB cases decreased 
5%–7% annually.  From 2002 to 2003, however, the total number of TB cases decreased by only 1.4%.  In 
2009, a total of 11,545 cases were reported from the 50 states and the District of Columbia.  This represents a 
decline of 10.5% from 2008 and of approximately 56.7% from 1992.  
Slide 3. TB Morbidity, United States, 2003-2009.  This slide provides the total number of reported U.S. TB 
cases and the associated TB rates for each of the past 7 years.  Rate is defined as cases per 100,000 popula-
tion.  The number of TB cases decreased from 14,836 in 2003 to 11,545 in 2009, and the TB rate also de-
creased from 5.1 in 2003 to 3.8 in 2009.
Slide 4. TB Case Rates, United States, 2009.  This map shows TB rates for 2009.  Thirty-four states had a 
rate of less than or equal to 3.5 TB cases per 100,000, the interim goal for the year 2000 established by the 
Advisory Council for the Elimination of Tuberculosis.  This group of states has remained fairly constant over 
the last decade; five states (CT, MI, NM, OR, and PA) joined the group in 2000, one state (MO) joined the 
group in 2001 (also in 1998 for one year only), and one state (KY) joined the group in 2003. In 2008, five 
more states (AZ, AR, OK, RI and WA) joined the group but one state (MA) left the group. In 2009, four more 
states (NC, TN, VA, IL, MN) joined the group but one state (WA) left the group. Eleven states and the District 
of Columbia (DC) reported a rate above the 2009 national average of 3.8 cases per 100,000: AK, CA, NV, FL, 
GA, HI, LA, MS, NJ, NY, and TX.  These eleven states and DC accounted for 63% of the national total and 
experienced substantial overall decreases in cases and rates from 1992 through 2009.
Slide 5. TB Case Rates by Age Group, United States, 1993–2009.  This slide shows the last 17 years’ de-
clining trend in TB rates by age group.  The largest declines occurred in persons 65 years and older (from 17.7 
per 100,000 in 1993 to 5.8 in 2009), in adults aged 45 to 64 years (from 12.4 to 4.3), in adults aged 25 to 44 
years (from 11.5 to 4.7), and in children under 15 years of age (from 2.9 to 1.0), each group having decreased 
more than 50%.  The rate declined by 40% in those 15 to 24 years of age (from 5.0 to 3.0).
Slide 6. Reported TB Cases by Age Group, United States, 2009.  This pie chart shows the age distribution 
of persons reported with TB in 2009.  Six percent were children under 15 years of age, 11% were age 15 to 
24, 34% were age 25 to 44, 30% were age 45 to 64, and 20% were at least 65 years old.
Slide 7. TB Case Rates by Age Group and Sex, United States, 2009.  This slide graphs the TB rates in 2009 
by age group and sex.  It shows that rates tended to increase with age, ranging from a low of 1 per 100,000 in 
children under 15 to a high of 8.4 per 100,000 in men 65 years and older.  The rates in men 45 years and older 
were approximately twice those in same-age women.
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Slide 8. TB Case Rates by Race/Ethnicity, United States, 1993–2009.  This slide shows the declining trend 
in TB rates by race/ethnicity during the last 16 years.  Asians and Pacific Islanders had the highest TB rates, 
which declined from 41.2 per 100,000 in 1993 to 23.1 in 2009, and had the smallest percentage decline over 
the time period (43%).  Rates declined by at least 65% over the time period in the other racial/ethnic groups: 
among non-Hispanic blacks or African-Americans, from 28.5 in 1993 to 7.6 in 2009 (73%); among Hispan-
ics, from 19.9 to 7.0 (65%); among American Indians and Alaska Natives, from 14.0 to 4.3 (69%); and among 
non-Hispanic whites, from 3.6 to 0.9 (75%).  Since 2003, the Asian and Pacific Islander race category has 
included persons who reported race as either 1) Asian only or 2) Native Hawaiian or Other Pacific Islander 
only.  Although these categories were reported separately beginning in 2003, they were merged for this slide 
to allow for continuity in reporting trends.
Several important factors likely contribute to the disproportionate burden of TB in minorities.  In persons who 
were born in countries where TB is common, TB disease may result from infection acquired in the country of 
origin.  Unequal distribution of TB risk factors, such as HIV infection, may also contribute to increased expo-
sure to TB or to an increased risk of developing TB once infected with M. tuberculosis. 
Slide 9. TB Case Rates by Age Group and Race/Ethnicity, United States, 2009.  This slide presents TB 
rates in 2009 by age group and race/ethnicity.  Risk increased with age across racial and ethnic groups, and 
rates were consistently higher in minority racial and ethnic groups than in non-Hispanic whites.  Rates were 
the highest in Asians and Native Hawaiians and Other Pacific Islanders, particularly in adult age groups.  The 
impact of foreign birth is a consideration in interpreting rate variations by race/ethnicity.  For example, 94% 
of cases in the Asian group occurred in foreign-born persons, compared with 73% of cases in Hispanics and 
32% of cases in non-Hispanic blacks or African-Americans.  Persons reporting two or more races totaled less 
than 1% of all cases.   
Slide 10. Reported TB Cases by Race/Ethnicity, United States, 2009.  In 2009, 84% of all reported TB 
cases occurred in racial and ethnic minorities (29% in Hispanics, 28% in Asians, 25% in non-Hispanic blacks 
or African-Americans, 1% in American Indians or Alaska Natives, and  1% in Native Hawaiians or Other 
Pacific Islanders), whereas 16% of cases occurred in non-Hispanic whites.  Persons reporting two or more 
races totaled less than 1% of all cases.  This is the sixth year that Hispanics have constituted the single largest 
percentage of TB cases among all racial/ethnic groups and the second year that Asians have surpassed non-
Hispanic blacks or African Americans as the second largest percentage of TB cases among all racial/ethnic 
groups.
Slide 11. Number of TB Cases in U.S.-born vs. Foreign-born Persons, United States, 1993–2009.  This 
graph plots the number of U.S.-born vs. foreign-born persons reported with TB each year, from 1993 through 
2009.  It illustrates the increase in the percentage of cases occurring in foreign-born persons during this pe-
riod, from 29% in 1993 to 59% in 2009.  Overall, the number of cases in foreign-born persons remained virtu-
ally level, with approximately 7,000–8,000 cases each year, until 2009 when the number dropped to 6,854. 
The number in U.S.-born persons decreased from more than 17,000 in 1993 to 4,571 in 2009.
Slide 12. Trends in TB Cases in Foreign-born Persons, United States, 1989–2009.  This slide shows trends 
in TB cases in foreign-born persons in the United States from 1989 through 2009. The percentage of TB cases 
accounted for by foreign-born persons increased from 23% in 1989 to 59% in 2009.
Slide 13. Reported TB Cases by Origin and Race/Ethnicity, United States, 2009.  Among U.S.-born 
persons with TB in 2009, 42% were non-Hispanic black or African-American, 32% were non-Hispanic white, 
19% were Hispanic or Latino, 3% were Asian, 2% were American Indian or Alaska Native, and 2% were 
Native Hawaiian or Other Pacific Islander.  Among the foreign-born, 44% were Asian, 36% were Hispanic or 
Latino, 13% were non-Hispanic black or African-American, and 5% were non-Hispanic white.  Cases among 
American Indians or Alaska Natives and among Native Hawaiians or Other Pacific Islanders constituted less 
than 1%, respectively, of the cases among the foreign-born and are not shown.  Persons reporting two or more 
races totaled less than 1% of all cases.  
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Slide 14. Percentage of TB Cases Among Foreign-born Persons, United States, 1999 and 2009.  The 
percentage range of the total number of TB cases that occurred in foreign-born persons in each state is high-
lighted for 1999 and 2009 in these side-by-side maps.  The number of states with at least 50% of cases in the 
foreign-born increased from 13 states in 1999 to 31 states in 2009. The number of states with at least 70% of 
cases in the foreign-born increased from two (HI and MN) in 1999 to fourteen (CA, CO, CT, MD, MN, NE, 
NH, NJ, NY, ND, RI, UT, VT and WA) in 2009 (not shown on slide). 
Slide 15. TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2009.  TB rates in 
foreign-born persons remain higher than those in the U.S.-born population.  From 1993 through 2009, the 
rates in U.S.-born persons decreased from 7.4 per 100,000 to 1.7, whereas the rates in foreign-born persons 
decreased from 34.0 per 100,000 to 18.7..
Slide 16. TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2009.  This is the 
same as Slide 15, but the rates are presented on a logarithmic scale to better illustrate the trend in TB rates 
among the U.S.-born and foreign-born. The lines show a greater rate of decline among the U.S.-born com-
pared with the foreign-born during this period..
Slide 17. Countries of Birth of Foreign-born Persons Reported with TB, United States, 2009.  This slide 
shows the overall distribution of the countries of birth of foreign-born persons reported with TB in 2009, with 
the top seven highlighted.  The list of countries has remained relatively constant since 1986, when informa-
tion on country of birth was first reported by all areas submitting reports to CDC. The seven top countries 
accounted for 62% of the total, with Mexico accounting for 23%; the Philippines, 12%; India, 8%; Vietnam, 
8%; China, 5%; Guatemala, 3%; and Haiti, 3%.  Persons from more than 135 other countries each accounted 
for 2% or less of the total, but altogether accounted for 38% of foreign-born persons reported with TB.
Slide 18. Percent of Foreign-born with TB by Time of Residence in U.S. Prior to Diagnosis, 2009.  The 
length of U.S. residence among foreign-born persons prior to their TB diagnosis in 2009 is shown in these 
stacked bars.  Overall, 14% had been in the United States for less than 1 year, 20% between 1 and 4 years, 
and 55% for at least 5 years.  The distribution is also shown for the top three countries of birth: Mexico, the 
Philippines, and India.  Among persons born in Mexico, 10% had been in the United States for less than 1 
year, 17% between 1 and 4 years, and 61% for at least 5 years. Among persons born in the Philippines, 13% 
had been in the United States for less than 1 year, 16% between 1 and 4 years, and 59% for at least 5 years.  
Among persons born in India, 15% had been in the United States for less than 1 year, 25% between 1 and 4 
years, and 46% for at least 5 years.
Slide 19. Primary Anti-TB Drug Resistance, United States, 1993–2009.  Primary drug resistance is shown 
for the past 17 years.  The graph starts in 1993, the year in which the individual TB case reports submitted to 
the national surveillance system began collecting information on initial susceptibility test results for patients 
with culture-positive TB.  Data were available for more than 85% of culture-positive cases for each year.  
Primary resistance was calculated by using data from persons with no reported prior TB episode. Resistance 
to at least isoniazid remained between 7.0% and 8.6%.  However, resistance to at least isoniazid and rifampin, 
known as multidrug-resistant TB (MDR TB), decreased from 2.5% in 1993 to 1.1% in 1997, and remained at 
approximately 1.0 % up to 2009 when it increased to 1.2%.
Slide 20. Primary MDR TB, United States, 1993–2009.  This graph focuses on trends in primary MDR TB 
(based on initial isolates from persons with no prior history of TB) in the United States from 1993 through 
2009.  The number of primary MDR TB cases, represented by bars, steadily declined from 407 in 1993 to 115 
in 2001.  Since then the total number of primary MDR TB cases has fluctuated from 89 to 132 cases, with 94 
cases reported for 2009.  Primary MDR TB, shown by the line, decreased from 2.5% in 1993 to approximate-
ly 1.1% in 1997, and remained approximately at 1.1% up to 2009 when it increased to 1.2%.
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Slide 21. Primary Isoniazid Resistance in U.S.-born vs. Foreign-born Persons, United States, 1993–2009.  
This graph shows primary isoniazid resistance in U.S.-born vs. foreign-born persons.  Based on initial isolates 
from persons with no prior history of TB, the percentage of isoniazid resistance was approximately two times 
higher among foreign-born persons than among U.S.-born persons.  In foreign-born persons, the percentage 
declined from 12.4% in 1993 to 10.1% in 2009.  In U.S.-born persons, the percentage decreased from 6.8% in 
1993 to 6.0% in 2009.  
Slide 22. Primary MDR TB in U.S.-born vs. Foreign-born Persons, United States, 1993–2009.  This graph 
highlights primary MDR TB in U.S.-born versus foreign-born persons.  The percentage with primary MDR TB 
has declined among both groups, although the decline in the U.S.-born has been greater.  As a result, the pro-
portion of primary MDR TB cases reported in foreign-born persons increased from approximately 25% in 1993 
to 88% in 2009 (not shown on slide).  Among the U.S.-born, the percentage with primary MDR TB remained 
between 0.4% and 0.7% from 1998 through 2008 and was 0.3% in 2009.  The percentage among foreign-born 
persons has fluctuated year by year, while averaging approximately 1.5% from 1999 through 2009.
Slide 23. Extensively Drug Resistant (XDR) TB, as Defined on Initial Drug Susceptibility Testing (DST), 
United States, 1993–2009.  This graph shows the annual number of counted XDR TB cases as defined on 
initial DST from 1993-2009, reported as of August 10, 2009. No XDR TB cases were reported in 2009. The 
most reported in a single year was 10 in 1993, while there were no cases reported in 2003 and 2009. There is 
no apparent trend in the number of cases over time. 
Slide 24. Reporting of HIV Test Results in Persons with TB by Age Group, United States, 1993–2009.  
This slide shows the completeness of reporting of HIV test results in persons with TB by age group from 1993 
through 2009.  The percentage of TB patients for whom test results were reported increased from 30% among 
all ages in 1993 to 61% in 2009.  Among adults aged 25–44 years, the percentage increased from 46% in 1993 
to 71% in 2009.  The numerator includes TB patients with positive, negative, or indeterminate HIV test results 
and persons from California reported with AIDS (HIV test results are not reported to CDC from California).
Slide 25. Estimated HIV Coinfection in Persons Reported with TB, United States, 1993–2009.  This slide 
provides minimum estimates of HIV coinfection among persons reported with TB from 1993 through 2009.  
Since the addition of the request for HIV status to the individual TB case report in 1993, incomplete reporting 
has provided a challenge to calculating reliable estimates.  Results from the cross-matching of TB and AIDS 
registries have been used to supplement reported HIV test results.  For all ages, the estimated percentage of 
HIV coinfection in persons reported with TB decreased from 15% to 6% overall and from 29% to 10% in per-
sons aged 25 to 44 years during this period. 
Slide 26. Mode of Treatment Administration in Persons Reported with TB, United States, 1993–2007.  In 
1993, the reporting areas began providing information about mode of treatment administration on the indi-
vidual TB case report form.  Treatment administered as only directly observed therapy (DOT) increased from 
21.7% in 1993 to 56.2% in 2007, the latest year with available data.  There was also an increase in the propor-
tion of patients who received at least some portion of their treatment as DOT (based on combining the percent-
age of patients who received only DOT and the percentage for whom some portion was self-administered).  In 
2007, 89.2% of patients received at least some portion of their treatment as DOT.
Slide 27. Completion of TB Therapy, United States, 1993–2007.  The reporting areas began providing infor-
mation on completion of therapy in 1993 through the individual TB case report form.  The calculations exclude 
persons with initial isolate rifampin resistant, or patient with meningeal disease, or pediatric patient (aged <15) 
with miliary disease or positive blood culture.  Overall completion of therapy has remained at approximately 
92-93% from 1998 through 2007. Completion in 1 year or less increased from 64% in 1993 to 84.3% in 2007, 
the latest year with available data.  The current DHHS Healthy People 2010 objective is completion of therapy 
in 1 year or less in 90% of patients.  CDC is working with state and local health departments to determine and 
evaluate reasons for apparently delayed completion of therapy, which may vary by jurisdiction.
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Tuberculosis Case Definition for Public Health Surveillance1
(Revised May 13, 2009) 
Clinical description
A chronic bacterial infection caused by Mycobacterium tuberculosis, usually characterized patho-
logically by the formation of granulomas. The most common site of infection is the lung, but other 
organs may be involved. 
Clinical case definition
A case that meets all of the following criteria: 
A positive tuberculin skin test result or positive interferon gamma release assay for •	 M. tuber-
culosis
Other signs and symptoms compatible with tuberculosis (TB) (e.g., abnormal chest radio-•	
graph, abnormal chest computerized tomography scan or other chest imaging study, or clini-
cal evidence of current disease)
Treatment with two or more anti-TB medications•	
A completed diagnostic evaluation•	
Laboratory criteria for diagnosis 
Isolation of •	 M. tuberculosis complex from a clinical specimen,* 
or
Demonstration of •	 M. tuberculosis complex from a clinical specimen by nucleic acid amplifi-
cation test,† 
or
Demonstration of acid-fast bacilli in a clinical specimen when a culture has not been or can-•	
not be obtained or is falsely negative or contaminated.
Case classification
Confirmed: a case that meets the clinical case definition or is laboratory confirmed
Comment
A case should not be counted twice within any consecutive 12-month period. However, a case oc-
curring in a patient who had previously had verified TB disease should be reported and counted 
again if more than 12 months have elapsed since the patient completed therapy. A case should also 
be reported and counted again if the patient was lost to supervision for greater than 12 months and 
TB disease can be verified again. Mycobacterial diseases other than those caused by M. tuberculosis 
complex should not be counted in tuberculosis morbidity statistics unless there is concurrent tuber-
culosis.
                                                                                                                  
*Use of rapid identification techniques for M. tuberculosis (e.g., DNA probes and mycolic acid high-pressure liquid 
chromatography performed on a culture from a clinical specimen) are acceptable under this criterion.
†Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species for clinical purposes. 
A culture isolate of M. tuberculosis complex is required for complete drug susceptibility testing and also genotyping. 
However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug 
Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced 
and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regula-
tions.   
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Appendix B
Recommendations for Counting Reported Tuberculosis Cases
(Revised May 13, 2009)
Since publication of the “Recommendations for Counting Reported Tuberculosis Cases”1 in July 
1997, numerous changes have occurred, and many issues have been raised within the field of tu-
berculosis (TB) surveillance.  This current version updates and supersedes the previous version.
A distinction should be made between reporting TB cases to a health department and counting 
TB cases for determining incidence of disease.  Throughout each year, TB cases and suspected 
cases are reported to public health authorities by sources such as clinics, hospitals, laboratories, 
and health care providers.  From these reports, the state or local TB control officer must deter-
mine which cases meet the current surveillance definition for TB disease and whether the case 
is countable.  These countable TB cases are then reported to the Centers for Disease Control and 
Prevention (CDC).  
Beginning in 2009, state and local TB control officers may also report to CDC those TB cases 
that are verified but not countable for morbidity statistics, as a measure of programmatic and case 
management burden. The noncountable report can include persons with TB disease recurring 
within a consecutive 12-month period after the patient completed TB therapy. 
I. Reporting TB Cases. CDC recommends that health care providers and laboratories be 
required to report all TB cases or suspected cases to state and local health departments 
based on the current “Tuberculosis Case Definition for Public Health Surveillance” (Ap-
pendix A). This notification is essential in order for TB programs to
Ensure case supervision•	
Ensure completion of appropriate therapy•	
Ensure completion of contact investigations•	
Evaluate program effectiveness•	
Assess trends and characteristics of TB morbidity•	
II. TB Surveillance. For purposes of surveillance, a case of TB is defined on the basis of 
laboratory or clinical evidence of active disease due to M. tuberculosis complex.*
________________________________
* Because most laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis from very closely related spe-
cies, these laboratories report culture results as being positive or negative for “Mycobacterium tuberculosis complex.” Although in 
almost all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. tuberculosis, other species are possible. For 
example, one study in San Diego found that 6% of human tuberculosis was caused by Mycobacterium bovis; cultures from these cases 
would be reported by most laboratories as being positive for M. tuberculosis complex. Other species in the Mycobacterium tuberculo-
sis complex include M. africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii. Although M. microti, M. canetii, M. caprae, 
and M. pinnipedii are newly described species, their inclusion in M. tuberculosis complex should not impact public health laboratories 
or programs, because only a few laboratories identify to the species level. These seven species are almost identical in DNA homology 
studies. In terms of their ability to cause clinical disease or be transmissible from person to person, M. bovis, M. africanum, M. mi-
croti, M. canetii, M. caprae, and M. pinnipedii behave like M. tuberculosis; therefore, disease caused by any of the organisms should 
be reported as TB, using the Report of Verified Case of Tuberculosis (RVCT). The only exception is the BCG strain of M. bovis, which 
may be isolated from persons who have received the vaccine for protection against TB or as cancer immunotherapy; disease caused by 
the BCG strain of M. bovis should not be reported as TB.
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a. Laboratory Case Definition
Isolation of •	 M. tuberculosis complex from a clinical specimen.  The use of rapid identi-
fication techniques for M. tuberculosis performed on a culture from a clinical specimen, 
such as DNA probes and high-pressure liquid chromatography (HPLC), is acceptable 
under this criterion.
OR
Demonstration of •	 M. tuberculosis from a clinical specimen by nucleic acid amplifica-
tion (NAA) test. NAA tests must be accompanied by cultures of mycobacterial species. 
However, for surveillance purposes, CDC will accept results obtained from NAA tests 
approved by the Food and Drug Administration (FDA) and used according to the ap-
proved product labeling on the package insert, or a test produced and validated in accor-
dance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) 
regulations.     
OR   
Demonstration of acid-fast bacilli (AFB) in a clinical specimen when a culture has not •	
been or cannot be obtained or is falsely negative or contaminated; historically this crite-
rion has been most commonly used to diagnose TB in the postmortem setting.  
b.   Clinical Case Definition. In the absence of laboratory confirmation of M. tuberculosis com-
plex after a diagnostic process has been completed, persons must have all of the following 
criteria for clinical TB:
Evidence of TB infection based on a positive tuberculin skin test result or positive inter-•	
feron gamma release assay for M. tuberculosis 
AND
One of the following:•	
(1) Signs and symptoms compatible with current TB disease, such as an abnormal chest 
radiograph or abnormal chest computerized tomography scan or other chest imag-
ing study, 
OR
(2) Clinical evidence of current disease (e.g., fever, night sweats, cough, weight loss, 
hemoptysis)
AND
Current treatment with two or more anti-TB medications• 
NOTE: The software for TB surveillance developed by CDC includes a calculated variable called “Vercrit,” 
for which one of the values is “Provider Diagnosis.”  “Provider Diagnosis” is selected when the user chooses 
to override a “Suspect” default value in the case verification screen as “Verified by Provider Diagnosis.”  Thus, 
“Provider Diagnosis” is not a component of the case definition for TB in the current “Tuberculosis Case Defini-
tion for Public Health Surveillance” (Appendix A).  CDC’s national morbidity reports have traditionally included 
all TB cases that are considered verified by the reporting areas, without a requirement that cases meet the pub-
lished case definition.
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III. Counting TB Cases. Cases that meet the current CDC surveillance case definition for 
verified TB are counted by 52 reporting areas with count authority (50 states, District of 
Columbia, and New York City) to determine annual incidence for the United States.  The 
remaining 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, 
Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. 
Virgin Islands) report cases to CDC but are not included in the annual incidence for the 
United States. The laboratory and clinical case definitions are the two diagnostic catego-
ries used in the CDC “Tuberculosis Case Definition for Public Health Surveillance.”
Most verified TB cases are accepted for counting based on laboratory confirmation 
of M. tuberculosis complex from a clinical specimen.
A person may have more than one discrete (separate and distinct) episode of TB.  If 
disease recurs in a person within any 12-consecutive-month period after the patient 
completed therapy, count only one episode as a case. However, if TB disease recurs 
in a person, and if more than 12 months have elapsed since the person completed 
TB therapy or was lost to supervision, the TB case is considered a separate episode 
and should be counted as a new case.  
Mycobacterial diseases other than those caused by M. tuberculosis complex should 
not be counted in TB morbidity statistics unless there is concurrent TB. 
a. Verified TB Cases
COUNT
Count only verified TB cases that meet the laboratory or clinical case definitions 
(see Section II).  The diagnosis of TB must be verified by the TB control officer 
or designee.  The current CDC surveillance case definition for TB describes and 
defines the criteria to be used in the case definition for TB disease. 
DO NOT COUNT
If diagnostic procedures have not been completed, do not count; wait for confirma-
tion of disease.  Do not count as a case the patient for which two or more anti-TB 
medications have been prescribed for preventive therapy for exposure to multidrug- 
resistant (MDR) TB, or while the diagnosis is still pending
b. Nontuberculous Mycobacterial Diseases (NTM)
COUNT
An episode of TB disease diagnosed concurrently with another nontuberculous my-
cobacterial disease should be counted as a TB case.
DO NOT COUNT
Disease attributed to or caused by nontuberculous mycobacteria alone should not be 
counted as a TB case.
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c. TB Cases Reported at Death
COUNT
TB cases first reported to the health department at the time of a person’s death are 
counted as incident cases, provided the person had current disease at the time of 
death. The TB control officer should verify the diagnosis of TB.
DO NOT COUNT
Do not count as a case of TB if there is no evidence of current disease at the time of 
death or at autopsy.
d. Immigrants, Refugees, Permanent Resident Aliens, Border Crossers,* and Foreign Visi-
tors3
COUNT
Immigrants and refugees who are examined after arriving in the United States and 
diagnosed with clinically active TB requiring anti-TB medications should be re-
ported and counted by the locality of their current residence at the time of diagnosis 
regardless of citizenship status.
Border crossers* who are diagnosed with TB and plan to receive anti-TB therapy 
from a locality in the United States for 90 days or more should be reported and 
counted by the locality where they receive anti-TB therapy.
Foreign visitors (e.g., students, commercial representatives, and diplomatic person-
nel) who are diagnosed with TB, are receiving anti-TB therapy, and have been, 
or plan to remain in, the United States for 90 days or more should be reported and 
counted by the locality of current residence.
*Border crosser — defined, by the U.S. Citizenship and Immigration Services 
(USCIS)2 as “an alien resident of the United States reentering the country after an 
absence of less than six months in Canada or Mexico, or a nonresident alien en-
tering the United States across the Canadian border for stays of no more than six 
months, or across the Mexican border for stays of no more than 72 hours.” Border 
crossers may go back and forth across the border many times in a short period.
DO NOT COUNT
Any person who was diagnosed and started on anti-TB drugs in another country 
should not be counted as a new case but should be reported as a verified noncount-
able TB case.  
Border crossers* and foreign visitors who are diagnosed with TB and receive anti-
TB therapy from a locality in the United States for less than 90 days but plan to 
return to their native country to continue therapy should not be reported or counted 
by the locality where they receive anti-TB therapy.
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e. Out-of-State or Out-of-Area Residents 
COUNT 
A person’s TB case should be counted by the locality in which he or she resides at 
the time of diagnosis.  TB in a person who has no address should be counted by the 
locality that diagnosed and is treating the TB.  The TB control officer should notify 
the appropriate out-of-state or out-of-area TB control officer of the person’s home 
locality to (1) determine whether the case has already been counted to avoid “dou-
ble counting,” and (2) agree on which TB control office should count the case if it 
has not yet been counted. 
DO NOT COUNT 
Do not count a case in a newly diagnosed TB patient who is an out-of-area resident 
and whose TB has already been counted by the out-of-area TB control office.
f. Migrants and Other Transients 
COUNT
Persons without any fixed U.S. residence are considered to be the public health 
responsibility of their present locality and their TB case should be reported and 
counted where diagnosed.
DO NOT COUNT
Cases in transient TB patients should not be counted when there is evidence that 
they have already been counted by another locality.  
g. Federal Facilities (e.g., Military and Veterans Administration Facilities)  
COUNT
Cases in military personnel, dependents, or veterans should be reported and counted 
by the locality where the persons are residing in the United States at the time of 
diagnosis and initiation of treatment.
However, if military personnel or dependents are discovered to have TB at a mili-
tary base outside the United States but are referred elsewhere for treatment (e.g., a 
military base located within the United States), the TB case should be reported and 
counted where treated and not where the diagnosis was made.
DO NOT COUNT
Do not count if the case was already counted by another locality in the United 
States.
h. Indian Health Service
COUNT
TB should be reported to the local health authority (e.g., state or county) and count-
ed where diagnosed and treatment initiated.  However, for a specific group such as 
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the Navajo Nation, which is geographically located in multiple states, health depart-
ments should discuss each case and determine which locality should count the case.
DO NOT COUNT
Do not count if the case was already counted by another locality. 
i. Correctional Facilities (e.g., Local, State, Federal, and Military)
COUNT
Persons who reside in local, state, federal, or military correctional facilities may 
frequently be transferred or relocated within and/or between various correctional 
facilities. TB in these persons should be reported to the local health authority and 
counted by the locality where the diagnosis was made and treatment plans were 
initiated.
DO NOT COUNT
Do not count correctional facility residents’ TB cases that were counted elsewhere 
by another locality or correctional facility, even if treatment continues at another 
locale or correctional facility. 
j. Peace Corps, Missionaries, and Other Citizens Residing Outside the United States
DO NOT COUNT
TB in persons diagnosed outside the United States should not be counted.  TB in 
these persons should be counted by the country in which they are residing, regard-
less of their plans to return to the United States for further work-up or treatment.
IV. Suggested Administrative Practices
To promote uniformity in TB case counting, the following administrative procedures 
are recommended:
(a) All TB cases verified by the 52 reporting areas with count authority (50 states, District 
of Columbia, and New York City) during the calendar year (by December 31) will be 
included in the annual U.S. incidence count for that year. All tuberculosis cases verified 
during the calendar year by a reporting area with count authority from one of the remain-
ing 8 reporting areas (American Samoa, Federated States of Micronesia, Guam, Marshall 
Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin Is-
lands) are also counted but are not included in the annual incidence for the United States. 
Cases for which bacteriologic results are pending or for which confirmation of disease is 
questionable for any other reason should not be counted until their status is clearly deter-
mined; they should be counted at the time they meet the criteria for counting. This means 
that a case reported in one calendar year could be included in the morbidity count for the 
following year. The reporting area with count authority should ensure that there is agree-
ment between final local and state TB figures reported to CDC. Currently, some reporting 
areas may not use this suggested protocol. Some of these areas may wait until the begin-
ning of the following year when they have received and processed all of the TB cases 
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for inclusion in the annual case count for the previous year.  If reporting areas decide to 
revise their protocols, they should be aware that their TB trends may change.
(b) TB is occasionally reported to health departments over the telephone, by letter or fax, or 
on forms other than the Report of Verified Case of Tuberculosis (RVCT). Such informa-
tion should be accepted as an official morbidity report if sufficient details are provided; 
otherwise, the notification should be used as an indicator of a possible TB case (suspect) 
which should be investigated promptly for confirmation.
V. TB Surveillance Definitions
Case - an episode of TB disease in a person meeting the laboratory or clinical 
criteria for TB as defined in the document “Tuberculosis Case Definition for Public 
Health Surveillance” (see Section II for criteria).
Suspect - a person for whom there is a high index of suspicion for active TB (e.g., 
a known contact to an active TB case or a person with signs or symptoms consistent 
with TB) who is currently under evaluation for TB disease.
Verification of a TB case - the process whereby a TB case, after the diagnostic 
evaluation is complete, is reviewed at the local level (e.g., state or county) by a TB 
control official who is familiar with TB surveillance definitions; if all the criteria for 
a TB case are met, the TB case is then verified and eligible for counting. 
Counting of a TB case - the process whereby a reporting area with count author-
ity evaluates verified TB cases against count criteria (e.g., assesses for case dupli-
cation). These cases are then counted for morbidity in that locality (e.g., state or 
county) and reported to CDC for national morbidity counting. Noncountable, veri-
fied cases may also be sent to CDC.
Mycobacterium tuberculosis complex (M. tuberculosis complex) - Because most 
laboratories use tests that do not routinely distinguish Mycobacterium tuberculosis 
from very closely related species, these laboratories report culture results as being 
positive or negative for “Mycobacterium tuberculosis complex.” Although in almost 
all cases of human disease, isolates in the M. tuberculosis complex are, in fact, M. 
tuberculosis, other species are possible. For example, one study in San Diego found 
that 6% of human tuberculosis was caused by Mycobacterium bovis; cultures from 
these cases would be reported by most laboratories as being positive for M. tuber-
culosis complex. Other species in the Mycobacterium tuberculosis complex include 
M. africanum, M. microti, M. canetii, M. caprae, and M. pinnipedii. Although M. 
microti, M. canetii, M. caprae, and M. pinnipedii are newly described species, their 
inclusion in M. tuberculosis complex should not impact public health laboratories or 
programs because only a few laboratories identify to the species level. These seven 
species are almost identical in DNA homology studies. In terms of their ability to 
cause clinical disease or be transmissible from person to person, M. bovis, M. afri-
canum, M. microti, M. canetti, M. caprae, and M. pinnipedii behave like M. tuber-
culosis; therefore, disease caused by any of the organisms should be reported as TB, 
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using the Report of Verified Case of Tuberculosis (RVCT). The only exception is 
the BCG strain of M. bovis, which may be isolated from persons who have received 
the vaccine for protection against TB or as cancer immunotherapy; disease caused 
by the BCG strain of M. bovis should not be reported as TB.
 
Nontuberculous mycobacteria (NTM) - mycobacteria other than Mycobacterium 
tuberculosis complex that can cause human infection or disease.  Common nontu-
berculous mycobacteria include M. avium complex or MAC (M. avium, M. intracel-
lulare), M. kansasii, M. marinum, M. scrofulaceum, M. chelonae, M. fortuitum, and 
M. simiae.  Other terms have been used to represent NTM, including MOTT (myco-
bacteria other than TB) and “atypical” mycobacteria.
Reporting area - areas responsible for counting and reporting verified TB cases to 
CDC.  Currently there are 60 reporting areas: the 50 states, District of Columbia, 
New York City, American Samoa, Federated States of Micronesia, Guam, Marshall 
Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, and U.S. Virgin 
Islands.  The annual incidence of tuberculosis for the United States is based on 52 
reporting areas (the 50 states, District of Columbia, and New York City).
Alien - defined by the U.S. Citizenship and Immigration Services (USCIS)2 as “any 
person not a citizen or national of the United States.”
Border crosser - defined, by the U.S. Citizenship and Immigration Services 
(USCIS)2 as “an alien resident of the United States reentering the country after an 
absence of less than six months in Canada or Mexico, or a nonresident alien en-
tering the United States across the Canadian border for stays of no more than six 
months, or across the Mexican border for stays of no more than 72 hours.”  Border 
crossers may go back and forth across the border many times in a short period.
Class A TB with waiver3 
All applicants who have tuberculosis disease and have been granted a waiver. 
Class B1 TB, Pulmonary3 
 
 No treatment 
Applicants who have medical history, physical exam, HIV, or CXR findings •	
suggestive of pulmonary TB but have negative AFB sputum smears and 
cultures and are not diagnosed with TB or can wait to have TB treatment 
started after immigration. 
Completed treatment 
Applicants who were diagnosed with pulmonary TB and successfully •	
completed directly observed therapy prior to immigration. The cover sheet 
should indicate if the initial sputum smears and cultures were positive and if 
drug susceptibility testing results are available. 
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Class B1 TB, Extrapulmonary3 
Applicants with evidence of extrapulmonary TB. Document the anatomic site of 
infection. 
Class B2 TB, Latent TB Infection (LTBI) Evaluation3 
 
Applicants who have a tuberculin skin test ≥10 mm but otherwise have a negative 
evaluation for TB. The size of the TST reaction, the applicant’s status with respect 
to LTBI treatment, and the medication(s) used should be documented. For appli-
cants who had more than one TST, whether the applicant converted the TST should 
be documented (i.e., initial TST <10 mm but subsequent TST ≥10 mm). 
Class B3 TB, Contact Evaluation3 
 
Applicants who are a recent contact of a known tuberculosis case. The size of the 
applicant’s TST reaction should be documented. Information about the source case, 
name, alien number, relationship to contact, and type of tuberculosis should also be 
documented.
Immigrant - defined by the USCIS2  as “an alien admitted to the United States as 
a lawful permanent resident.  Immigrants are those persons lawfully accorded the 
privilege of residing permanently in the United States.  They may be issued immi-
grant visas by the Department of State overseas or adjusted to permanent resident 
status by the USCIS of the United States.”
Permanent Resident Alien - see Immigrant. 
Waivers3 - A provision allows applicants undergoing pulmonary or laryngeal 
tuber culosis treatment to petition for a Class A TB with waiver. Waivers should be 
pursued for any immigrant or refugee who has a complicated clinical course and 
would benefit from receiving treatment of their tuberculosis in the United States. 
Applicants diag nosed with tuberculosis disease who are both smear- and culture-
negative and will be traveling to the United States prior to start of treatment do not 
need to complete the waiver process.
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